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Disruption of blood-brain barrier (BBB) is a key secondary event that exacerbates 
brain damage following traumatic brain injury (TBI). BBB disruption is particularly 
damaging to the developing brain – which is highly vulnerable to various stress stimuli, 
resulting in increased brain swelling, disrupted cerebral blood flow (CBF) autoregulation, 
long-term disabilities and death following TBI in young demographic. Unsurprisingly, 
BBB disruption and the resultant cerebral edema have emerged as therapeutic targets in 
juvenile TBI. It is therefore important to understand the molecular players and 
mechanisms involved in TBI-induced BBB disruption in the juvenile brain. To this end, 
the endothelial caveolins and c-Jun N-terminal kinases (JNKs) were identified as 
proteins of interest in the regulation of brain endothelial permeability after injury. These 
were investigated under a three-fold aim. The first was to characterize the acute and 
long-term histological and functional changes occurring following injury to the developing 
brain. Second was the attempt to profile the changes in expression patterns of caveolins 
after juvenile TBI in conjunction with BBB disruption.  And lastly, the effects of molecular 
agents that target JNK (DJNKI-1) and caveolin (cavtratin) pathways respectively were 
examined on BBB integrity, and on imaging, histological and functional outcomes.  
To achieve these aims, an experimental model of TBI in juvenile rats was 
developed and characterized. Evidence emerged that long-term white matter dysfunction 
occurs in this model, in parallel with delayed neurodevelopment and persistence of 
xxi 
behavioral deficits, which mimics data from clinical and longitudinal TBI observations. 
There was both acute and long-term increase in the expression level of caveolin-1 in the 
endothelium and reactive astrocytes following juvenile TBI. Furthermore, acute 
administration of cavtratin, a peptide mimetic of caveolin-1 scaffolding domain, markedly 
reduced edema formation and lesion volume without improving sensorimotor outcome in 
the acute time points. However, competitive inhibition of the JNK pathway with acute 
administration of DJNKI-1 markedly ameliorates BBB permeability, reduced edema 
formation, and improves neuroimaging and neurological outcomes at both acute and 
chronic time points. These findings could potentially be exploited for future therapeutic 
applications in juvenile brain trauma.  
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CHAPTER ONE 
INTRODUCTION:  
ENDOTHELIAL TIGHT JUNCTIONS, CAVEOLINS, AND C-JUN N-
TERMINAL KINASES IN CONTEXT OF JUVENILE TRAUMATIC 
BRAIN INJURY 
 
Traumatic Brain Injury (TBI): Prevalence and Long-Term 
Outcome 
Traumatic brain injury (TBI) is ‘caused by a bump, blow or jolt to the head or a 
penetrating head injury that disrupts the normal function of the brain’ (Faul, 2010). 
Increasingly higher incidence rate of TBI and accompanying mortality and disability is 
seen in the United States (Coronado et al., 2011) and in other countries around the 
world (Tagliaferri et al., 2006, Kiening and Unterberg, 2007, Moppett, 2007), making it a 
global menace and potential pandemic. According to Center for Disease Control (CDC) 
reports, an annual average of 53,014 deaths was associated with TBI in the US alone 
between 1997 and 2007 (about 18 deaths per 100,000 population) (Coronado et al., 
2011). The leading causes of TBI-related deaths during this period are: firearm-related 
incidents, motor vehicle accidents, and falls (Coronado et al., 2011).  
TBI is an increasingly troubling public health concern among childhood/pediatric 
populations (Schneier et al., 2006, Kochanek et al., 2010), with childhood and pediatric 
being defined as the developmental period between birth and adolescence (Faul, 2010). 
In trauma centers in the United States, head injury represents 75 – 97% of all pediatric 
trauma deaths (Yeates et al., 2002, Schneier et al., 2006). In comparison to other age 
groups, the pediatric populations have higher proportion of annual TBI-related 
2 
emergencies (close to half a million) (Faul, 2010, Dawodu, 2011), and experience longer 
hospital stays, increased mortality, and protracted neurological and cognitive deficits 
(Schwartz et al., 2003, Keenan and Bratton, 2006, Coronado et al., 2011), all associated 
with enormous economic burden (Schneier et al., 2006). These statistics underscore the 
higher risk of TBI facing the pediatric populations.   
Another important point to note is that TBI incidence rate is higher for males than 
females at every age (Faul, 2010). For example, there is a disproportionate male-to-
female TBI incidence ratio of 4:1 in US pediatric populations. Previous investigators 
have highlighted factors thought to be responsible for this male-to-female disparity, 
including higher activity levels and increased participation in risky sports by males 
(Centers for Disease and Prevention, 1997). It has been estimated that nearly 300,000 
sports-related TBIs occur in the United States per annum (Sosin et al., 1996, Centers for 
Disease and Prevention, 1997). 
Long-term problems associated with moderate to severe TBI include 
sensorimotor (postural instability, dyspraxia, pain in the face and extremities, etc.) (Davis 
and Dean, 2010), neuropsychiatric (e.g. anxiety disorder, depression, etc.) (Brown et al., 
1981, Yeates et al., 2002, Schwartz et al., 2003, Nicholl and LaFrance, 2009), and 
cognitive deficits (e.g. poor attention and executive function deficit; thought and impulse 
disorder) (Chadwick et al., 1981, Max et al., 2000). These dysfunctions have been 
shown to last for decades post-TBI (Thomsen, 1984, 1992, Morton and Wehman, 1995, 
Sbordone et al., 1995, Hoofien et al., 2001). These TBI-associated long-term problems 
originate from various pathophysiological processes and mechanisms set in motion post-
TBI. This is the focus of next sub-section below.   
 
 
 
3 
Traumatic Brain Injury: Mechanisms of Primary and Secondary 
Injuries 
 TBI processes are generally classified into either primary or secondary injury 
mechanism. Primary injury consists of the initial insult(s) to the cranium and brain tissue, 
and may manifest as either focal (e.g. skull fractures, intracranial hematomas, 
lacerations, contusions, penetrating wounds) or diffuse injuries (e.g. diffuse axonal 
injury, acceleration and deceleration injury) (Gennarelli, 1993, Dawodu, 2011). Strict 
adherence to preventatives measures such as wearing of helmet (during cycling, sports 
events or dangerous industrial work) and using seatbelts or child-restraint (in 
automobiles) may reduce the damage caused by primary injury (Dawodu, 2011).  
 Secondary injury, however, consists of a complex array of cellular processes and 
pathophysiological events which are delayed consequences of the initial insult, and may 
continue for a long time (Park et al., 2008, Dawodu, 2011). Secondary injuries may 
include: impaired cerebral blood flow and hemodynamics, ischemia, hypoxia, 
excitotoxicity, impaired metabolism, increased free radical formation, disruption of blood-
brain barrier, and edema. Unlike primary injury, the gradual onsets of the secondary 
injury mechanisms make them theoretically amenable to treatment (Park et al., 2008). 
Research efforts are therefore geared towards utilizing this window of opportunity 
through development of therapies (e.g. pharmacological agents aimed at reducing 
blood-brain barrier damage and curtailing brain edema) that could potentially minimize 
secondary injury damage and facilitate functional recovery (Donkin and Vink, 2010, 
Shlosberg et al., 2010). 
 
How the Juvenile Brain Differs from Adult Brain with and without 
TBI 
For the rest of this dissertation, the term ‘juvenile TBI’ is used to indicate TBI 
occurring in the pediatric/childhood period. Mounting evidence is showing that juvenile 
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brain is uniquely different from adult brain both in terms of natural physical and 
physiological status and also in terms of response to TBI (Giza and Prins, 2006, Giza et 
al., 2007, Ibrahim et al., 2012, Maxwell, 2012). First, there are differences in the physical 
attributes of juvenile heads, skulls, and brains versus those of adults. The pediatric skull 
is thinner, flexible, and more pliable than adult skull (Giza, 2006). There is, for instance, 
an open fontanelle in infants which is thought to make them more susceptible to 
subdural hematoma following TBI (Khilnani, 2004, Giza, 2006). This flexibility affects the 
forces being transmitted to the brain tissue following trauma and the handling of 
increased intracranial pressure (ICP) (Giza, 2006).  Other pediatric anatomical features 
such as disproportionately large head-to-body ratio, weaker neck muscles, and large 
subarachnoid space in which the brain can move more freely compared to adults further 
predispose the pediatric population to TBI (Zuckerman and Conway, 1997, Giza, 2006), 
and especially increases the rate of occurrence of diffuse axonal injury (DAI) (Gleckman 
et al., 1999). 
Developmental processes in the pediatric brain are unique and different from 
those of adult brain (Giza et al., 2007, Maxwell, 2012). Maturation of brain cells and 
structures, and changes of synaptic density and integrated brain functions all continue 
well into adulthood (Giza et al., 2007, Groeschel et al., 2010). For instance, myelination 
of axons in some brain regions continues progressively post-partum and lasts into the 
third decade of life (Ballesteros et al., 1993, Luna et al., 2004, Blakemore and 
Choudhury, 2006, Maxwell, 2012). The unmyelinated fibers in immature brains are 
preferentially vulnerable to structural and functional damage after TBI (Reeves et al., 
2012), resulting in cognitive and behavioral alterations (Jonsson et al., 2013). TBI-
associated injury to unmyelinated axons is thought to affect emerging skills more 
vigorously than established skills possibly due to disruption of developing neural 
networks mediating the skills (Lehnung et al., 2001, Jonsson et al., 2013). 
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Young age is considered a risk factor for complications resulting from secondary 
injuries such as disruption of neural and sensory-motor pathways (Kriel et al., 1989, 
Anderson et al., 2005, Anderson et al., 2012, Crowe et al., 2012). In the developing 
brain, brain water content is higher than in adult brain (Counsell and Rutherford, 2002), 
resulting in reduced brain compliance and making the brain more susceptible to diffuse 
swelling (Aldrich et al., 1992, Giza, 2006, Lenroot and Giedd, 2006). The developing 
brain is in associated with higher cerebral blood flow (CBF) which may be related to 
lower cerebrovascular resistance, and post-traumatic hyperemia and diffuse cerebral 
swelling which are more common in children (Suzuki, 1990, Zwienenberg and Muizelaar, 
1999, Giza, 2006, Udomphorn et al., 2008).  
Approximately 50% of children who suffer severe TBI will develop diffuse 
cerebral swelling (DCS) which has been defined as ‘‘compressed or obliterated 
mesencephalic cisterns, cerebrospinal fluid (CSF) spaces, and/or small to normal size 
ventricles in the absence of other intracranial pathology” (Aldrich et al., 1992, Adelson, 
2009). Although DCS is noted as the most common cause of brain death in both 
pediatric and adult TBI (Becker et al., 1977, Marshall et al., 1979), it is however about 
3.5 times more common in children than adults (Zimmerman et al., 1978, Aldrich et al., 
1992, Adelson, 2009). Moreover, childhood victims of TBI who present with DCS have 
been estimated to have three-fold higher mortality than those without it (Aldrich et al., 
1992, Bauer et al., 1999). About 50% of all children who present DCS following jTBI 
suffer mortality within 6 days (Aldrich et al., 1992), while those that surviving bear long-
lasting neurological deficits (Yeates et al., 2002, Schwartz et al., 2003). Neuropathologic 
changes associated with DCS include: obliterated CSF spaces, vascular congestion, 
edema (both cytotoxic and vasogenic), varying degrees of herniation, and cell death 
(Adelson, 2009). Furthermore, DCS in jTBI has been linked to the endangerment of BBB 
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by oxidative stress due to diminished antioxidant capacity in the juvenile brain compared 
to adult brain (Bauer et al., 1999, Fan et al., 2003).  
Experimental evidence has been provided in support of age-dependent 
differences in cerebral and systemic hemodynamic  responses following brain injury 
(Armstead, 1999). Younger age is found to be associated with increased impairment of 
cerebral autoregulation (triggering hypo- or hyperperfusion) and poorer outcomes 
following moderate to severe TBI (Vavilala et al., 2004, Freeman et al., 2008). Neonates 
and infants have a limited range of brain autoregulation compared to adults (Armstead, 
2005), which predisposes them to cerebrovascular dysfunction following jTBI. 
The unique vulnerabilities of juvenile brains to TBI highlighted above have 
triggered a rethink among scientists on the extent to which ‘brain plasticity’ (defined as 
brain’s ability to repair itself) during development could make up for the damage done, 
and foster structural brain repair and functional recovery following jTBI (Anderson et al., 
2005, Anderson et al., 2012). An emerging opinion is that brain plasticity is insufficient to 
make up for the vulnerabilities of the juvenile brain by canceling out the deleterious 
structural and functional effects of jTBI (Anderson et al., 2005, Giza, 2006). The damage 
done to the developing brain by jTBI often results in decades-long or life-long 
complications and deficits of sensory-motor, cognitive, and neuropsychiatric nature (Max 
et al., 2000, Hoofien et al., 2001, Yeates et al., 2002, Davis and Dean, 2010), and these 
highlight the need for further research into how to facilitate better outcomes (Anderson et 
al., 2005, Giza et al., 2007). 
 
Introduction to Blood-Brain Barrier (BBB) 
The BBB is a dynamic interface comprising of various cell types and molecules 
that work in concert to physically and chemically separate the brain parenchyma from 
the systemic circulation and its cargo (Hawkins and Davis, 2005). It comprises of a 
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physical and chemical barrier to diffusion of peripheral blood content into the brain, as 
well as a transport barrier, and a metabolic barrier (Ballabh et al., 2004, Abbott et al., 
2006). Three cellular elements form the foundation of the BBB: the capillary endothelial 
cells, the astrocytic endfeet, and the pericytes (Ballabh et al., 2004). The tight junctions 
(TJs) between adjacent capillary endothelial cells form the major ‘physical barrier’ to 
paracellular transport (Abbott et al., 2006). The molecular constituents of TJs are 
discussed elaborately in section 2.2 below. The presence of specific transporters and 
transport systems on the luminal (e.g. breast cancer resistance protein [BCRP]) and 
abluminal (e.g. lipoprotein receptor-related protein 1 [LRP1]) surfaces of the capillary 
endothelium ensures selective transcellular transport of compounds in either direction 
between peripheral blood and brain (Zlokovic, 2008). The selectiveness of these 
transport systems gives the brain a much less degree of transcytosis and endocytosis 
than peripheral endothelium, and forms the basis of the ‘transport barrier’ function of the 
BBB (Abbott et al., 2006). The ‘metabolic barrier’ function of the BBB is spearheaded by 
intracellular and extracellular enzymes (e.g. peptidases and nucleotidases which can 
metabolize unwanted peptides and ATP, and cytochrome P450 which can inactivate 
various neuroactive and toxic compounds) (el-Bacha and Minn, 1999, Abbott et al., 
2006) marshaled against unwanted substrates. The perivascular endfeet of astrocytes 
ensheathes more than 99% of the cerebrovascular surface (Iadecola and Nedergaard, 
2007). It provides a communication route between brain endothelium and neurons, 
thereby facilitating the coupling of vascular and neuronal activities in several of the 
brain’s blood vessels (Iadecola and Nedergaard, 2007, Dunn et al., 2013). Pericytes 
enclosed within endothelial basal laminal perform maintenance, regulatory and repair 
roles crucial to the integrity of the BBB (Winkler et al., 2011). 
 Contrary to the belief in previous decades that the BBB of neonates and infants 
is structurally and/or functionally immature (Barcroft, 1938, Saunders et al., 1999), 
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growing evidence suggests that tight junctions of the human BBB is fully formed at birth 
(Abbott et al., 2010, Saunders et al., 2012), although there is progressively increase in 
the expression of some efflux transporters (e.g. p-glycoprotein)  during development (Ek 
et al., 2010, Ek et al., 2012, Saunders et al., 2012). By the 14th week of gestation, the 
key TJ proteins – claudin-5 and occludin – are detectable in the fetal capillary 
endothelium and show the same distribution pattern as seen in adult brain (Virgintino et 
al., 2004). Furthermore, pioneering studies in the 1950s showed that there is a post-
mortem BBB to trypan blue in stillborn human fetuses by the 12th week of gestation 
(Grontoft, 1954). Observations in rodents corroborate these findings. In experimental 
mice, BBB begins to form between E11 and E17 with identifiable TJs and restriction of 
transendothelial movement of polar solutes (Abbott et al., 2010). The high 
transendothelial electrical resistance (TEER) characteristic of adult BBB is exhibited by 
E21 using in situ measurements of TEER in cerebral blood vessels of anaesthetized rats 
(Butt et al., 1990, Butt, 1995). Recent experimental data from stroke even suggests that 
the neonates’ BBB may be less permeable compared to adults following induction of 
ischemic event (Fernandez-Lopez et al., 2012). In spite of the presence of intact BBB at 
birth however, the developing cerebral vessels are still believed to be more fragile than 
adult vessels, which could render the brain more susceptible not only to drugs and 
toxins, but also to neuropathologic conditions underlying cerebral damage and 
neurological disorders (Saunders et al., 2012). The after-birth loss of placental efflux 
transporters (Ek et al., 2010, Ek et al., 2012, Saunders et al., 2012) and the vulnerability 
of blood vessels in the white matter to systemic inflammatory insults at this critical stage 
of development (Stolp et al., 2005a, Stolp et al., 2005b, Stolp and Dziegielewska, 2009) 
are possible contributors to this vulnerability. 
TJ proteins are crucial to the BBB and play a significant role in the evolution of 
secondary brain injuries (Castejon, 2012, Thal et al., 2012).  As such, limiting and 
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reversing TJ damage following TBI have become important therapeutic avenues for 
halting the progression of some secondary injury mechanisms (Ballabh et al., 2004, 
Hawkins and Davis, 2005, Shlosberg et al., 2010). A brief review of the structural and 
molecular constituents of brain endothelial TJs under physiological condition follow. 
 
Structural and Molecular Constituents of Brain Endothelial Tight 
Junction 
 Endothelial TJ forms a major physical and structural barrier that impedes the 
movement of substances from the periphery into brain parenchyma between adjacent 
endothelial cells – paracellular permeability (Reese and Karnovsky, 1967, Brightman et 
al., 1970, Ballabh et al., 2004).  It consists of three main integral membrane protein 
families (occludins, claudins and junctional adhesion molecules [JAMs]) and several 
cytoplasmic accessory proteins (including zonula occludens [ZO-1, ZO-2, and ZO-3], 
cingulin, etc.) (Vorbrodt and Dobrogowska, 2004, Liebner et al., 2011). In addition to 
tight junctions, adherens junctions – which comprise of cadherin-catenin complexes and 
their associated proteins – further strengthen the mechanical attachments between 
adjacent endothelial cells and contribute to the regulation of TJ proteins (Schulze and 
Firth, 1993, Wolburg and Lippoldt, 2002, Taddei et al., 2008, Komarova and Malik, 
2010). The main TJ proteins as well as key accessory proteins are described below. 
 
Claudins 
The first proteins in the claudin family (claudins-1 and 2) were reported in 1998 
(Furuse et al., 1998a, Furuse et al., 1998b). The list soon grew to include up to 24 more 
claudin proteins (Morita et al., 1999, Furuse et al., 2002). Particularly abundant in brain 
endothelial TJs are claudins-5 and -12 (Ohtsuki et al., 2008, Guerra, 2011). Unlike 
occludins, there is a strong consensus that claudins are the indispensable protein 
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molecules responsible for establishing the physical and structural barrier properties of 
TJs (Furuse et al., 1999, Morita et al., 1999, Wolburg and Lippoldt, 2002, Liebner et al., 
2011). The ~22 kDa claudin proteins show the same structural pattern – four membrane-
spanning regions, two extracellular loops and two cytoplasmic domains, a short N-
terminus and a long C-terminal sequence (Heiskala et al., 2001). There is no homology 
between the claudin and occludin protein families, although they are structurally similar 
(Liebner et al., 2011). Functional investigations showed that transfection of one or more 
claudin genes into cells that naturally do not possess TJs leads to the formation of TJ 
morphology with reduced paracellular flux (Amasheh et al., 2005, Ohtsuki et al., 2007). 
The TJ phenotype is maintained through homophilic and heterophilic interactions 
between the extracellular loops of claudins (Morita et al., 2003). Furthermore, the 
carboxyl terminals of claudins are known to bind with cytoplasmic zona occludens to 
ensure structural integrity of the TJs (Ballabh et al., 2004). Claudins are hence 
fundamental to both the formation and maintenance of brain endothelial TJs (See Fig. 
1).  
 
Occludins 
Furuse and colleagues (1993) were the first to describe the 65-kD occludins in 1993 
as being localized to the TJs of epithelial and endothelial cells. Occludins are made up of 
two extracellular loops, four transmembrane domains, and C- and N-terminal 
cytoplasmic domains (Feldman et al., 2005) (See Fig. 1). Experiments have revealed 
that the morphology and functional capacity of TJs are not compromised in occludin-
deficient mice (Saitou et al., 2000), although these mice developed some undesirable 
conditions including chronic inflammation and hyperplasia of gastric epithelium, and 
calcifications in the brain parenchyma and blood vessels. (Saitou et al., 2000, Wolburg 
and Lippoldt, 2002). These observations suggest that occludins are not primarily 
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required for TJ formation at the onset (Saitou et al., 2000). However, phosphorylation of 
occludin is known to regulate TJ permeability in both G-protein-dependent and -
independent manner in mature endothelial cells, independent of cytoskeletal changes 
(Hirase et al., 2001). Furthermore, the external loops, as well as the transmembrane and 
C-terminal cytoplasmic domains of occludin were found to be important in regulating 
paracellular permeability, while the N-terminus was determined to be essential for 
neutrophil migration during inflammation (Sakakibara et al., 1997, Lacaz-Vieira et al., 
1999, Huber et al., 2000, Hirase et al., 2001). Moreover, occludin was demonstrated to 
be responsible for sealing of TJs (Lacaz-Vieira et al., 1999). These reports suggest that 
occludin is needed by mature endothelial cells for regulating rather than establishing 
their barrier properties (Wolburg and Lippoldt, 2002). 
 
Junctional Adhesion Molecules (JAMs) 
JAMs (JAM-A, JAM-B and JAM-C) contribute to the assembly of TJ 
structures(Bazzoni, 2003). They belong to the immunoglobulin superfamily and possess 
a single transmembrane domain with two immunoglobulin-like loops in their extracellular 
portion (Ballabh et al., 2004). JAMs codistribute with and help regulate homophilic and 
heterophilic interactions among TJ component molecules (Martin-Padura et al., 1998, 
Wolburg and Lippoldt, 2002). Homophilic interactions among JAMs linking adjacent 
endothelial cells help stabilize intercellular junctions and organize tight junctional 
structures (Bazzoni, 2003) (See Fig. 1). During pathological conditions however, 
heterophilic interactions between JAMs and leukocyte integrins help facilitate leukocyte 
transmigration (Wolburg and Lippoldt, 2002). JAMs contribute to the regulation of 
paracellular permeability. Knocking down JAM-A results in increased barrier permeability 
together with concomitant reduction in claudins in intestinal epithelial cell cultures 
(Severson and Parkos, 2009). In rat cold cortical injury, there was an acute decrease in 
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JAM-A which was concomitant with BBB breakdown (Yeung et al., 2008). Mechanisms 
through which JAMs regulate endothelial permeability include: control of endothelial 
actomyosin contractility, modulation of myosin light chain (MLC) phosphorylation, and 
interactions with TJ scaffolding proteins ZO-1, cingulin, etc. (Orlova et al., 2006, 
Stamatovic et al., 2008). 
 
Accessory Proteins – Zona Occludens (ZOs), Cingulin, and 
Integrins 
Zona Occludens (ZOs) 
Zona Occludens were so named because early micrographs revealed them as a 
zone or band between adjacent epithelial cells whose membranes have joined together 
and formed a virtually impermeable barrier to fluid, and therefore, the ZOs ‘occlude’ the 
space between the adjacent plasma membranes (Brightman and Palay, 1963, Farquhar 
and Palade, 1963). ZO-1 (220 kDa), ZO-2 (160 kDa), and ZO-3 (130kDa) have major 
sequence similarities and belong to the membrane-associated guanylate kinase-like 
protein family (MAGUKs) (Wolburg and Lippoldt, 2002). They all have three PDZ 
domains (PDZ1, PDZ2, and PDZ3), one SH3 domain, and one guanyl kinase-like (GUK) 
domain (Wolburg and Lippoldt, 2002). These domains function as protein binding 
molecules to facilitate signal transductions and help anchor tight junction proteins to the 
cytoskeleton (Wolburg and Lippoldt, 2002, Ballabh et al., 2004) (Fig. 1). The PDZ1 
domain of ZO-1, ZO-2, and ZO-3 has been reported to bind directly to the C-terminus of 
claudins (Itoh et al., 1999). Furthermore, occludin interacts with the GUK domain on ZO-
1 (Mitic et al., 2000). Importantly, actin, the primary cytoskeleton protein, binds to C-
terminal of ZO-1 and ZO-2, and this complex cross-links transmembrane elements and 
thereby provides structural support to the endothelial cells (Haskins et al., 1998, Ballabh 
et al., 2004). 
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Cingulin 
Cingulin has been reported to be expressed in endothelial cells of the BBB, and 
the junction-associated coiled-coil protein (JACOP) in other endothelial and epithelial 
cells (Wolburg et al., 2009). Its structure and organization is conserved throughout the 
vertebrates. Cingulin is an important component of BBB in that it interacts with actin and 
myosin, ZO-1 and several other TJ proteins (Bazzoni et al., 2000). Cingulin binds to 
these tight junction-associated proteins through conserved domains on the targets and 
therefore   help to stabilize tight junctional structures (Heiskala et al., 2001, Wolburg and 
Lippoldt, 2002, Hawkins and Davis, 2005).  
 
Integrins  
Integrins were first described in 1987 (Hynes, 1987). Functionally, they serve as 
receptors for cell adhesion to extracellular matrix (ECM) proteins, play crucial roles in 
cell-to-cell adhesions and cell motility, and maintain transmembrane connections to the 
cytoskeleton (Bazzoni et al., 2000, Juliano, 2002) (See Fig. 1). They are vital in the 
maintenance of signal transduction within and the structural stability of endothelial tight 
junction (Juliano, 2002). Integrins exist in various affinity states for their ligands, and 
these affinity states are regulated by calcium ions and R-Ras and Rap1 small GTPases 
(Juliano, 2002). Knock-out studies of some integrins isoforms resulted in hemorrhage, 
lack of platelet aggregation, impaired leukocyte recruitment, impaired inflammatory 
responses, vessel dilation, and cerebral hemorrhage (Chen and Sheppard, 2007, 
Wolburg et al., 2009). Endothelial integrins also play crucial roles during development in 
the establishment of proper connections between endothelial cells and astrocytes 
(gliovascular unit) under physiologic conditions, and are also crucial for angiogenesis 
(Wolburg et al., 2009).  
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Changes in Brain Vascular Structure and Functions following 
Juvenile TBI 
There is paucity of clinical data on changes occurring specifically in the 
endothelial TJ protein structures and in the BBB in general following TBI in juvenile 
humans (Graham, 2001).  A few postmortem studies have provided some insights into 
macrostructural changes in jTBI. Intracranial hemorrhages – including subdural (SDH), 
subarachnoid (SAH), extradural (EDH), and intracerebral (ICH) hemorrhages – are 
common in postmortem studies of the brains of childhood victims of TBI resulting from 
falls, with SDH being the most frequently seen (Chadwick et al., 1991, Kim et al., 2000, 
Agarwal et al., 2005). In addition, Adelson and colleagues reported low cerebral blood 
flow (CBF) (i.e. hypoperfusion) in the early period after severe TBI in young children 
which was associated with poor functional outcome measured with Glasgow Outcome 
Score (GOS) (Adelson et al., 1997, Adelson et al., 2011). Alterations in CBF in the 
juvenile TBI patients contribute to ischemia and disruption of the BBB (Verive et al., 
2012).  
Furthermore, as earlier noted in section 1.3 (par. 4), one of the pathologic 
features of diffuse cerebral swelling (DCS) seen as a clinical presentation of severe jTBI 
is vascular congestion (Adelson, 2009). Vascular congestion may be indicative of 
thrombosed cerebral blood vessels (Adams et al., 1982, Adelson et al., 1996) and 
portends occurrence of further cerebrovascular dysfunctions (Reithmeier et al., 2005). 
Vascular congestion is preceded and facilitated by cerebral autoregulatory dysfunction 
and hyperemia (Reithmeier et al., 2005). Clinical and experimental studies both highlight 
increased intracranial pressure (ICP) as another key consequence of cerebral 
autoregulatory dysfunction post-jTBI (Barie et al., 1993, Biagas et al., 1996) and cerebral 
edema (Vink and Van Den Heuvel, 2004). 
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Experimentally, cerebral autoregulatory dysfunction in the developing brain is 
linked to excessive activation of N-Methyl D-Aspartate (NMDA) receptor by glutamate 
(Armstead et al., 2011a), hyperactivation of mitogen activated protein kinase (MAPK) 
pathways including c-Jun N-terminal Kinase (JNK) (Armstead et al., 2011a), impairment 
to ATP- and calcium-sensitive potassium (K+) channels on cerebral vessels (Armstead, 
1997, Armstead et al., 2011b), and altered nitric oxide (NO) bioavailability (Verive et al., 
2012) and vasodilatory function (Armstead, 2000). Other Endothelium-dependent 
systems (Verive et al., 2012) such as caveolae and their constituent caveolin proteins in 
lipid rafts (Prisby et al., 2006) also affect cerebral autoregulation in pediatric head 
trauma. Interestingly, caveolins, which are known to influence other factors of cerebral 
autoregulation such as endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) 
(Bucci et al., 2000, Bernatchez et al., 2005), and possibly JNK (Tourkina et al., 2008), 
have not been well-researched in juvenile TBI. 
Findings from microdialysis show that pro-inflammatory cytokines such as 
interleukin-1-β (IL-1β) and tumor necrosis factor-α (TNF-α) are elevated in the CSF of 
children with moderate to severe TBI (Morganti-Kossman et al., 1997, Buttram et al., 
2007, Cederberg and Siesjo, 2010). These cytokines have been shown experimentally 
to induce BBB disruption following TBI via upregulation of hypoxia inducible factor-α 
(HIF-1α) and vascular endothelial growth factor-A (VEGF-A) (Argaw et al., 2006). In a 
follow-up study, caveolin-1 and eNOS were shown to mediate the BBB disruption effects 
of VEGF-A, and the systemic administration of cavtratin – a selective eNOS inhibitor – 
abrogates this VEGF-A-induced BBB disruption and ameliorates neurologic deficits in a 
CNS inflammatory model in young adult mice (Argaw et al., 2012). There is also a 
possibility of developmental differences in cytokines sampled from cerebral microdialysis 
between juvenile and adult TBI patients (Friess et al., 2012), but more studies need to 
be designed and carried out to fully compare these two groups.  
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In experimental juvenile TBI in rodents, genes associated with 
neuroinflammation, cytokine activities and immune processes were found to be 
invariably upregulated acutely, while genes associated with development, 
neurotransmission, neuroplasticity, and, to some extent, metabolism were found to be 
mostly downregulated (Babikian et al., 2010). These suggest that juvenile brain is 
assaulted acutely by neuroinflammation following brain injury and it may be more 
vulnerable to neuroinflammatory insults compared to adult brain (Swaiman et al., 2012). 
Inflammatory response in the developing brain is more robust than in adult brain and is 
characterized by greater disruption of the BBB and elaboration of cytokines (Potts et al., 
2006). Various studies have determined an increased vulnerability of the juvenile BBB to 
oxidative stress following jTBI, possibly due to much lower activities of antioxidant 
enzymes (such as glutathione peroxidase [GPx] and manganese superoxide dismutase 
[MnSOD]) in the juvenile brain compared to adult brain (Bauer et al., 1999, Bayir et al., 
2002, Fan et al., 2003, Babikian et al., 2010). 
Activated matrix metalloproteinases (MMPs) are known to cause degradation of 
vascular basal laminal matrix proteins (e.g. collagen, fibronectin, laminin) and 
breakdown of tight junction proteins (including claudins and occludins) following injury to 
adult brain (Morita-Fujimura et al., 2000, Asahi et al., 2001). MMP-2 was found to have 
increased expression and activity between 12 and 72 hours post-injury in an 
experimental model of jTBI to P7 rats (Sifringer et al., 2007). In contrast to the 
prominence of MMP-2 in juvenile TBI, MMP-9 was found to be more prominent in adult 
rodents with TBI (Wang et al., 2000, Asahi et al., 2001). Baseline activity of MMP-9 was 
also detectable in infant rodent brains unlike in adult brains (Sifringer et al., 2007). These 
suggest that the temporal expression and activity profiles for various MMPs may differ 
dependent on age, and these developmental differences should be considered in 
therapeutic efforts aimed at MMPs.  
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From the points reviewed in this section, it is clear that the juvenile brain has a 
number of vulnerabilities with regards to changes occurring in its cerebral vascular 
structure and functions following brain trauma. Key molecular targets that could be 
investigated for pharmacological manipulation aimed at arresting secondary brain 
damage arising from cerebrovascular dysfunctions also emerged. These include the 
endothelial caveolins and c-Jun N-terminal kinases.  
 
Changes in Brain Vascular Structure and Functions following 
Adult TBI 
Adult TBI patients (as well as experimental animals) share several similarities as 
well as differences from juvenile patients in terms of structural and functional changes in 
the brain vasculature following TBI. A wave of molecular changes that alter both 
structure and function of brain vasculature is unleashed by the initial TBI impact in the 
adult brain (Shlosberg et al., 2010, Chodobski et al., 2011). BBB disruption, which is 
characterized by breakdown of TJ proteins and increased permeability, is typically 
biphasic in nature according to experimental TBI data in adult rodents (Baldwin et al., 
1996, Baskaya et al., 1997). This is also suggested in some clinical data in adult TBI 
patients (Tomkins et al., 2001, Tomkins et al., 2008). The delayed arm of BBB disruption 
has been linked with transcriptional changes in the neurovascular unit which precipitates 
delayed neuronal dysfunction, cell death, and degeneration (Shlosberg et al., 2010). 
Apoptosis of some endothelial cells following TBI also promotes increased BBB 
permeability and eventual neuronal loss (Nag et al., 2005). These events have been 
proposed to influence long-term TBI complications such as cognitive and psychological 
impairments (Zlokovic, 2008, Shlosberg et al., 2010). 
Endothelial structures that form the physical and mechanical barriers to 
paracellular diffusion or permeability undergo active breakdown in adult TBI (Zhao et al., 
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2007, Khan et al., 2009, Chodobski et al., 2011). The levels of expression of claudin-5 
and occludin decrease at acute time points following TBI (Zhao et al., 2007). 
Experimental evidence further suggest that transcellular permeability may also be 
enhanced following adult brain trauma (Preston et al., 2001), possibly through increased 
number and activity of caveolae (the caveolins-based, cave-like structures in the 
endothelial lipid rafts) (Nag et al., 2007, Nag et al., 2009) which facilitate transcytosis – 
the vesicle-mediated transfer of substances across the cell through binding of ligands to 
membrane receptors or surface charges, followed by internalization – among other 
functions (Abbott et al., 2006, Komarova and Malik, 2010). Ultrastructural morphology 
consistent with increased pinocytotic activity (such as swollen endothelial cells, clearer 
cytoplasm, increased vacuolization, and increase in number of pinocytotic vesicles) was 
reported in brain microvessels of adult TBI patients (Vaz et al., 1997). There have been 
calls (Minshall et al., 2003, Yuan and Rigor, 2010) for more studies to further investigate 
the role of caveolae and caveolins in the regulation of endothelial barrier permeability in 
both pediatric and adult TBI. 
Compromise of BBB permeability following TBI in the adult brain results in many 
secondary phenomena which include multi-focal, intraparenchymal hemorrhages in both 
ipsilateral and contralateral brain regions (Chodobski et al., 2011). There is also a lower 
regional cerebral blood flow to the pericontusional area (Schroder et al., 1998, von 
Oettingen et al., 2002). BBB damage following TBI in adult brains results in leakage of 
blood-borne factors and proteins such as albumin (Shapira et al., 1993), immunoglobulin 
G [IgG] (Hooper et al., 2005), fibrinogen (Tyagi et al., 2008), thrombin (Xi et al., 2003), 
extravasation of red blood cells (RBCs) (Chodobski et al., 2011), and aggregation of 
platelets and leukocytes (Stein et al., 2002, Schwarzmaier et al., 2010).  
Each of these leaked or released factors and cells further effect changes in brain 
vascular structure and function following adult TBI. Extravasated albumin has been 
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linked with neuroinflammatory processes such as increased calcium concentration and 
proliferation of microglial cells (Hooper et al., 2005, Chodobski et al., 2011), activation of 
MAPK pathways and synthesis of proinflammatory cytokines such as IL-1β in microglia 
and astrocytes (Ralay Ranaivo and Wainwright, 2010), increase in microglial production 
of NO which is mediated by MAPK pathway (Hooper et al., 2009), and induction of 
MMPs (Ralay Ranaivo et al., 2012) which can further degrade the endothelial 
extracellular matrix. Invading leukocytes can also release degrading MMPs to the 
traumatized brain parenchyma (Borregaard et al., 2007, Chodobski et al., 2011). 
Fibrinogen could induce further endothelial barrier permeability by signaling 
through the MAPK pathway (Tyagi et al., 2008). Fibrinogen causes rearrangement of 
microglial cytoskeleton, increases their size and phagocytic activity, thereby influencing 
post-traumatic neuroinflammation (Adams et al., 2007). Fibrinogen may also inhibit 
neurite outgrowth and promote post-traumatic astroglial scar formation (Schachtrup et 
al., 2007, Chodobski et al., 2011).  
Although pretreatment with low dose of thrombin is neuroprotective in vivo 
(Chodobski et al., 2011), release of thrombin in high concentration post-TBI exacerbates 
BBB disruption and edema formation, and causes apoptosis of neurons and astrocytes 
(Xi et al., 2003). Thrombin stimulates microglial release of pro-inflammatory mediators 
by signaling through MAPK including c-Jun N-terminal kinases (JNKs) (Waetzig et al., 
2005). Thrombin also augments oxidative stress by causing increase in microglial 
expression of inducible nitric oxide synthase (iNOS) and inducing release of NO (Ryu et 
al., 2000) which is a potent vasodilator and an inducer of endothelial hyperpermeability 
(Yuan and Rigor, 2010). It has also been demonstrated in vitro that thrombin directly 
induces contraction of brain endothelial cells which could result in increased paracellular 
permeability (Nagy et al., 1995). 
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Release of blood-borne factors and cells into brain parenchyma is a hallmark of 
what has been traditionally termed ‘vasogenic edema’ (Donkin and Vink, 2010). Edema 
in brain pathologies has for several decades been classified as either ‘cytotoxic edema’ 
– characterized by swelling of astrocytes and neurons due to failure of sodium-
potassium pump and resultant retention of sodium and water while the BBB remains 
intact – or ‘vasogenic edema’ – characterized by BBB breakdown and flow of normally 
excluded intravascular proteins into the parenchyma (Klatzo, 1967, Unterberg et al., 
2004, Donkin and Vink, 2010). Recently, however, the complexity of cerebral edema has 
necessitated the addition of variants of these two traditional categories. These variants 
include: ionic edema – which occurs when plasma osmolality falls below brain osmolality 
and results in net movement of water from vasculature into brain interstitial fluid, all in 
absence of gross BBB breakdown (Simard et al., 2007, Donkin and Vink, 2010); anoxic 
edema – which occurs within minutes of cessation of CBF to a brain region, depriving it 
of oxygen and glucose, and characterized by swelling of astrocytes and neurons (Badaut 
et al., 2011); and hydrostatic edema – which occurs when cerebral perfusion pressure 
increases to the level where autoregulatory mechanisms fails (Donkin and Vink, 2010). 
Debates in scientific literature over which classes of edema predominate following TBI 
has persisted for decades (Donkin and Vink, 2010). The complexity and heterogeneity of 
TBI which is impossible to replicate in a single experimental model has precluded a 
consensus regarding the temporal profile of edema following brain injuries. Most 
researchers, however, agree that post-TBI, edema occurs as a continuum that starts 
with vasogenic edema (with observable tight junction and BBB breakdown) which occur 
within hours of TBI, followed by cytotoxic edema which develops over days and may 
persist for weeks (Barzo et al., 1997, Marmarou, 2003, Donkin and Vink, 2010). 
The brain microvessels surrounding major white matter tracts and in the 
hippocampi are especially vulnerable to damage and leakage following TBI to adult 
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brains (Dietrich et al., 1994, Chodobski et al., 2011). Hemorrhagic contusions were 
found at the gray-white matter interphase under somatosensory cortex in lateral fluid-
percussion injury model in adult rats (Dietrich et al., 1994). Microvessels coursing the 
subcortical white matter such as the corpus callosum are also highly susceptible to 
damage following TBI (Chodobski et al., 2011). Vascular mechanisms is also frequently 
advanced to explain the selective vulnerability of the hippocampus (especially in the 
CA1, CA3, and dentate gyrus) to damage following TBI in adult humans and in 
nonhuman primates (Kotapka et al., 1991) and in rodents (Gao et al., 2011) and other 
animals (Kirino, 1982). Selective damage to both white matter and hippocampi 
contribute significantly to sensorimotor and cognitive deficits following adult TBI (Gao et 
al., 2011, Alwis et al., 2012). Clear-cut vulnerability of the hippocampi and white matter 
in the juvenile brain compared to those in the adult brain has not been unequivocally 
demonstrated despite some evidence pointing toward this (Pullela et al., 2006). 
Vasogenic edema particularly spreads and is more frequently observed in the structured 
cerebral white matter rather than the less ordered grey matter (Kimelberg, 1995, Vink 
and Van Den Heuvel, 2004). This is because the movement results from pressure 
gradients involving the least tissue resistance. The profuse swelling along white matter 
tracts impacts the structural and functional integrity of the fibers (Feigin et al., 1973, Huh 
et al., 2008). 
Several molecular mediators in the neurovascular unit following TBI to the adult 
brain demonstrate time-dependent, biphasic effects on the brain, with the acute or 
chronic phase displaying either beneficial or detrimental impact on the brain’s vascular 
structure and function (Xing et al., 2012). For instance, MMPs degrade neurovascular 
matrix, damage the BBB, exacerbate edema and hemorrhage, and leads to neuronal 
death in the acute phase of TBI in patients (Grossetete et al., 2009) and animals (Morita-
Fujimura et al., 2000, Wang et al., 2000). MMPs have however been found to promote 
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neurovascular remodeling in the delayed phases (7 – 14 days) of experimental brain 
injury in adult rodents (Zhao et al., 2006, Zhang et al., 2010). This biphasic effects are 
yet to be studied in juvenile rodents. Other mediators displaying these time-dependent 
effects include trophic factors released by reactive astrocytes (e.g. VEGF, bFGF, PDGF, 
BDNF, etc.) and NMDA-type glutamate receptors (Xing et al., 2012). 
BBB disruption contributes significantly to the development of secondary 
complications of TBI, one of which is disrupted neurovascular coupling (Golding, 2002, 
Iadecola and Nedergaard, 2007, Lok et al., 2007). Neurovascular coupling denotes the 
association of neural activity in a particular brain locale to concomitant changes in 
cerebral blood flow (CBF) (Pasley and Freeman, 2008). The magnitude and spatial 
location of blood flow changes are tightly linked to changes in neural activity through a 
complex sequence of coordinated events involving neurons, glia, and vascular cells 
(Golding, 2002). In normal brain, local release of metabolic by-products such as carbon 
dioxide (CO2), NO, adenosine, lactate, hydrogen ion (H+) and potassium ion (K+) 
influence local CBF to match or ‘couple’ neural activity to blood flow (Lok et al., 2007, 
Peterson et al., 2011). Following TBI, however, uncoupling often occurs whereby local 
cerebral glucose utilization increases while local CBF decreases (Golding, 2002, Bor-
Seng-Shu et al., 2012). Breakdown in normal activities and interactions between cells 
making up the neurovascular units (which include endothelium, astrocytes, pericytes, 
microglia and neurons) results in neurovascular uncoupling (Shlosberg et al., 2010). 
Influx and release of several vasoactive factors due to BBB disruption (Hawkins and 
Davis, 2005) and disturbance of cerebral autoregulation (Bor-Seng-Shu et al., 2012) 
further exacerbate neurovascular uncoupling. 
Post-traumatic epilepsy is another well-documented complication of TBI which 
disruption of BBB contributes to (Tomkins et al., 2001, Tomkins et al., 2008, David et al., 
2009). Abnormal brain electrical activities observed on electroencephalogram (EEG) 
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(which is indicative of abnormal neuronal signaling) were localized to brain regions with 
clear signs of BBB disruptions in brains of patients suffering from post-traumatic epilepsy 
(Tomkins et al., 2011). Experimental studies have implicated astrocytic dysfunction 
together with altered potassium and glutamate homeostasis in this post-traumatic 
epilepsy (Gupta and Gupta, 2006, David et al., 2009). Hemoglobin/Iron toxicity (Iudice 
and Murri, 2000) has also been implicated in post-TBI epilepsy. Children who are victims 
of severe TBI appear to have a lower risk of developing post-traumatic epilepsy 
compared to their young adult (Pitkanen and McIntosh, 2006) and aged (Herman, 2002) 
counterparts. In a retrospective population-based study conducted on data from a very 
large sample of patients (n = 1.6 million people) in Denmark spanning three-and-a-half 
decades, long-term risk (up to 10 years or longer) of post-traumatic epilepsy was found 
to be increased with increased injury severity, age, and family history of epilepsy 
(Christensen et al., 2009). Children are, however, reported to have a slightly higher risk 
of early (i.e. occurring within 7 days of injury) post-traumatic epilepsy compared to adults 
following severe TBI (Khan and Banerjee, 2010). 
Disruption of BBB has notable negative consequences (besides neurovascular 
uncoupling) on all major cell types within the brain following adult TBI. Reduced CBF 
results in the creation of an oxygen- and nutrients-starved zone (Shlosberg et al., 2010), 
with concomitant neuronal death (Park et al., 2008).  Astrocytes (Chodobski et al., 2011) 
and pericytes (Dore-Duffy et al., 2000) respond to breakdown of BBB following brain 
trauma (Al Ahmad et al., 2009). Astrocytic foot processes swell due to high intake of 
potassium ions, and this leads to failure of glutamate transporters and reversal of 
glutamate uptake (Kimelberg et al., 1995, Park et al., 2008).  Reversal of glutamate 
uptake floods the extracellular space with excessive glutamate, which is a major culprit 
in neuronal excitotoxicity (van Landeghem et al., 2006, Park et al., 2008). Astrogliosis, 
marked by abnormal proliferation of the astrocytes, occurs in response to release of 
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factors (thrombin, albumin, cytokines, etc.) and migration of peripheral cells into the 
parenchyma following BBB disruption (Chodobski et al., 2011), and neuronal cell death 
(Myer et al., 2006). Reactive astrogliosis occurs in a graduated fashion depending on 
injury severity, and is linked with both detrimental and beneficial effects on neurons 
which may be time-dependent (Myer et al., 2006, Laird et al., 2008, Wu et al., 2010).  
NMDA and AMPA receptors on neurons are hyperactivated by the excessive 
glutamate present in the parenchyma, leading to excessive Ca2+ and Zn2+ influx – a 
hallmark of excitotoxicity that eventually kill the cells (Yi and Hazell, 2006, Park et al., 
2008, Zhu et al., 2009). Ca2+ influx activates several enzymes including proteases such 
as calpains that damage components of neuronal and axonal cytoskeleton (Saatman et 
al., 2010). Events such as cellular depolarization, increased oxidative stress, 
mitochondrial dysfunction and caspase activation are linked to excitotoxicity (Zhao et al., 
2003, Park et al., 2008).  
Following BBB disruption, intraparenchymal microglial cells become activated 
and motile, migrating to the injured site within a rapid time frame (Nimmerjahn et al., 
2005, Ramlackhansingh et al., 2011). The rapid time frame in which microglia react to 
BBB disruption suggests involvement of blood-borne and chemoattractive factors 
(Chodobski et al., 2011). Microglial activation was found to persist in some clinical cases 
for several years (up to 17 years) after TBI, even at regions distal from the focal impact 
area (Ramlackhansingh et al., 2011). This highlights chronic inflammatory response that 
evolves over time and the potential for intervention to be beneficial for long intervals after 
TBI.  It has been linked with both beneficial and deleterious effects.  
Blood-derived leukocytes that infiltrate into brain parenchyma following BBB 
disruption in adult TBI further exarcebate inflammatory response with consequent 
deleterious effect on BBB integrity, observed as increased permeability and aggravation 
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of edema (Wedmore and Williams, 1981, Lindbom, 2003, Schmidt et al., 2007, Kenne et 
al., 2012).  
 
Search for Therapeutic Avenues for Controlling BBB Disruption 
and Edema in Juvenile TBI 
As highlighted in the preceding sections, BBB disruption is central to acute and long-
term secondary brain damage following TBI (Shlosberg et al., 2010). The gradual 
evolution and biphasic nature of BBB breakdown allow a therapeutic window of 
opportunity to halt the progression of secondary injury on its track (Beauchamp et al., 
2008, Park et al., 2008). To this end, the restoration of BBB integrity (Shlosberg et al., 
2010) and abrogation of edema formation (Huh and Raghupathi, 2009, Fukuda et al., 
2012) are emerging targets for brain protection following juvenile TBI.  
Most of past research efforts aimed at investigating interventions for brain trauma 
have been focused on adult TBI (Adelson et al., 2003), which is reflected in the common 
use of adult rodents and primates (Prins and Hovda, 2003). Scientific observers have 
therefore called for more studies focusing on juvenile TBI (Adelson et al., 2003, Taylor, 
2004), especially given that majority of TBI cases occur in children and young adults 
(Langlois et al., 2006, Rutland-Brown et al., 2006, Giza et al., 2007). 
Although preclinical studies on drug agents such as corticosteroids, non-steroidal 
anti-inflammatory drugs (NSAIDs), monoaminergic substances, cyclosporine, and 
cannabinoids for combating post-TBI secondary damage were highly promising, 
randomized control trials on these agents have had mostly negative results (Edwards et 
al., 2005, Beauchamp et al., 2008, CRASH-2, 2011). One of the factors responsible for 
failure of most of these trials may be the inability of the tested drugs to ameliorate BBB 
disruption and edema formation on the brain post-TBI (Vink and Van Den Heuvel, 2004). 
Trials targeting pediatric TBI patients (which are scarce) have also not met with much 
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success (Natale et al., 2006). A search for safe and potent pharmacological agents that 
could act at the level of brain vasculature and ameliorate post-traumatic BBB disruption 
(Shlosberg et al., 2010) is therefore warranted, particularly for the under-researched 
young demographic. It is not a guarantee that a drug that limits BBB disruption and 
edema in juvenile TBI will also be effective in adult TBI, due to potential differences in 
the severity, duration, and mechanisms of BBB disruption and edema following injury to 
the juvenile brain versus adult brain (Giza et al., 2007, Huh and Raghupathi, 2009).  
Another desirable property for any potential pharmacological agent targeting BBB 
damage and edema in jTBI is the ability to act in more than one cell type and attenuate 
multiple secondary injury factors (Vink and Van Den Heuvel, 2004). This is important 
because juvenile TBI, not unlike adult TBI, is a multifactorial and multifaceted 
pathological phenomenon (Anderson and Yeates, 2010) that affects all major cell types 
in the brain (Potts et al., 2006, Chodobski et al., 2011). Moreover, BBB is a dynamic 
interface that is part of the neurovascular unit, and damage to the BBB elicits responses 
from all cell types that are part of that unit (e.g. endothelial cells, astrocytes, microglia, 
pericytes, and neurons [see sections 2.3 and 2.4 above]) (Chodobski et al., 2011). Post-
traumatic cerebral edema and neuroinflammation also affect all cell types in the 
neurovascular unit (Chodobski et al., 2011). Therefore, while the search is not for a 
‘panacea’ – an unrealistic universal drug that ameliorates or cures all pathophysiological 
problems associated TBI in every cell of the developing brain – it is nonetheless 
desirable that potential drugs have multiple targets and regulate signaling cascades that 
are not limited to only one cell type in the brain (Vink and Van Den Heuvel, 2004). 
Yet another coveted property which a new drug should possess if it to be used in 
juvenile TBI cases is the ability to reverse the neurological and cognitive deficits that 
characterize trauma to the developing brain (Adelson et al., 2000, Ajao et al., 2012). The 
long-lasting nature of some of these deficits highlighted earlier in section 1 often leaves 
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survivors of moderate to severe TBI saddled with residual and emergent functional 
problems of sensorimotor, cognitive and psychiatric nature (Max et al., 2000, Yeates et 
al., 2002, Davis and Dean, 2010). The ability to reverse these deficits and restore normal 
function long-term will be suitable for a drug to be used in jTBI cases. 
Two groups of proteins that are of primary interest to this dissertation with respect to 
their potential to influence endothelial barrier permeability, edema formation, and a few 
other pathological processes in the neurovascular unit (such as neuronal apoptosis and 
disruption in cerebral blood flow autoregulation) are caveolins (cav-1, cav-2 and cav-3) 
and c-Jun N-terminal kinases (JNK-1, JNK-2, and JNK-3). Varied isoform mix of 
caveolins and JNKs are present in most of the cell types constituting the neurovascular 
unit (endothelial, neuronal, astrocytic, etc.) and both affect signaling cascades and 
processes in these cell types under physiological and pathological conditions. 
Pharmacological agents that mimic caveolins (see section 4) or inhibit JNKs (see section 
5) are available for use in in vitro and in vivo studies investigating these proteins. These 
agents have potentials for clinical translation. Ultimately, the main focus of this project is 
investigating the roles of caveolins and JNKs in regulating BBB disruption and edema 
formation, and how drugs mimicking or targeting these molecules might correct 
neurological and cognitive deficits following juvenile TBI both short-term and long-term. 
The next two sections provide background information and elaborate on the importance 
of caveolins and JNKs to BBB regulation. 
 
Caveolae and Caveolins in Brain Pathologies 
 Caveolae were first identified and morphologically described almost 
simultaneously by Eichi Yamada (who gave the name ‘caveolae’ which means ‘little 
caves’) (Yamada, 1955) and the late Nobel laureate and cell biologists George E. 
Palade (Palade, 1953) in the early 1950s. Caveolae appear under electron microscope 
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as vesicular plasma membrane invaginations that are usually 50 – 100 nm in diameter 
(Palade, 1953). They are early components of what are later called ‘lipid rafts’ – 
specialized membrane microdomains that are highly enriched in cholesterol, 
glycosphingolipids and glycolipoproteins (Simons and van Meer, 1988, Lajoie and Nabi, 
2010). George Palade proposed the first functional hypothesis for caveolae – 
transcytosis (Travis, 1993), but definitive proof of this was delayed by technical restraints 
for decades until caveolae could be isolated and their structural units examined. 
Caveolins, the integral membrane structural proteins that form oligomeric assemblies 
necessary for the characteristic shape and functions of the caveolae in brain lipid rafts 
(Sargiacomo et al., 1995, Predescu et al., 2007), were discovered in the early 1990s in 
the lab of Dr. Richard G. Anderson (Rothberg et al., 1992). The lab was able to raise 
antibodies which label the caveolae membrane proteins. Research into the molecular 
structure and functions of caveolins blossomed from there onwards. 
The caveolin gene is conserved across various species of metazoan (vertebrate 
and invertebrate animals). It has being studied in some invertebrate (e.g. Apis mellifera, 
honeybee; C. elegans, roundworm; Crassostrea gigas, pacific oyster; etc.) and non-
mammalian (e.g. Danio rerio, zebrafish; Xenopus laevis, frog; etc.) systems.  Amongst 
mammals, caveolin gene and protein products have been studied notably in mice, rats, 
pigs, monkeys and humans (Tang et al., 1997, Schlachetzki and Pardridge, 2003, Spisni 
et al., 2005, Kirkham et al., 2008). There are three main isoforms of caveolins – 
caveolins-1, 2 and 3 – and their presence has been reported in humans and in non-
human species (Scherer et al., 1997, Razani et al., 2002a, Shin et al., 2003). The three 
isoforms enjoy a wide distribution in various tissues and organs of the human body 
(Virgintino et al., 2002, Das et al., 2007a, Tourkina et al., 2008). Whereas all three 
caveolin isoforms are present in the brain, their localization differs.  Caveolins-1 and 2 
usually form hetero-oligomers and predominantly localize to the caveolae (Cohen et al., 
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2004, Schwencke et al., 2006) and some cytosolic organelles such as endoplasmic 
reticulum, mitochondria and Golgi (Li et al., 2001, McCaffrey et al., 2007) in brain 
endothelial cells (Cameron et al., 1997, Virgintino et al., 2002). However, caveolin-1 has 
been found in smaller concentrations in some neurons, astrocytes and ependymal cells 
under both physiological and pathological conditions (Galbiati et al., 1998b, Shin et al., 
2005, Head et al., 2008, Head et al., 2010). Caveolin-3 is predominantly found in 
astrocytes in the brain (Ikezu et al., 1998, Virgintino et al., 2002), and in skeletal, 
cardiac, and smooth muscles in the periphery (Song et al., 1996).  
Early transcription of caveolin gene and expression of its isoforms have been 
observed in several animal models. Cav-1 immunoreactivity in human fetal tissues 
has been observed from mid to late gestation (14 to 39 weeks) in patterns similar to that 
of adult tissues (Barresi et al., 2006). There were, however, some positive staining 
pattern in the fetal tissues (e.g. in urothelium) not seen in adult tissue, which suggests 
novel roles for cav-1 during embryogenesis (Barresi et al., 2006). Cav-1 mRNAs have 
been shown to localize in primitive blood vessels of embryonic mice lungs starting at 
E10 (Ramirez et al., 2002), suggesting that the caveolins are intact at birth in rodents. 
The level of cav-1 mRNAs in rodent cortex peaks at P12 – during active brain 
development (Cameron et al., 1997) – and decreases with age (Head et al., 2010). In 
chicken, cav-3 immunoreactivity was observed as early as E4, when it is localized to the 
neural tube and myotome, and seen in glia of chicken brain at E6 (Shin et al., 2003). 
Cav-3 immunoreactivity changes at various stages of embryogenesis in a non-linear 
manner, suggesting that the gene and protein play active roles in early development 
(Shin et al., 2003). Caveolin-1 was shown to be required for proper dorsoventral 
patterning in zebrafish embryogenesis (Mo et al., 2010). The abnormal phenotypes in 
zebrafish embryos caused by ablation of Cav-1 – which include weak dorsalization, early 
tailbud protrusion, curved bodies, deformed notochord and somites, and shortened tails 
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– were rescued by the expression of human Cav-1, suggesting that cav-1 function is 
conserved in both species (Mo et al., 2010).  
Meanwhile, the caveolins scaffold several signaling molecules through their 
scaffolding domain (CSD) (Sargiacomo et al., 1995, Cameron et al., 1997, Couet et al., 
1997a, Couet et al., 1997c, Garcia-Cardena et al., 1997, Razani et al., 2002b, Lajoie and 
Nabi, 2010). The CSD binds well-defined caveolin-binding motifs (CBM) present in 
signaling proteins, such as protein kinases (Galbiati et al., 1998a, Okamoto et al., 1998) 
and in enzymes such as endothelial nitric oxide synthase (eNOS) (Garcia-Cardena et 
al., 1996, Couet et al., 1997a, Bucci et al., 2000). For instance, in peripheral endothelial 
cells, cav-1, via its CSD, functions as a potent endogenous inhibitor of the p42/44-MAPK 
and JNKs (Wang et al., 2006, Tourkina et al., 2008, Tourkina et al., 2010).  
Furthermore, the binding of caveolin to eNOS through CSD-CBM interaction 
(Garcia-Cardena et al., 1997) is widely implicated in the control of endothelial 
permeability both in the periphery (Bucci et al., 2000, Siddiqui et al., 2011) and in the 
brain (Gu et al., 2011). Synthesis of NO by eNOS is negatively regulated by caveolin-1 
in both brain and peripheral endothelia (Bucci et al., 2000, Bernatchez et al., 2005). 
Thus, cav-1 regulates the concentration of NO – the most potent endogenous 
vasodilator known (Cooke and Dzau, 1997) and a mediator of increased endothelial 
permeability (Lal et al., 2001, Yuan and Rigor, 2010) (See Fig. 2). A synthetic peptide 
(called Cav-AP, cavtratin, or CSD peptide), made by fusing the CSD of caveolin-1 with a 
transporter sequence, is being used to investigate mimicry of cav-1 function in 
experimental studies (Bucci et al., 2000, Argaw et al., 2012). 
Caveolin-1 mRNAs, protein levels, and activation states are changed in response 
to brain injuries such as cold cortical injury (Nag et al., 2007, Nag et al., 2009), brain 
ischemia (Jasmin et al., 2007), and experimental spinal cord injury (Shin et al., 2005, 
Shin, 2007). Decrease in cav-1 has been implicated in neurodegenerative disorders 
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such as Alzheimer’s disease (Head et al., 2010). Increase in cav-1 (Nag et al., 2007) 
and its phosphorylated forms (Nag et al., 2009) was observed up to four days following 
cold cortical injury model in adult rats, and in the clip compression model of spinal cord 
injury in rats (Shin, 2007). These reported changes in cav-1 are usually associated with 
BBB or blood-spinal cord barrier breakdown and vasogenic edema (Shin et al., 2005, 
Nag et al., 2007, Gu et al., 2011, Li et al., 2012). In both the brain and in peripheral 
organs, Cav-1 has been recognized as a potent tumor-suppressor in many forms 
metastatic cancers (Engelman et al., 1998, Gratton et al., 2003, Cohen et al., 2004, 
Williams and Lisanti, 2005). The Cav-1 gene is localized in a tumor suppressor locus at 
7q31.1(Sloan et al., 2004).  There are, however, a few models in which Cav-1 may 
function as a tumor promoter (Williams et al., 2005, Williams and Lisanti, 2005). 
Endothelial caveolins have been associated with various structural components 
and signaling pathways of the BBB [See (Komarova and Malik, 2010) for a recent review 
detailing the roles of caveolins in regulating brain endothelial permeability]. It is well-
established that caveolins regulate the transcellular route of endothelial permeability via 
transcytosis (Komarova and Malik, 2010, Yuan and Rigor, 2010). Transcytosis is a 
process in which solutes can traverse the interior of endothelial cells via receptor-
mediated vesicle endocytosis – a form of transcellular transport – originating at caveolae 
(Predescu and Palade, 1993, Simons and Ikonen, 1997, Predescu et al., 2007) (See 
Fig. 2). However, caveolins also influence the paracellular route of endothelial 
permeability. For instance, claudins and occludins are found in isolated caveolae, where 
they interact with caveolins (Nusrat et al., 2000, McCaffrey et al., 2007, Song et al., 
2007, Stamatovic et al., 2009, Itallie and Anderson, 2012) (See Fig. 2). The level of 
oligomeric claudin-5 and occludin seen in normal brain endothelial caveolae (McCaffrey 
et al., 2007) is reduced during pathological conditions such as hypoxia-reoxygenation 
(McCaffrey et al., 2009). Such reduction engenders tight junction and BBB disruption 
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(McCaffrey et al., 2008). Several receptors and signaling molecules that are known to 
mediate endothelial permeability possess caveolin binding motifs (CBMs) and are 
morphologically and/or biochemically linked with caveolins within the caveolae (See 
Table 1) (Couet et al., 1997a, Couet et al., 1997b, Okamoto et al., 1998, Razani et al., 
2002b, Komarova and Malik, 2010).  
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Table 1: Caveolae-Localized and Caveolin-Interacting Molecules Implicated in 
Mediating Endothelial Permeability. Adapted from (Razani et al., 2002b).  
 
Molecule with 
Caveolar 
Localization 
 
Class 
 
M 
 
B
Interact 
with 
Caveolins
 
References 
Receptor Tyrosine 
Kinase (RTK), e.g. 
VEGFR-2 
Endothelial 
Receptor 
+ + + (Feng et al., 1999a, 
Feng et al., 1999b, 
Labrecque et al., 
2003) 
G-Protein Coupled 
Receptors (GPCR), 
e.g. Bradykinin B2 
receptor 
Endothelial 
Receptor 
+ +  (Haasemann et al., 
1998, Ju et al., 2000, 
Chini and Parenti, 
2004) 
Integrin Receptor Endothelial 
Receptor 
+ + + (Echarri and Del 
Pozo, 2006, Ning et 
al., 2007, Shi and 
Sottile, 2008) 
Calcium Intracellular 
Second 
Messenger 
 + + (El-Yazbi et al., 2008, 
Pani and Singh, 
2009) 
Cyclic AMP (cAMP) Intracellular 
Second 
Messenger 
 + + (Schwencke et al., 
1999, Razani and 
Lisanti, 2001) 
NO-Cyclic GMP 
(NO-cGMP) 
Intracellular 
Second 
Messenger 
 + + (Garcia-Cardena et 
al., 1996, Linder et 
al., 2005) 
Myosin Light-Chain 
Kinase/Phosphotase 
(MLCK/MLCP) 
Protein 
Kinase / 
Phosphotase
 + + (Somara et al., 2011, 
Cunningham and 
Turner, 2012, Rigor et 
al., 2012) 
Protein Kinase C 
(PKC) 
Protein 
Kinase 
+ + + (Lisanti et al., 1994, 
Oka et al., 1997, 
Rybin et al., 1999) 
Focal Adhesion 
Kinase (FAK) 
Protein 
Kinase 
 + + (Lee et al., 2002, 
Pelkmans et al., 
2005) 
Rho Family 
GTPases 
Protein 
Kinase 
 + + (Somara et al., 2011) 
Matrix 
Metalloproteinases 
(MMPs), e.g.  MMP-
2 and MMP-9 
                  
Protease 
 + + (Puyraimond et al., 
2001, Phillips and 
Birnby, 2004) 
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A Disintegrin and 
Metalloproteases 
(ADAMs) 
Protease  + + (Wilke and Bubeck 
Wardenburg, 2010) 
Fibrinogen Extracellular 
Matrix Protein 
+ +  (Kurozumi et al., 
1983) 
Bradykinin Endogenous 
Vasoactive 
substance 
 + + (Liu et al., 2010) 
Vascular Endothelial 
Growth Factor 
(VEGF) 
Endogenous 
Vasoactive 
substance 
 + + (Feng et al., 1999a, 
Feng et al., 1999b, 
Bauer et al., 2005) 
Nitric Oxide (NO) Endogenous 
Vasoactive 
substance 
 + + (Garcia-Cardena et 
al., 1996, Bernatchez 
et al., 2005, Linder et 
al., 2005) 
Endothelial Nitric 
Oxide Synthase 
(eNOS) 
Endogenous 
Vasoactive 
substance 
 + + (Garcia-Cardena et 
al., 1997, Bucci et al., 
2000) 
Sphingosine-1-
Phosphate (S1P) 
Endogenous 
Vasoactive 
substance 
 + + (Rosen and Goetzl, 
2005, Singleton et al., 
2006, Yuan and 
Rigor, 2010) 
Angiopoietin-1    
(Ang-1) & Tie-2 
Endogenous 
Vasoactive 
substance 
+ + + (Yoon et al., 2003) 
      
 
  M = morphological evidence; B = biochemical evidence 
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Strong evidence has also emerged from several in vivo and in vitro brain 
endothelial and brain disease models that support beneficial roles for caveolins in the 
maintenance of TJ proteins (Jasmin et al., 2007, Song et al., 2007, Gu et al., 2011). In 
an in vivo brain inflammatory model, VEGF-A was found to reduce claudin-5 expression 
and induce BBB disruption by signaling through VEGF-2 receptor (VEGFR2) and eNOS 
(Argaw et al., 2012). Both VEGFR2 and eNOS are negatively regulated by caveolin 
(Garcia-Cardena et al., 1996, Feng et al., 1999a) and by cavtratin (Bucci et al., 2000, 
Gratton et al., 2003). Cavtratin also reverses VEGF-mediated decrease in claudin-5 
expression (Argaw et al., 2012). This observation, however, is by no means universal, as 
some reports have suggested that caveolin-1 could play a less beneficial role (e.g. 
redistribution of claudin-5 and occludin, which may lead to transient increase in BBB 
permeability early on after brain insults) at least transiently in some models such as in 
vitro inflammatory and drug-stimulated models of brain endothelial cells (Stamatovic et 
al., 2009, Park et al., 2011) and in early ischemic stroke models (Liu et al., 2012). This 
highlights the need to investigate the physiologic roles of caveolins and their potential 
roles in human pathology (Minshall et al., 2003, Sellers et al., 2012). 
Interestingly, cav-1 knockouts (-/-) mice display unique defects that include 
impaired angiogenic response (Woodman et al., 2003), aberrations in endothelium-
dependent relaxation, contractility and vascular tone (Drab et al., 2001, Razani et al., 
2001), and, importantly, microvascular hyperpermeability (Schubert et al., 2002). The 
increased microvascular permeability was observed in peripheral organs (lung, heart, 
spleen, kidney, liver, and skeletal muscle) and in the brain (there is a two-fold increase in 
the level of extravasated radio-iodinated BSA in the brains of cav-1 knockout mice) 
(Schubert et al., 2002). In vivo knockdown of cav-1 expression in mouse lung endothelia 
with siRNA resulted in dilated interendothelial junction, with concomitant increase in lung 
vascular permeability to albumin and increased plasma NO concentration (Miyawaki-
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Shimizu et al., 2006). In an ischemic stroke study in mice, cav-1 knockouts have worse 
outcome than the wild-type (WT), with increased cerebral volume of infarction, impaired 
cerebral angiogenesis, and increased cerebral apoptotic cell death (Jasmin et al., 2007).  
Stimulation of brain microvascular endothelial cells (BMECs) with the chemokine 
CCL2 reduces expression of cav-1, accompanied with decrease in the expression of 
occludin (Song and Pachter, 2004, Song et al., 2007).  Although, a sharp increase in 
cav-1 level has been reported to precede the decrease in expression of claudin-5 and 
occludin in cold cortical injury models in adult rats (Nag et al., 2007), there are no 
definitive proofs that increase in cav-1 in this model is altogether detrimental. 
Furthermore, in a cerebral ischemic-reperfusion injury model, Gu and colleagues 
demonstrated extensively that Cav-1 plays a critical role in protecting BBB integrity 
through inhibition of MMPs activity in brain microvessels and other brain tissues (Gu et 
al., 2011, Gottschall and Barone, 2012). This is through cav-1’s inhibition of eNOS 
activity and resultant reduction of NO production – overproduction of NO has been 
shown to increase MMP-9 activity (Gursoy-Ozdemir et al., 2000, Gursoy-Ozdemir et al., 
2004). Exposure of human brain endothelial cells (HBMEC) to high concentration of 
unconjugated bilirubin (a model to mimic hyperbilirubinemia) acutely increases the 
expression of endothelial caveolin-1 with intact tight junction integrity, whereas 
prolonged exposure results in reduction in caveolin-1 expression and tight junction 
compromise (Palmela et al., 2012). The putative beneficial role of cav-1 in these models 
is possibly related to its regulation of the phosphorylation states, distribution, and 
oligomerization of TJ proteins, all of which are essential in maintaining functional inter-
endothelial TJs (Kachar and Reese, 1982, McCaffrey et al., 2007, Stamatovic et al., 
2009, Wolburg et al., 2009).   
Regulation of brain endothelial permeability is undoubtedly a complex process 
with intricately interwoven molecular players and mechanisms (Abbott et al., 2006, 
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Shlosberg et al., 2010, Yuan and Rigor, 2010). In addition to factors that have been 
mentioned previously, JNK activation appears to contribute tremendously to TJ and BBB 
disruption in some brain disease models (Tai et al., 2010, Tu et al., 2011). The 3 JNK 
isoforms are known to have well-conserved caveolin-binding motif (CBM) (Okamoto et 
al., 1998). Cav-1 inhibits JNK activation endogenously in the periphery, such as in 
models of fibrotic lung disease (Tourkina et al., 2008) and in cardiac ischemic-
reperfusion (IR) injury (Das et al., 2007b). Such JNK inhibition has been shown to result 
in increased expression and strengthening of tight junction proteins in the periphery 
(Kojima et al., 2010, Samak et al., 2010). Furthermore, cav-1 inhibits the expression of 
proinflammatory cytokines in macrophages and endothelial cells in part by regulating 
JNK activation (Wang et al., 2006). A drug that restored caveolin-1 expression in a 
mouse model of pulmonary inflammation and fibrosis was also found to simultaneously 
inhibit MAPK activation, including JNK activation (Meng et al., 2012). This evidence 
opens up the possibility that endogenous interaction between cav-1 and JNK within brain 
endothelial cells may influence BBB permeability. The role of caveolin-1 in mediating 
JNK inhibition is yet to be researched in brain trauma models. 
The roles of caveolin in regulating both transcellular and paracellular routes of 
endothelial permeability continues to be under investigation in some models (Minshall et 
al., 2003, Komarova and Malik, 2010). However, to date, there are no reported studies 
that characterize the expression of brain endothelial caveolins in a juvenile model of TBI 
in association with BBB dysfunctions.  There have also been no reports on how drugs 
that target or mimic the caveolins (e.g. cavtratin) impact histological, neurological and 
cognitive outcomes following juvenile TBI. 
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The c-Jun N-terminal Kinases (JNKs): Expression and Inhibition 
following Brain Injuries 
The c-Jun N-terminal kinases (JNKs) were first described in the early 1990s as 
consisting of serine/threonine protein kinases which phosphorylate the N-terminal 
transactivation domain of the c-Jun transcription factor upon activation by stress stimuli 
(Pulverer et al., 1991, Derijard et al., 1994). JNKs are members of a mitogen activated 
protein kinase (MAPK) subfamily. The other two MAPK subfamilies are p38 and ERK 
(Widmann et al., 1999, Plotnikov et al., 2011). There are three JNK genes – JNK1, JNK2 
and JNK3 (Pulverer et al., 1991, Derijard et al., 1994, Kallunki et al., 1994, Gupta et al., 
1996). Alternative splicing of these genes yield 10 identified JNK isoforms (Waetzig and 
Herdegen, 2005). All 3 JNK genes are highly conserved across various species ranging 
from yeast to mammals (Goberdhan and Wilson, 1998, Kirkham et al., 2008).  
In mammals, JNK1 and JNK2 are ubiquitously expressed, while JNK3 is primarily 
expressed in the heart, brain, endocrine pancreas and testis (Waetzig et al., 2006). 
JNKs are found in various cell types in the brain, including neurons (Lannuzel et al., 
1997, Herdegen et al., 1998), endothelial cells (Etienne et al., 1998, Waetzig et al., 
2006), and astrocytes (Migheli et al., 1997, Xie et al., 2004). Basal JNK activity level in 
the brain is 15 to 30-fold higher than in other tissues under physiological conditions (Xu 
et al., 1997, Coffey et al., 2000). JNKs in the brain are activated even further following 
external stimuli and pathological events (Borsello and Bonny, 2004). 
 JNKs are activated by dual phosphorylation of threonine (Thr) and tyrosine (Tyr) 
residues within a unique Thr-Pro-Tyr motif located in subdomain VIII of the kinases (Ip 
and Davis, 1998). This phosphorylation is catalyzed by upstream kinases – MKK 4 and 7 
(Widmann et al., 1999, Kyriakis and Avruch, 2001, Waetzig et al., 2006). A wide range of 
environmental and biological stressors are capable of activating JNKs, and these include 
UV light, inflammatory cytokines, reactive oxygen species (ROS), growth factors, protein 
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synthesis inhibitors, as well as physical and biomechanical perturbations (Davis, 1999, 
Borsello and Bonny, 2004). JNKs can also be deactivated by some specific 
phosphatases (Palacios et al., 2001, Masuda et al., 2010).  
In terms of function, JNKs are essential for normal brain development and 
organogenesis in general during embryonic development (Haeusgen et al., 2009). 
Postnatally, JNKs play various roles ranging from regulation of cell survival and 
apoptosis to proliferation (Nishina et al., 2004, Waetzig and Herdegen, 2005, Waetzig et 
al., 2006, Haeusgen et al., 2009). They are also activated under pathological conditions 
both in the brain (Brecht et al., 2005, Bogoyevitch, 2006) and in the periphery (Cui et al., 
2007, Chaudhury et al., 2010). 
Most of the studies on JNK pathway in rodent brains have focused predominantly 
on neuronal activation triggered by excitotoxic events (Lennmyr et al., 2002, Borsello et 
al., 2003, Cui et al., 2007, Haeusgen et al., 2009). There is however increasing evidence 
that JNK is also activated in glial cells (Xie et al., 2004) and brain endothelial cells (Lo et 
al., 2005, Kacimi et al., 2011), and that such activation in non-neuronal cells negatively 
impacts neuronal cell death and function (Xie et al., 2004). Zhu and colleagues (2003) 
reported the hyperactivation of JNK in murine cerebral microvascular endothelial 
(bEND.3) cells in vitro. Such overt JNK hyperactivation in brain endothelial cells has 
been implicated in clinical pathologies including Alzheimer’s disease, strokes and 
multiple sclerosis (Vukic et al., 2009, Grammas, 2011). Kusaka et al (2004) reported an 
acute hyperactivation of JNK following subarachnoid hemorrhage (SAH) in rat brain 
endothelium. Benakis et al (2010) reported the modulation of non-neuronal inflammatory 
processes in the brain by DJNKI-1, a competitive JNK inhibitor that was injected 
peripherally. Studies have indicated that DJNKI-1 crossed the BBB and penetrated the 
cerebral cortex within 1.5 hours after intraperitoneal (i.p.) injection in rodents, and could 
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remain stable in brain parenchyma for at least 3 weeks (Repici et al., 2007, Ploia et al., 
2011, Sclip et al., 2011).  
Experimental and clinical observations show that JNK phosphorylation initially 
drops, but begins to rise at 1.5 hours and peaks at 9 hours after stroke (Gao et al., 
2005). Phosphorylation of c-Jun, a JNK substrate, follows a similar pattern, peaking at 8 
hours post-stroke (Borsello et al., 2003, Gao et al., 2005). Activation of JNK in ischemic 
strokes has been linked with mitochondrial apoptotic pathway and nuclear translocation 
of MADD (MAP kinase-activated death domain-containing protein) in neurons (Putcha et 
al., 2003, Centeno et al., 2007). Increase of Phospho-JNK was also reported in the brain 
tissues from 6 TBI patients, and experimental reports have confirmed this increase from 
1 to 48 hours post-injury in a CCI model in adult mice (Ortolano et al., 2009). 
Hyperactivation of JNK in CNS pathologies has been linked with BBB disruption (Tu et 
al., 2011). 
The inhibition of JNK pathway has been shown to be beneficial in some models 
of adult and juvenile brain damage. Borsello et al (2003) reported that the competitive 
JNK-inhibitor, DJNKI-1, protects against NMDA-induced neurotoxicity in hippocampal 
neurons cultured from 2-day old rat pups. Using the drug (DJNKI) after TBI in newborn 
piglets, Armstead et al (2011a) showed that inhibiting the JNK pathway mitigates 
cerebral hemodynamic dysfunctions observed in jTBI. Moreover, deletion of JNK3 gene 
protects neonatal mice against cerebral hypoxic-ischemic (HI) injury (Kuan et al., 2003, 
Pirianov et al., 2007). Tu et al (2011) also showed that in overweight rat pups (P7 and 
P21), experimental HI brain injury results in BBB breakage strongly mediated by JNK 
overactivation.  
Experimental evidence suggests that JNK hyperactivation will likely increase 
endothelial hyperpermeability both in the periphery (Chen et al., 2006, Hu et al., 2013) 
and in the brain (Yatsushige et al., 2007, Tu et al., 2011) (See Fig. 3). Activated JNK 
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and its substrates (e.g. phosphorylated c-Jun) are strong regulators of TJ proteins in the 
periphery (Betanzos et al., 2004, Carrozzino et al., 2009, Kojima et al., 2010, Samak et 
al., 2010). For example, inhibition of JNK pathway in mammary epithelial cells enhances 
TJ barrier function through modulation of claudin-5 expression (Carrozzino et al., 2009). 
Furthermore, the protein c-Jun, a substrate phosphorylated by JNK, exerts regulatory 
control on TJ proteins in epithelial cells (Betanzos et al., 2004). In human pancreatic 
cells, JNK strongly regulates TJ proteins at the tricellular contacts (Kojima et al., 2010). 
With regard to brain endothelial cells, activation of JNK and c-Jun has been shown in 
vitro to increase cerebral endothelial cell permeability through disruption of 
interendothelial TJ complexes (Etienne et al., 1998, Adamson et al., 1999, Wolburg and 
Lippoldt, 2002).  
Meanwhile, certain molecular mediators of endothelial hyperpermeability known 
to interact with caveolins are also linked with increased JNK activation under 
pathological conditions such as inflammation. These include VEGF and VEGFR2 (Upon 
ligand binding, VEGFR2 activates multiple protein kinase-dependent signaling including 
JNK pathway to induce hyperpermeability) (Kumar et al., 2009), protein kinase C (PKC) 
(Yuan and Rigor, 2010), and src-kinase (Yoshizumi et al., 2000) (See the preceding 
section above for literature evidence of links between JNKs and caveolae/caveolins). 
Inhibitors of JNK pathway have been shown to reduce and reverse TJ disruption in 
injured brain-derived endothelial cells through decreased inducible nitric oxide synthase 
(iNOS) activation and NO production (Kacimi et al., 2011). Furthermore, under 
inflammatory condition in human lung microvascular endothelial cells, bradykinin 
potentiates eNOS-derived NO generation in part through JNK signaling (Lowry et al., 
2013). Hence, mounting evidence suggests that caveolins and JNKs both play key roles 
in mediating the eNOS-NO pathway in the endothelium (Minshall et al., 2003, Balligand 
et al., 2009). JNK is also highly activated in laminar shear stress experiments performed 
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on endothelial cells (Yoshizumi et al., 2003) with concomitant increase in caveolins and 
caveolae number (Frank and Lisanti, 2006). 
Recovery of neurological and cognitive function in both the short- and long-term 
is a desirable property for any pharmacological agent to be used for juvenile TBI. To this 
end, it is important to note that DJNKI-1, a competitive JNK inhibitor (see below), has 
been shown to ameliorate behavioral deficits in experimental models of stroke (Esneault 
et al., 2008), neuroinflammation (Palin et al., 2008), and spinal cord injury (Repici et al., 
2012) in adult rodents, even when injected peripherally. D-JNKI-1 was also successfully 
used to arrest the progression of hearing loss in a model of cochlear implantation trauma 
(Eshraghi et al., 2006). The action of DJNKI-1 in various forms of CNS injuries possibly 
extend beyond brain endothelial cells (where it could reduce BBB disruption) (Tu et al., 
2011, Repici et al., 2012) to neurons (where it reduces excitotoxicity and neuronal cell 
death) (Borsello et al., 2003), astrocytes (Huang et al., 2009, Kang et al., 2011), and 
microglia (Repici et al., 2012). Hence, DJNKI-1 could potentially mitigate several aspects 
of secondary brain damage in various cells simultaneously to maximize recovery. 
Meanwhile, the possibility of systemic mode of action for DJNKI-1, which is beneficial to 
recovery, has been raised in some in vivo experimental studies (Lehnert et al., 2008, 
Touchard et al., 2010, Benakis et al., 2012).  
The drug, DJNKI-1, is a synthetic, protease-resistant and cell-penetrating peptide made 
by linking HIV-TAT transporter peptide sequence to the 20-amino acid JNK-binding motif 
of JIP-1 (Borsello et al., 2003). The D-retro-inverso synthesis (i.e. made with D-amino 
acids) of DJNKI-1 gives it strong resistance against proteolytic degradation and 
increases its stability in the body (Borsello et al., 2003, Borsello and Bonny, 2004).  The 
peptide functions through competitive inhibition of all JNK isoforms (see Fig. 3).  DJNKI-
1 selectively blocks access of JNK to c-jun and other downstream substrates such as 
JunB, JunD, and c-myc by competing for the JNK-binding site of JIP-1(Borsello et al., 
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2003, Borsello and Forloni, 2007) (see Fig. 3). The potential for therapeutic 
effectiveness of DJNKI-1 in jTBI is pegged on its ability to modulate upstream and 
downstream arms of the secondary injury cascade, including excitotoxicity, hypoxia-
ischemia, BBB disruption, edema, neuroinflammation and apoptosis (Yang et al., 1997, 
Kuan et al., 2003, Tu et al., 2011).  
 
Research Aims 
Juvenile TBI is a field that has not been well-researched, and in which no 
pharmacological agent has been successfully translated for clinical use. A reliable and 
reproducible animal model of jTBI is needed as a starting point to test various 
hypotheses.  A controlled cortical impact (CCI) model of TBI [modeled after one 
described by Brody et al. (2007)] in juvenile (P17) rats has been developed for this 
purpose (Ajao et al., 2012). This model could be used to probe the effects of juvenile TBI 
on neurobehavioral function, brain morphology and molecular structures. Effects of jTBI 
on brain structures and functions at both acute and latter time point(s) need to be 
thoroughly studied to enhance the clinical relevance of the model. For instance, effect of 
TBI on the morphology and function of the developing white matter is not well studied. 
Neurological and cognitive tests could also be carried out longitudinally to establish 
functional deficits resulting from brain injury in this model. 
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Having established the relevance of caveolin-1 and JNK activation to secondary 
events that occur in juvenile brain injury in the preceding sections, the CCI model could 
be used to study changes in protein expression of caveolin-1 and activation of JNK 
following jTBI.  Moreover, the potential therapeutic effects (functional and/or histological) 
of pharmacological mimicry of caveolin function and inhibition of JNK could be examined 
with the use of cavtratin and DJNKI-1 respectively on jTBI animals. The role caveolin-1 
and JNK activation are playing in aggravating or reversing BBB disruption could be 
studied with the use of cavtratin and DJNKI-1 respectively. 
Literature evidence reviewed so far suggest parallel molecular pathways that link 
endothelial caveolins and JNKs to the control of paracellular and transcellular 
permeability pathways, which may have important consequences on BBB integrity and 
TBI outcome. This theory has never been examined in the context of jTBI. We therefore 
hypothesize that:  
 
Following juvenile TBI, upregulation and activation of caveolins-1 in brain 
endothelial cells endogenously attenuate BBB disruption and edema, while JNK 
hyperactivation exacerbates BBB disruption, with concomitant morphological 
damage and functional deficits in the short- and long-term.  
 
This hypothesis will be tested in controlled cortical impact (CCI) model of TBI in 
juvenile (P17) rats. The questions raised above will be explored under the following 
three aims.  
 
Aim 1: Characterize the acute and long-term neurological, electrophysiological 
and histological changes following juvenile TBI.   
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Hypothesis: Induction of controlled cortical impact injury in P17 rat pups will engender 
observable adverse outcomes on neurological function and on brain tissue properties 
that will last for weeks after the initial insult.  
A battery of neurological and cognitive tests will be carried out longitudinally on rats 
subjected to CCI and on their sham counterparts. Electrophysiological profiles of these 
rats as well as their histology will be observed from juvenile period into early adulthood. 
Lesion volume and T2 changes will also be measured. 
  
Aim 2:  Characterize changes in the expression pattern and immunoreactivity of 
caveolins-1, 2, and 3 after juvenile TBI in conjunction with BBB disruption and 
edema formation. 
Hypothesis: Decrease in the tight junction protein levels and resultant opening of the 
BBB will be associated with increase in the expression of caveolins-1, 2 and 3 in brain 
endothelial cells following juvenile TBI.  
The expression level of caveolins will be determined via immunohistochemistry and 
immunoblotting at 1, 3, 7 and 60 days post-jTBI. BBB disruption will be confirmed via 
IgG staining and edema formation will be assessed with MRI.  
 
Aim 3:  Examine the effect of DJNKI-1 treatment (JNK Inhibition) and cavtratin 
treatment (pharmacological mimicry of caveolin scaffolding domain) on BBB 
integrity and caveolin-1 expression following juvenile TBI.       
Hypothesis: Inhibition of JNK pathway and treatment with cavtratin will reduce and 
reverse damage to tight junction proteins and prevent BBB disruption.   
A cohort of rats will receive i.p. injection of DJNKI-1 after jTBI. A separate cohort of 
rats will be treated with cavtratin following jTBI. Changes in the expression of the TJ 
proteins, caveolin-1 and BBB properties will be assessed at 1, 3, 7, 60 days after injury. 
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MRI will be used to assess brain water diffusion and edema formation. 
  
The diagrammatic representation below (Fig. 4) highlights the key players examined 
in this project, and illustrates the hypothesized mechanism and effects of the two 
pharmacological agents used – DJNKI-1 and cavtratin (CSD peptide). 
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PROLOGUE TO CHAPTER 2A 
TRAUMATIC BRAIN INJURY IN YOUNG RATS LEADS TO 
PROGRESSIVE BEHAVIORAL DEFICITS COINCIDENT WITH 
ALTERED TISSUE PROPERTIES IN ADULTHOOD 
 
Chapter 2 describes the progressive behavioral deficits resulting from juvenile 
brain trauma, and their associated morphological and molecular changes, in a rodent 
model. The clinical relevance of emergent motor and behavioral impairments that 
persists for months in rodents that were subjected to focal brain injury is emphasized. 
The chapter highlights the vulnerability of the developing brain to TBI.  
The aim of this chapter is to characterize the acute and long-term histological 
and neurological changes that occur in juvenile TBI using a customized controlled (CCI) 
model in P17 rats. Morphological and molecular changes in both gray (e.g. at the lesion 
and perilesion cortex) and white matter (especially the corpus callosum) structures were 
examined over a 60-day (d) post-injury period. Changes in injury volume across 60 post-
injury days, as well as electrophysiological changes were also investigated. A battery of 
tests was employed to examine neurological and behavioral outcomes following juvenile 
TBI over the 60d period. The hypothesis for this chapter is that induction of CCI in P17 
rat pups will engender observable and testable adverse outcomes on neurological and 
behavioral functions, and on brain tissue properties, which will last for weeks following 
the initial insult. The chapter justifies the suitability of the CCI model for carrying out 
testing of drugs aimed at limiting secondary injury processes, and improving histological 
and functional outcomes. 
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This chapter has been published as a scientific article in the July 20, 2012 edition 
of the Journal of Neurotrauma (volume 29, pages 2060 - 2074) under the same title as 
above. It is complete with abstract, introduction, methods, results and discussion 
sections. There are 8 figures with detailed figure legends in the manuscript. The authors 
of the manuscript and their professional affiliations are listed on the first page. 
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Abstract 
Traumatic brain injury (TBI) affects many infants and children, and results in 
enduring motor and cognitive impairments with accompanying changes in white matter 
tracts, yet few experimental studies in rodent juvenile models of TBI (jTBI) have 
examined the timeline and nature of these deficits, histologically and functionally. We 
used a single controlled cortical impact (CCI) injury to the parietal cortex of rats at post-
natal day (P) 17 to evaluate behavioral alterations, injury volume, and morphological and 
molecular changes in gray and white matter, with accompanying measures of 
electrophysiological function. At 60 days post-injury (dpi), we found that jTBI animals 
displayed behavioral deficits in foot-fault and rotarod tests, along with a left turn bias 
throughout their early developmental stages and into adulthood. In addition, anxiety-like 
behaviors on the zero maze emerged in jTBI animals at 60 dpi. The final lesion 
constituted only ~3% of brain volume, and morphological tissue changes were evaluated 
using MRI, as well as immunohistochemistry for neuronal nuclei (NeuN), myelin basic 
protein (MBP), neurofilament-200 (NF200), and oligodendrocytes (CNPase). White 
matter morphological changes were associated with a global increase in MBP 
immunostaining and reduced compound action potential amplitudes at 60 dpi. These 
results suggest that brain injury early in life can induce long-term white matter 
dysfunction, occurring in parallel with the delayed development and persistence of 
behavioral deficits, thus modeling clinical and longitudinal TBI observations. 
 
Key words  
Behavior; CNPase; juvenile traumatic brain injury; magnetic resonance imaging; myelin; 
neurofilament-200 
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Introduction  
Traumatic brain injury (TBI) in children is a major cause of death and disability 
(Schneier et al., 2006, Kuppermann et al., 2009), and it has been suggested that 
developmental neuroplasticity assists in the recovery of younger individuals (Jane and 
Francel, 1996, Giza and Prins, 2006). However, clinical and experimental reports 
indicate that TBI results in lasting structural and functional damage. Clinically, TBI to the 
frontal cortex has been associated with disruptions in motor function, problem solving, 
spontaneity, memory, judgment, impulse control, and social behavior (Levin et al., 1987). 
Although the underlying cellular and molecular pathophysiology is not fully understood, 
post-TBI behavioral deficits such as aggressive behavior, anxiety, and depression, as 
well as an increased risk for epilepsy may last for months to years (Fujii and Ahmed, 
2002, Giza and Prins, 2006, Lippert-Gruner et al., 2006). Only a small number of 
experimental TBI studies have evaluated and shown extended behavioral deficits (Prins 
and Hovda, 1998, Adelson, 2000, Huh and Raghupathi, 2007). Little is known about 
changes in the tissue properties in association with behavioral modifications. 
Several clinical and experimental observations have shown that white matter 
tracts are highly vulnerable to TBI-induced secondary injury, and that their damage may 
contribute to cognitive deficits after TBI (Huh and Raghupathi, 2007, Levin et al., 2007, 
Wagner et al., 2007). Post-natal day (P) 17 in rats, which corresponds to the juvenile 
population, is a critical myelination period, as it marks the peak of myelin basic protein 
(MBP) synthesis in the developing rat brain (Bjelke and Seiger, 1989, Akiyama et al., 
2002). Previous studies have shown changes in myelination after environmental stress 
in rats at P17, including changes in MBP (Kodama et al., 2008). Early life stress, such as 
premature weaning at P17, has been associated with increased anxiety and increased 
MBP in adulthood (Kodama et al., 2008). To date, experimental juvenile TBI studies 
have not focused on the timeline of the behavioral deficits seen in association with 
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alterations in white and gray matter tissue properties using a combinatorial approach of 
magnetic resonance imaging (MRI), immunohistochemistry, and electrophysiology. 
The clinical literature led us to hypothesize that an early-life injury such as TBI 
would elicit enduring behavioral deficits associated with functional and morphological 
changes in the brain tissue that persist into adulthood. We used a single controlled 
cortical impact (CCI) injury to the parietal cortex of P17 rats, at an age of active myelin 
sheath formation, and evaluated the animals over a period of 60 days post-injury (dpi). 
We carried out a large battery of behavioral tests to assess a wide spectrum of motor 
and cognitive functions, and each of the tests that we employed measured a unique 
aspect of the spectrum of deficits reported after juvenile TBI (jTBI) in humans. We used 
MRI to evaluate anatomical changes (areas of lesion and corpus callosum [CC]). Tissue 
was collected to assess morphological and molecular changes in gray and white matter, 
as well as for in vitro axonal conductivity. We present findings of extended behavioral 
deficits coincident with significant changes in white matter tract properties observed in 
adulthood, and characterized using MRI, immunohistochemistry, and electrophysiology. 
 
 
Methods 
Animals 
All protocols and procedures were approved by the Institutional Animal Care and 
Use Committee of Loma Linda University, and are in compliance with the U.S. 
Department of Health and Human Services Guide. Juvenile male Sprague-Dawley rats 
(P17; Harlan, Indianapolis, IN) were housed with their dams on a 12-h light-dark cycle at 
constant temperature and humidity. Pups were weaned at P24, housed two rats per 
cage, and fed with standard lab chow and water ad libitum. All groups of animals used in 
the study had identical sham or CCI surgical parameters. One group of animals (n = 8 
sham, n = 7 CCI) was studied longitudinally for MRI (3, 30, and 60 dpi), and all 
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behavioral tests (3, 7, 30, and 60 dpi). At 60 dpi, a final immunohistochemistry study was 
carried out on sham (n = 5) and CCI (n = 6) animals. Additional groups of animals were 
evaluated at each time point for immunohistochemistry at 3 dpi (n = 3 sham, n = 4 CCI), 
7 dpi (n = 5 sham, n = 5 CCI), and 30 dpi (n = 5 sham, n = 5 CCI), and for 
electrophysiology at 60 dpi (n = 4 sham, n = 4 CCI). 
 
Juvenile Traumatic Brain Injury Model 
CCI was induced in juvenile rats as previously described in our adult experiment 
(Obenaus et al., 2007). Briefly, P17 juvenile rats were anesthetized with isoflurane 
(Webster Veterinary Supply, Inc., Sterling, MA) and placed in a mouse stereotaxic frame 
(David Kopf Instruments, Tujunga, CA). Following a midline skin incision over the skull, a 
5-mm craniotomy was performed over the right fronto-parietal cortex (bregma: 1mm 
anterior-posterior and 2mm medial-lateral). CCI was accomplished using a 3-mm 
rounded-tip metal impactor fixed to an electromechanical actuator and centered over the 
exposed dura at a 20o angle to be parallel to the cortical surface (Leica Microsystems 
Company, Richmond, IL). The CCI was delivered at a 1.5-mm depth from the cortical 
surface with impact duration of 200 msec at a velocity of 6 m/sec. The surgical site was 
sutured after recording any bleeding or herniation of cortical tissues. Body temperature 
was maintained at 37oC during surgery. Buprenorphine (0.01 mg/kg; dilution: 0.01 
mg/mL) was injected subcutaneously for pain relief before the animals were returned to 
their dams. The sham animals underwent identical procedures except for the cortical 
impact. 
 
Magnetic Resonance Imaging and Analysis 
MRI was performed in vivo at 3 and 30 dpi followed by high resolution ex vivo 
imaging at 60 dpi as previously described (Badaut et al., 2007). For in vivo MRI, rats 
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were anesthetized using isofluorane (1-2%), placed in a temperature controlled cradle 
containing a volume radiofrequency (RF) coil and imaged on a 11.7T MRI (8.9 cm bore,) 
or on a larger bore (40 cm) 4.7T MRI (Bruker Biospin, Billerca, MA) based on the size of 
the animals. T2 weighted imaging (T2WI) to determine TBI volume was acquired using: 
a repetition time/echo time (TR/TE) = 3278.3/20 ms; 256 X 256 matrix; 1 mm slice 
thickness; 1 mm interleaved; average of 2 acquisitions; number of slices = 20; and a field 
of view (FOV) = 2.2 cm for a total imaging time of 28 min on 11.7T MRI; and a repetition 
time/echo time (TR/TE) = 3563.4/20 ms; 256 X 256 matrix; 1 mm slice thickness; 1 mm 
interleaved; average of 2 acquisitions; number of slices = 25; and a field of view (FOV) = 
2.8 cm for a total imaging time of 30 min on 4.7T MRI.  The utilization of two different 
field strengths did not alter the measurements performed in our experiments (Obenaus 
et al., 2011). 
For ex vivo MRI, animals were transcardially perfused with 4% paraformaldehyde 
(PFA) prepared in phosphate buffered saline (PBS), the brains were immersed in same 
solution overnight, and then transferred to PBS with sodium azide (0.1%) before ex vivo 
scanning using the 11.7T magnet. T2WI was acquired using: a repetition time/echo time 
(TR/TE) = 3278.3/20 ms; 256 X 256 matrix; 1 mm slice thickness; 1 mm interleaved; 
average of 2 acquisitions; number of slices = 20; and a field of view (FOV) = 2.2cm for a 
total imaging time of 28 min on 11.7T MRI. We previously reported no volumetric 
differences between in vivo and ex vivo MRI (Obenaus et al., 2011). Volumetric analyses 
of the total brain volume and percent lesion/brain volume were performed on T2WI using 
Cheshire image processing software (Hayden Image Processing Group, Waltham, MA) 
and Amira (Mercury Computer Systems, Visage Imaging, Inc., San Diego, CA, USA). 
Lesion volume was defined as those regions containing abnormal hypo- and/or hyper-
intense signals. All tissue below the skull level was included, but in the rare instances 
when tissue herniated and extended above the level of the skull, it was excluded.  Injury 
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volume was adjusted using total brain volume to correct for individual differences and 
age-related brain growth. Area measurements of the CC at 60 dpi were selected from 
the MR images at bregma level +1 mm, anterior to the lesion, and included all visible 
portions of the CC.  The coronal section with the same visible anatomical landmarks was 
chosen for analysis for all animals by a blinded experimenter. 
Behavioral Testing 
All behavioral tests at each time-point were carried out on sham and CCI animals 
within a 3-hour morning time-block (8 – 11 am). Sham and CCI animals were interleaved 
in testing sequence. 
 
Foot-fault  
Foot-fault testing was carried out on an elevated wire mesh (2.5 cm X 30 cm 
rectangular holes/grid spacing) raised 76 cm above the floor at 1, 3, 7, and 60 dpi. Rats 
were placed in the middle of the wire mesh and movements were video-recorded for a 
period of 60 sec in two separate trials, 30 min apart (Schmanke et al., 1996). When a 
rodent’s paw slipped completely through the wire mesh, it was considered as an 
individual fault. The average foot-fault score was calculated from the total number of 
faults from two 60 sec trials, and a percentage was calculated from sham levels. 
 
Beam Balance  
A square Plexiglas beam balance (61 cm long) labeled in 2.5 cm increments was 
employed in these experiments. Juvenile animals were tested on a 0.65 cm wide beam 
at 1, 3, and 7 dpi, and adult animals were tested on a 2.5 cm wide beam at 30 and 60 
dpi according to size requirements. Animals were placed at the midpoint of the beam, 
perpendicular to the longitudinal axis, and allowed to walk unrestricted in either direction 
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for 60 sec, with two trials 20 min apart. The number of falls, total time spent on the 
beam, and the distance covered by each animal was recorded. 
 
Rotarod 
Rotarod evaluation was performed on all the animals at 30 and 60 dpi (Rotamex-
5, Columbus Instruments, Columbus, OH). A rotating 7 cm-wide spindle, accelerating at 
a rate of 2 RPM every 5 sec until the animals fell off, was used to evaluate performance 
during two trials (15 min apart). Latency to fall was recorded as a measure of motor 
coordination and balance (Recker et al., 2009), and the two fall latencies were averaged. 
 
Open Field 
Open field testing assessed general exploratory behavior and activity levels at 30 
and 60 dpi.  Each animal was placed in an empty plastic bin (50 cm long, 36 cm wide, 45 
cm high), and activity was video-recorded for 30 min (Noldus Ethovision, Noldus 
Information Technology, Inc., Leesburg, VA). Total distance traveled was assessed as a 
measure of overall activity levels.  
 
Zero Maze  
An elevated zero maze apparatus was used to evaluate anxiety levels at 30 and 
60 dpi.  The circular apparatus was composed of a 10 cm wide track (100 cm outer-
diameter) with walls (30 cm high) enclosing half of the track with the other half remaining 
open and brightly lit. Animals were given 1 trial of 5 min duration and the percentage of 
time spent in the enclosed half was recorded. Generally, spending more time in the dark 
quadrants of the track is associated with increased anxiety-like behaviors. 
 
Morris Water Maze (MWM)  
Cued and spatial water maze performance was assessed over 3 days as a 
measure of learning and spatial memory functions at 30 and 60 dpi. A computerized 
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tracking device (Noldus Information Technology, Inc., Leesburg, VA) recorded the 
rodent’s swim path (Hartman et al., 2005). The water maze consisted of a 110 cm 
diameter metal tank filled with opaque water. An escape platform (11 cm diameter) was 
adjusted so that the platform’s surface was 2 cm above the water surface for cued 
testing, and submerged 1 cm below the water surface for the spatial learning and 
memory tasks. In the cued task, the platform was placed in one of four quadrants, and 
the location of the platform changed for each block of trials. Animals were given 10 trials 
(60 sec maximum) in 5 blocks of 2 consecutive trials with a 5 sec inter-trial interval. For 
each trial, the rat was released into the tank opposite the platform location and allowed 
to search for the platform. If the rat had not located the platform within 60 sec, it was 
guided to it. Animals were allowed to remain on the platform for 15 sec after each trial. 
For the spatial testing, the platform remained in the same location for all 10 trials 
and the rat was released into the tank at one of four release points and allowed to find 
the platform.  A probe trial was administered 1.5 hrs later, in which the platform was 
removed from the tank, and the rats were allowed to swim for 60 sec. The percentage of 
time spent in the quadrant where the platform was previously located was calculated. 
Left/right turn bias and swim speed was also calculated during the probe trial with the 
percentage of left and right turns measured for each rat.  
 
Tissue Processing and Immunohistochemistry 
Rats were transcardially perfused with 4% PFA prepared in PBS at 3, 7, 30 and 
60 dpi, the brains were immersed in same solution overnight, and then transferred to 
PBS with sodium azide (0.1%). Brains were immersed in 30% sucrose at 4oC for 48 
hours and then frozen on dry ice and stored at -20oC. Sham and CCI brains were cut as 
coronal cryostat sections (50µm) throughout the entire length of the brain (Leica 
CM1850, Leica Microsystems GmbH, Wetzlar, Germany). All antibody incubations were 
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carried out in PBS (Fisher Scientific, Pittsburg, PA) containing 0.25% Triton X-100 and 
0.25% bovine serum albumin (BSA) (both from Sigma-Aldrich Co., St. Louis, MO). After 
washes in PBS, sections were blocked for 1.5 hours in PBS with 1% BSA, and then 
incubated overnight at 4°C with mouse anti-neuronal nuclei (mouse anti-NeuN – 1:500, 
Chemicon International, Temecula, CA), anti-myelin basic protein (mouse anti-MBP – 
1:1000 for classical or 1:200 for infra-red analysis, Chemicon International, Temecula, 
CA; rabbit anti-MBP – 1:1000 for classical or 1:200 for infra-red analysis, Abcam Inc., 
Cambridge, MA), oligodendrocyte marker anti-CNPase (1:1000 for classical or 1:400 for 
infra-red analysis, Abcam Inc., Cambridge, MA) or anti-neurofilament-200 (NF200 – 
1:1000 for classical or 1:250 for infra-red analysis; Sigma-Aldrich Co., St. Louis, MO) 
antibodies. After rinsing in PBS, sections were incubated for 2 hours at room 
temperature with goat anti-mouse secondary antibody coupled with Alexa-Fluor-488 
(1:500 or 1:1000; Molecular Probes, Invitrogen) or with goat anti-mouse secondary 
antibody coupled with Alexa-Fluor-800 and goat anti-rabbit secondary antibody coupled 
with Alexa-Fluor-680 for infra-red analysis (1:1000; Molecular Probes, Invitrogen) and 
subsequently washed in PBS 3x10 min. Sections for classical immunofluorescence were 
mounted on glass slides and coverslipped with anti-fading medium vectashield 
containing DAPI (Vector, Vector Laboratories, Burlingame, CA). Sections for infra-red 
analysis were mounted on glass slides and dried. Negative control staining where the 
primary antibody was omitted showed no detectable labeling. Immunostaining was 
carried out the same day with the same antibody mix for both sham and CCI animals for 
each time point. 
 Automated counting of NeuN positive nuclei was performed as previously 
described (Badaut et al.) in the dorsal parietal cortex (close to injury) and in the piriform 
cortex (distant from the injury) in coronal sections that exhibited a visible TBI lesion 
cavity. NeuN is a specific marker of neuronal nuclei only, allowing the opportunity to 
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count the number of positive neurons stained with NeuN, but not other cell types such as 
astrocytes, oligodendrocytes, or microglia (Mullen et al., 1992). The region of interest 
(ROI) for the ipsilateral parietal cortex (ipsi-parietal cortex) was drawn close to the lesion 
cavity (Figure 5) and contralateral parietal cortex (contra-parietal cortex) was a mirror 
image of the ipsi-parietal cortex outline in the contralateral hemisphere. Similar regions 
were drawn in sham animals at the same anatomical regions. All values were collected 
using an epifluorescent microscope (Olympus, BX41, Center Valley, PA USA) and each 
ROI contained 80-95 different fields (422 µm x 338 µm) quantified using Mercator 
software (Explora-Nova, La Rochelle, France). The threshold and morphological user-
defined parameters were selected to maximize visualization of NeuN-positive staining in 
the regions of interest, and parameters were kept consistent for all animals. The 
Mercator program automatically counted only NeuN positive nuclei (Figure 4A). 
Accuracy of counting was previously tested on slices from control rats stained with 
NeuN, and no significant differences were observed between the two hemispheres (data 
not shown).  
 NF200, MBP, and CNPase coronal sections that were immunostained with infra-
red secondary antibodies were scanned using the same parameters for sham and CCI 
with a Licor-Odyssey scanner at 21 µm/pixel resolution (Licor Bio-science, Lincoln, NE, 
USA).  The infra-red method proposed to quantify the immunohistochemistry has been 
recently described by different authors (Wong, 2004; Brunet et al., 2011) and by our 
group (Badaut et al., 2007; Badaut et al., 2011). For surface area measurements of the 
CC with NF200 (Figure 5C) and MBP (Figure 6E), an average area was obtained from 
fields-of-interest drawn with the Licor-Odyssey analysis software around the entire CC 
on at least 3 coronal sections located anterior to the injury site at a distance from the 
disrupted CC directly below the injured area. Tissue processing after MRI and prior to 
immunohistochemistry (sucrose fixation, freezing, cryosectioning) may result in a 
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different degree of decrease in CC area from immunohistochemistry compared to MRI. 
Alternatively, slice thickness on MRI (1mm) compared to immunohistochemistry (50 m) 
could also account for these differences. For infra-red analysis on specific regions, 
integrated intensity (I.I.) values were obtained from 4 – 8 coronal sections spaced at 
least 1.2 mm apart throughout the longitudinal brain axis (as available per brain region). 
For NF200 and CNPase, identical fields-of-interest were drawn using Licor-Odyssey 
software on both ipsilateral and contralateral hemispheres only for an analysis on the 
medial CC (near longitudinal fissure, adjacent to injury) and lateral CC (dorsal to rhinal 
fissure, ventral to injury) and a global I.I. average value was calculated for the CC only. 
For MBP, identical fields-of-interest were drawn using Licor-Odyssey software on both 
ipsilateral and contralateral hemispheres for the following brain regions: anterior 
commissure, medial CC (near longitudinal fissure, adjacent to injury), lateral CC (dorsal 
to rhinal fissure, ventral to injury), cingulate cortex, medial parietal cortex, lateral parietal 
cortex (dorsal to rhinal fissure, ventral to injury), and temporal/entorhinal cortex (ventral 
to rhinal fissure, ventral to injury). For MBP, statistical comparisons revealed no within 
group differences across bregma levels or ipsilateral versus contralateral hemispheres, 
meaning there was similar immunoreactivity for all white matter structures, and similar 
immunoreactivity for all gray matter structures within individual sham and CCI groups. 
Therefore, a global I.I. average value was calculated for the white matter tracts (anterior 
commissure, medial and lateral CC) and the cortical gray matter (cingulate, medial and 
lateral parietal, temporal/entorhinal cortices). 
 
Electrophysiology 
 At 60 dpi, a separate cohort of rats was anesthetized with 3.5% isoflurane, 
decapitated and their brains dissected to prepare coronal slices of the CC. Slices (400 
µm thick) were cut using a vibratome (Electron Microscopy Sciences, Hatfield, PA, USA) 
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in ice-cold artificial cerebrospinal fluid (ACSF) composed of (in mM): 130 NaCl, 3.5 KCl, 
1.25 NaH2PO4xH2O, 10 MgSO4x7H2O, 0.50 CaCl2, 24 NaHCO3, 10 glucose and 
saturated with carbogen (95% O2 + 5% CO2) at a pH of 7.4. Slices were prepared from 
a brain region anterior to the injury site (bregma +0.5mm), transferred to a recording 
chamber, and superfused for at least 80 minutes with carbogen-saturated ACSF with 
Mg2+ concentration reduced to 1.5 mM and Ca2+ concentration elevated to 2.0 mM. 
During all electrophysiological recordings, slices were continuously perfused at a rate of 
2-3 ml/min and maintained at 25oC. A stimulation electrode was placed in the callosal 
fiber tract ipsilateral to the lesion ~0.5 mm lateral to the longitudinal fissure to deliver 
square current pulses 0.05 ms in duration at 0.02 Hz (see inset Figure 8). Compound 
action potentials (CAP) were recorded with glass electrodes (tip resistance 1–3 MΩ) 
filled with 3 M NaCl and positioned in the contralateral CC, 1.0 mm from the stimulation 
electrode, and the depth was adjusted to yield a maximal CAP (~140 µm depth).  
Responses were amplified (Axoclamp, Axon Instruments, Foster City, CA) and digitized 
at a sampling rate of 10 kHz, and analyzed using Clampfit (Axon Instruments) and 
MiniAnalyses (Synaptosoft) software.  The CAP is characterized as a biphasic waveform 
produced by fast-conducting, myelinated axons representing the N1 peak and slower, 
unmyelinated axons representing the N2 peak. The excitability of the myelinated fibers 
was assayed by evaluating the amplitude of the N1 peak of the CAP at incrementally 
increasing stimulation intensities (0.5 mA increments) until the maximal CAP amplitude 
was reached. Maximal CAP amplitude was used from each animal and averaged.  
 
Statistical Analyses 
All data are presented as mean ± SEM, and statistical analyses were done using 
GraphPad InStat version 3.05 (GraphPad Software, San Diego CA) and 
Sigmastat/Sigmaplot (SPSS Inc.). For behavioral data, a Kolmogorov and Smirnov test 
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was first performed to assess the Gaussian distribution, and parametric data were 
analyzed using unpaired Student t-tests and ANOVA testing followed by Tukey-Kramer 
for multiple comparisons, while non-parametric data was evaluated with Wilcoxon and 
Kruskal-Wallis tests to assess group differences. Repeated measures ANOVAs were 
used in cases where longitudinal data were collected on the same groups. MRI and 
immunohistochemical findings were assessed by unpaired Student t-tests for normally 
distributed data, or Mann-Whitney U analysis. 
 
Results  
All juvenile TBI (jTBI) rats survived the CCI injury (P17) from 1 day to 2 months 
post-TBI (adulthood; P77). There were no significant weight differences between the CCI 
and sham groups during the study.  
 
Behavioral Testing  
Because the TBI lesion was located in the parietal cortex, which contains 
somatosensory processing areas, a series of motor tests were performed to evaluate the 
functional impact of jTBI two months after the initial injury. We found significant 
impairments on the foot-fault task, with an increased number of faults at 7 dpi (p<0.05) 
and 60 dpi (p<0.001) (Figure 1A) compared to shams. In the CCI animals, we observed 
temporal changes from 1 dpi to 60 dpi (repeated ANOVA, p<0.001) in the number of 
faults (Figure 1A), supporting the concept of progressive motor impairments over time. 
The beam balance results show impaired performance in CCI animals, with less 
distance traveled compared to shams from 1 to 60 dpi (Figure 1B, *p<0.05, **p<0.01) 
and no changes within each group’s performance over time. Sensorimotor coordination 
was assessed using the rotarod (Figure 1C) and revealed that CCI animals were unable 
to stay on the rotating cylinder as long as shams at 30 dpi (p<0.05). CCI animals 
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appeared to recover from this deficit by 60 dpi, indicating impaired coordination that 
resolved over time (Figure 1C). Analysis of turn bias from MWM tests demonstrated a 
significant left turn bias in CCI rats at 30 dpi (p<0.05) that was maintained at 60 dpi 
(p<0.05) (Figure 1D). Taken together, these results reveal impaired sensorimotor skills 
of CCI animals that persisted until adulthood.  
We also administered a comprehensive battery of tests to assess exploratory 
behavior (open field), anxiety-like behaviors (zero maze), and learning and memory 
(MWM) abilities at 30 and 60 dpi. In open field testing, the total distance traveled in 30 
min by the CCI group was significantly less than in sham animals at 30 dpi (p<0.05) but 
not at 60 dpi (Figure 2A). These and the above rotarod data (Figure 1C) suggest that 
certain aspects of motor function recovered after TBI, whereas others did not.  Analysis 
of the first 3 minutes of the open field test, as a marker of exploratory behavior in a novel 
environment (Figure 2B), showed that CCI animals moved significantly less when initially 
placed into the novel environment compared to sham groups at 60 dpi (p<0.05), 
consistent with decreased motor/exploratory behaviors. Both CCI and sham animals 
explored less during the first 3 minutes at 60 dpi than at 30 dpi (p<0.001), suggesting an 
effect of general maturation and/or repeated exposure to the open field. Similarly, the 
zero maze-test revealed no group differences in anxiety-like behaviors (measured as 
increased time spent in the enclosed half of the track) at 30 dpi, but a significant 
increase in anxiety-like behaviors in CCI animals at 60 dpi (p<0.05) (Figure 2C). Our 
open field data suggest reduced motor performance at 30 dpi, whereas reduced 
exploratory behavior may be related to the emerging anxiety-like behaviors in the 
elevated zero maze occurring at 60 dpi. 
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FIG. 1. (A) Sensorimotor functions were tested with the foot-fault test. There was a 
significant increase in the number of faults in controlled cortical impact (CCI) rats 
compared to their sham counterparts at 7 and 60 dpi (*p < 0.05, **p < 0.01). (B) 
Balance and coordination skills were measured with the beam balance test. The 
distance covered by CCI animals was significantly decreased compared to sham 
animals at 1, 3, 7, and 60 dpi. (C) Balance and coordination skills were tested with 
the rotarod test. Fall latency was significantly lower in CCI animals at 30 dpi (*p < 
0.05). (D) Turn bias measurements indicated that the percentage of left turns 
(contralateral to the injury) at 30 and 60 dpi was significantly increased in CCI 
compared to sham animals (*p < 0.05; SEM, standard error of the mean). 
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FIG. 2. (A) During open-field testing, the overall distance traveled over 30 min (10 
blocks of 3 min each) revealed a significant decrease in activity in the controlled 
cortical impact (CCI) group compared to sham animals at 30 dpi (*p < 0.05). 
(B) The first 3-min block of activity was evaluated in sham and CCI animals, as this 
time would normally be used to explore the new environment into which they have 
been placed. At 60 dpi (but not at 30 dpi) there was a significant difference in the 
distance traveled in CCI compared to sham animals (*p < 0.05), when the CCI 
animals showed decreased exploratory activity.  (C) The zero maze was used to 
assess anxiety-like behaviors, and in this test more time spent in the dark is thought 
to correlate with increased anxiety. We observed a significant increase in the time 
spent in the dark at 60 dpi (*p < 0.05). (D) Cumulative distance traveled by the rats to 
find the platform at 30 and 60 dpi was no different between the CCI and sham 
groups in the Morris water maze spatial test.
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Learning and memory abilities after jTBI were evaluated on the cued and spatial 
versions of the MWM at 30 and 60 dpi (Figure 2D). Although both groups improved over 
time, no performance differences in overall swim speed, cued learning or spatial learning 
/ memory were observed between sham and CCI at either time point.   
 
MRI-Derived Lesion Volumes and Surface Area of Corpus 
Callosum 
MRI at 3, 30 and 60 dpi was used to non-invasively measure lesion volumes (Figure 3) 
and the area of the CC (Figure 5A, B). The relative lesion volume measured from the 
T2WI might be influenced by edema formation, inflammation and cell death. Sham 
animals had little or no abnormalities at the site of the craniotomy, whereas CCI animals 
demonstrated brain injury as evidenced by increased tissue edema (Figure 3A, arrows at 
3 and 30 dpi). No prominent midline shift was observed in the MR images in this model 
and there were only a few CCI animals that exhibited herniation of brain tissue. At 30 
and 60 dpi, MRI revealed a cortical cavity that circumscribed the TBI site in fronto-
parietal cortex (Figure 3A), and a 3D reconstruction (Figure 3B) revealed the rostro-
caudal extent of the lesion cavity in the parietal cortex 60 days after jTBI. Lesion 
volumes were significantly increased in CCI animals compared to sham controls at 3 dpi 
(3.5% vs. 0.4% of brain volume; p<0.001), 30 dpi (3.0% vs. 0.3%; p<0.001), and 60 dpi 
(2.9% vs. 0.1%; p<0.001) (Figure 3C). Lesions volumes, as defined using the 
parameters of hyper- and hypo-intensity described in the Methods, decreased across the 
3 time-points within the CCI and sham groups (p<0.05, Figure 3C). Decreased lesion 
volume may be a consequence of decreased edema and inflammation over time. MRI at 
60 dpi was used to analyze the surface area of the CC, measured at bregma +1mm 
anterior to the site of the injury in CCI animals and in a comparable coronal section in 
shams, and showed a global decrease of 21% compared to shams (p<0.05) at 60 dpi 
(Figure 5A, B). 
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FIG. 3. (A) Magnetic resonance imaging (MRI) at 3, 30, and 60 dpi identifies the 
lesion (arrows) as an increase in the signal intensity at 3 and 30 dpi, and as a hole 
at 60dpi, corresponding to the formation of the lesion cavity. (B) A three-dimensional 
reconstruction of the brain (gray) and lesion (red) at 3 dpi extends to include*3%of 
the total brain volume. (C) The lesion volumes were significantly larger in controlled 
cortical impact (CCI) rats compared to their sham counterparts receiving craniotomy 
only (**p < 0.001) at all time points during our 60-day observation period.   
Color image is available online atwww.liebertonline.com/neu
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Immunohistochemical Changes following CCI 
 The consequences of jTBI on gray and white matter were studied at 60 dpi using 
immunostaining for a neuronal marker (NeuN), neuronal process marker (NF200), 
oligodendrocyte marker (CNPase) and myelin basic protein (MBP), both at the level of 
and remote from the site of injury. In sham animals, an intact cortex was observed 
(Figure 4A, 5A left, 6A left), whereas a cavity at the lesion site extending to the level of 
the CC was seen in the CCI animals (Figure 4C, arrow).  This lesion impacted a 
relatively small portion of the parietal cortex (in accordance with the results obtained 
from MRI), and may be directly responsible for some of the observed behavioral deficits.  
In Figure 4, NeuN staining reflects the numerical index of NeuN-positive nuclei 
used to assess neuronal number and DAPI staining shows no difference in cell density 
in images co-labeled with NeuN. The positive DAPI cells without NeuN are those of non-
neuronal cells in the cortex such as astrocytes, microglia, and endothelial cells. 
Quantitative analyses of NeuN positive cells near the injury, in the ipsilateral and 
contralateral parietal cortex, revealed a 35% decrease in CCI compared to sham 
animals (p<0.05) (Figure 4B, D, E). Quantification of NeuN in the piriform cortex, a 
cortical region distant from the injury site, did not show any changes in the number of 
neurons between groups (688 ± 117 positive NeuN cells/mm2 in sham versus 545 ± 60 
positive NeuN cells/mm2 in CCI). At 60 dpi, our NeuN staining intensity did not change 
significantly (Figure 4A, C) in contrast to studies showing increased brain NeuN during 
the first days after injury (Liu et al., 2009). Therefore, while the intensity level, or actual 
brightness of NeuN staining is unchanged, the NeuN-positive nuclei reflecting neuronal 
number is decreased after injury. At 60 days, the observed loss of parietal neurons may 
be a contributing factor to sensorimotor dysfunction.  
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FIG. 4. (A–D) Neuronal nuclei (NeuN) immunohistochemistry at 60 dpi in the sham (A 
and B) and controlled cortical impact (CCI; C and D) groups showed the lesion cavity 
in the parietal cortex (arrow in C). The number of NeuN-positive neurons (green) was 
decreased in CCI (D) compared to sham (B) animals in the parietal cortex (Par Cx) at 
close proximity to the injury site, in tissue adjacent to the cavity. Nuclei of all cell types 
were stained with DAPI (blue in B and D), and automated counting of the NeuN-
positive cells in the parietal cortex (E) showed a significant reduction in CCI compared 
to sham animals in the ipsilateral and contralateral hemispheres (*p < 0.05; scale bars 
in A and C= 200 µm; in B and D= 50 µm; DAPI, 4,6-diamino-2-phenylindole). 
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 Similar to MRI analysis (Figure 5A, B), area measurements of the CC from infra-
red NF200 stained coronal sections (Figure 5A, C) at 60 dpi showed a significant 
decrease after 7 dpi in the CC (31±1% of sham, p<0.01) that was still present at 60 dpi 
(42±4% of sham, p<0.005, Figure 5C). CC area measurements from MBP 
immunostaining also showed a similar decrease in CCI animals compared to shams 
(p<0.05, Figure 6E). CC area changes from MRI were highly correlated with 
measurements from infra-red NF200 (r2= 0.505, p<0.05) or infra-red MBP (r2= 0.433, 
p<0.05). Differences in the size of the decrease in CC area between CCI and shams 
from MRI and immunostaining are potentially due to tissue processing and analysis 
(details in Methods). However, it is clear that both quantification methods demonstrate a 
significant decrease in CC area at 60 dpi following CCI. 
 In addition to these gross morphological changes to the CC surface area 
following jTBI, infra-red NF200 (Figure 5), infra-red CNPase (Figure 7) and infra-red 
MBP (Figure 6) immunoreactivities were quantified to address the question of whether 
NF200, CNPase and MBP immunoreactivities were altered. Quantification of NF200 
infra-red staining intensity in the CC was not significantly changed between sham and 
CCI at 60 dpi (Figure 5A, H). Classical immunostaining with NF200, including higher 
magnification images of the CC, showed similar morphological staining patterns between 
sham and CCI (Figure 5D-G). NF200 appears more punctate in the gray matter cortex in 
both sham and CCI. In the white matter, there are no obvious distorted fiber tracts, or 
interrupted fiber tracts that are commonly observed in other white matter injuries and 
models (e.g. optic nerve injury, Wang et al. 2011; spinal cord injury Cho et al., 2009; 
Iannotti et al., 2011). In the CC, CNPase staining intensity was not significantly changed 
(Figure 7A, F), in accordance with our observations at higher magnification showing no 
gross changes in the pattern of staining between the sham and CCI groups (Figure 7B-
E). Classical CNPase immunolabeling identified occasional positive cells in the CC that 
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were consistent in shape and size with expected oligodendrocyte morphology (Figure 
7B-E). Although no changes were detected with these antibodies and quantification 
methods, it remains possible that other axonal changes are occurring at the 
ultrastructural or molecular level. 
 However, in contrast to the NF200 and CNPase staining, the immunostaining 
and higher magnification images for MBP in Figure 6 reveal stark differences between 
sham and CCI. As expected during brain development (Bjelke and Seiger, 1989, 
Akiyama et al., 2002), sham animals demonstrated a significant global increase in MBP 
immunoreactivity between ages 20 to 60 days in the CC (increased 25±4%, p<0.005, 
data not shown). Quantification of infra-red MBP immunoreactivity in CCI (% of sham) 
revealed a biphasic change, with an initial increase (25±5%) in CCI compared to sham 
animals at 3 dpi, normalization at 7 and 30 dpi, and then an increase (33±9%) at 60 dpi 
in white matter tracts (Figure 6D). MBP immunoreactivity was increased in CCI at 3 dpi 
and 60 dpi in all anterior-to-posterior white matter tracts (average values of anterior 
commissure, medial and lateral CC, from bregma +1.7 to -6.0 mm, Figure 6A, D) and 
was also increased in CCI animals in the CC structure alone (average values of medial 
and lateral CC only, from bregma +1.7 to -6.0 mm, Figure 6A, p<0.05, graph not shown). 
MBP staining in the cortex and anterior commissure values alone were higher in CCI 
compared to sham from bregma +1.7 to -6.0 mm, but did not reach significance (data not 
shown). MBP staining was consistent across bregma levels within groups, and no 
differences were detected for comparisons of individual white matter structures within 
each individual sham or CCI group. Mosaic images and higher magnification of classical 
immunostaining demonstrate increased MBP after jTBI at 60 dpi (Figure 6B, C). The 
coronal slices in sham animals show uniform MBP staining throughout individual white 
matter locations including the CC (Figure 6B). In contrast, CCI animals have a higher 
staining intensity level in the CC (Figure 6C).  Similar results were obtained using a 
76 
 
 
 
 
 
FIG. 5. (A) Slices from magnetic resonance imaging (MRI) and neurofilament-200 
(NF200) immunostaining show a decreased corpus callosum (CC) size on MRI 
(green and yellow outlines), and NF200 immunostaining (arrows). (B) Quantification 
of the CC area from the MRI at 60 dpi (mm2) showed a significant decrease in CCI 
animals (*p < 0.05). (C) Quantification of the CC area from the NF200 infrared 
immunostaining (% of sham animals) shows a significant decrease in the CCI group 
at 7, 30, and 60 dpi (*p < 0.05). (D–G) Classical immunostaining with NF200 images 
at higher magnification in the corpus callosum (CC, red dashed outlines), and 
overlying cortex (Cx), showed similar morphological staining patterns, and no 
changes between the sham (D and E) and CCI (F and G) groups. (H) Infrared (IR) 
quantification of NF200 staining intensity in the CC was unchanged between groups 
at 60 dpi (scale bar in A= 1mm; in D and F = 500 µm; in E and G= 50 µm; A.U., 
arbitrary units). 
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FIG. 6. Myelin basic protein (MBP) immunostaining in the sham (A, B, and G) and 
controlled cortical impact (CCI; A, C, F, and G) animals from bregma + 1.7mm to - 
6.0mm. (A) MBP immunoreactivity using infrared antibodies with mouse anti-MBP 
(ms-MBP) was increased in the CCI animals compared to sham animals at the 
anteroposterior bregma level in white matter tracts. This global increase of MBP 
was also seen distant from the lesion cavity (asterisk in A). (B and C) Higher 
magnification images of classical MBP immunostaining show higher intensity in the 
corpus callosum (CC) compared to the striatum (STR) and cortex (CX), in (B) sham 
and (C) CCI animals, and increased MBP staining in the CC white matter of CCI 
animals (insets in B and C). (D) Quantification of infrared MBP staining showed a 
significant increase in the white matter tracts (CC and anterior commissure) of CCI 
animals compared to sham animals at 3 and 60 dpi (*p < 0.05). (E) CC area 
measurements of MBP immunostaining showed a decrease in CCI animals 
compared to sham animals (p < 0.05). (F) Doubleimmunolabeling with infrared MBP 
antibodies recognizing two different epitopes, mouse anti-MBP (ms-MBP, green) 
and rabbit anti-MBP (rb-MBP, red), showed co-localization in the merged images. 
(G) The intensity of the rb-MBP was increased in the CCI compared to the sham 
group, as indicated by ms-MBP (asterisks in A, F, and G indicate the lesion cavity; 
scale bars in A, F, and G= 1mm; in B and C= 200 µm; in insets in B and C= 50 µm).
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second antibody raised in rabbit against MBP (Abcam) with a different epitope located 
from amino acid 150 to the N-terminus, in comparison to the antibody raised in mouse 
against MBP (Chemicon) that recognizes an epitope from amino acids 116-131. Both 
antibodies showed similar staining patterns and increases in CCI (Figure 6F-G). 
 
Corpus Callosum Compound Action Potentials (CAP) following 
CCI  
To assess the functional consequences of jTBI on the CC, we evaluated 
electrical transmission within the CC of CCI and sham animals at 60 dpi. N1 amplitudes 
of CAP reflect excitability of fast conducting myelinated axons (Figure 8) and represent 
the sum of all individual action potentials (Bolton and Carter, 1980, Velumian et al.).  The 
average N1 amplitudes in CCI animals were significantly reduced compared to 
responses recorded from sham operated animals (p<0.005) (Figure 8). This suggests an 
impairment of axonal conductance in the CC of CCI animals that is possibly associated 
with a decrease in the thickness of the CC (surface area) and increased MBP 
(immunoreactivity). 
In summary, our data indicates that the CCI is a focal injury at the time of impact 
with formation of a cavity under the site of the impact, but immunohistochemistry and 
electrophysiology data suggest that the resulting jTBI continues to pathologically affect 
the brain in a diffuse pattern, primarily along white matter tracts. 
 
Discussion  
Using a CCI model of brain injury in juvenile rats, we have demonstrated for the 
first time that TBI in the developing brain is associated with acute sensorimotor deficits 
that persist into adulthood and also showed the delayed appearance at 60 dpi of 
abnormal anxiety-like behaviors. The morphological changes within the gray matter (the 
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presence of a cavity and reduced number of neurons) and the white matter tracts 
(decreased area of the CC from MRI and histology) were associated with increased 
MBP immunostaining and reduced trans-callosal electrical conductance remote from the 
lesion site. Our findings on the zero maze are consistent with the accepted notion that 
anxiety-like behaviors involve several brain regions such as the amygdala, and the 
parietal and frontal cortical areas. We believe our global analysis of gray and white 
matter tissue properties also demonstrate that a local impact evolves to a global change 
that may affect overall brain function. Specifically, our results suggest that TBI in juvenile 
rats produces long-lasting changes in gray and white matter properties and impairments 
of electrical signaling in major axonal pathways that may explain the observed 
sensorimotor deficits and anxiety-like behaviors.  
Our observations in this jTBI rodent model corroborate clinical reports that 
highlight the persistence of neurological, cognitive, behavioral, and psychosocial 
sequelae after childhood TBI (Lippert-Gruner et al., 2006, Goold and Vane, 2009). In 
human subjects, these impairments last from a few months to 50 years post-injury and 
impact activities of daily living (Yeates et al., 2002, Brenner et al., 2007). A wide range of 
deficits have been clinically described, including slowed information processing, 
impaired judgment, attention deficit hyperactivity disorder, hampered reasoning and 
problem-solving skills, mood disorders, anxiety, aggression and anti-social behaviors 
(Cattelani et al., 1998, Max et al., 2004, Brenner et al., 2007, Prigatano, 2008). 
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FIG. 7. (A) CNPase immunolabeling along white matter tracts is shown in 
representative coronal sections near the lesion (bregma - 1.8mm), and anterior 
to the lesion cavity (bregma + 0.5mm), with bright levels of CNPase staining with 
infrared (IR) antibodies localized to white matter tracts in the corpus callosum 
(CC; groups of red arrows). (B–E) Classical CNPase staining at higher 
magnification shows similar staining patterns in the CC (red dashed outlines), 
and on individual oligodendrocyte cell bodies (arrows), and processes 
(arrowheads) of (B and C) sham, and (D and E) controlled cortical impact (CCI) 
animals. (F) Quantification of infrared staining in the CC across several coronal 
slices shows no statistically significant differences between the sham and CCI 
groups for CNPase staining levels (CX, cortex; asterisk in A indicates lesion 
cavity; scale bar in A=1mm; in B and D= 200 µm; in insets in C and E = 20 µm; 
A.U, arbitrary units). 
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FIG. 8. Electrophysiology in the corpus callosum (CC) at 60 dpi shows N1 
amplitudes recorded after compound action potentials (CAP) were evoked. The 
stimulating electrode (S) was placed on the side of injury (or sham surgery), 
located approximately 1mm from the recording electrode (R). Quantification 
shows that N1 amplitudes were significantly decreased in controlled cortical 
impact animals compared to sham animals (*p < 0.005).
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A focal injury to the parietal sensorimotor cortex in P17 rats resulted in a 35 mm3 
lesion volume (~3% of total brain volume) at 60 dpi (Figure 3B), which is comparable to 
previously published data (Prins et al., 2005). The lesion volume remained relatively 
stable over 60 dpi (Figure 3C) despite the emergence of specific motor and behavioral 
impairments. In fact, motor dysfunction was observed within the first week and persisted 
until 60 dpi (Figure 1). Early increases in foot faults and decreased distance covered on 
beam balance tests are similar to results described in a closed head injury model using 
P17 mice (Adelson et al., 2000). The recovery that we observed in rotarod testing in the 
CCI group at 60 dpi may be due to a combination of learning effects, age-related brain 
development, and reduced sensitivity of this particular test to small deficits in motor 
planning, proprioception and coordination which other tests such as foot fault can detect 
(Barreto et al., 2010). In accordance with other investigators (Prins and Hovda, 1998), 
we did not find major deficits in spatial learning and memory using water maze testing at 
30 and 60 dpi. However, jTBI induced the development of anxiety-like behaviors that 
emerged only in adulthood (Figure 2C), which was revealed by the longer time spent in 
the enclosed part of the zero maze combined with reduction of the exploratory activity in 
the first 3 minutes of open field testing (Figure 2B). These results are similar to clinical 
observations of the delayed onset of anxiety in adult patients after TBI (Whelan-
Goodinson et al., 2009). The acute decrements in motor function (i.e., increased of 
incidence of foot faults and asymmetric turning behavior) are likely the result of the initial 
lesion and local neuronal cell death in the sensorimotor cortex (Nishibe et al., 2010) 
(Figures 1 - 4). The persistence and progressive worsening of these motor functions 
could possibly be due to the cavitation of the motor cortex as well as to impaired axonal 
conductance associated with the global changes in white matter tracts (Figure 1, 4 - 8). 
As noted above for the rotarod test, the absence of differences between the groups for 
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open field testing at 60 dpi (Figure 2A) may be due to learning or habituation effects 
resulting from repeated testing (Russell and Williams, 1973). 
Clinical imaging studies have emphasized the vulnerability of white-matter 
pathways, such as the CC and anterior commissure, after TBI (Holshouser et al., 2005, 
Wilde et al., 2006, Wu et al., 2010). These structural changes may alter the level of 
MBP, a primary protein involved in myelin sheath formation. Several reports have 
studied MBP in human serum and cerebrospinal fluid (CSF) following pediatric and adult 
TBI, as a potential biomarker of injury severity (Berger et al., 2005, Sandler et al., 2010). 
For example, serum MBP was increased in children for up to 2 weeks following TBI 
(Berger et al., 2005). Thus, we sought to explore the relation between white matter tract 
changes using MRI, histology and electrophysiology and behavioral changes in 
adulthood after jTBI. Morphological analysis of white matter tracts using MRI and 
histology revealed decreased callosal thickness starting at 7 dpi that persisted to 60 dpi, 
findings that are similar to white matter loss observed in humans (Kraus et al., 2007, Wu 
et al., 2010). Our data show the CC is damaged in this CCI model at the site of the 
impact, but also at distance from the lesion site, with no recovery over time (Fig 3-8). 
The permanently decreased area of the CC over the 60-day observation period 
(measured with MRI, NF200 and MBP) contrasts with the temporal callosal changes in 
MBP staining that we measured by infra-red quantitative-immunohistochemistry (Figure 
5, 6). We found early increased MBP staining at 3 dpi, which may reflect injury-induced 
myelin changes. Indeed, increased MBP levels were previously reported in an adult rat 
TBI model and attributed to MBP fragmentation at 3 dpi (Liu et al., 2006). MBP staining 
was normalized to sham levels at 7 dpi and 30 dpi, despite the significant decreases in 
CC thickness (Figure 5, 6). In adult TBI models, early myelin fragmentation is due to 
increased calpain activity that also normalizes 7 days after TBI (Liu et al., 2006). 
However, our MBP staining normalization was transient and by 60 dpi we observed a 
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global increase in MBP staining in white matter tracts throughout the anterior-posterior 
extent of the brain in CCI compared to sham (bregma +1.7 to -6.0 mm) (Figure 6A). We 
also showed an absence of CNPase and NF200 staining changes in the CC, in parallel 
with increased MBP staining at 60 dpi. Thus, increased MBP staining is likely not a result 
of increased number of oligodendrocytes (CNPase) in the white matter. It remains 
possible that MBP fragmentation may play a role, or overexpression associated with an 
attempt of the brain to compensate for myelin loss (Ihara et al., 2010), but the exact 
mechanism needs further exploration in this CCI model. Previous studies indicate that 
glucocorticoids may influence MBP, as they are known to enhance the rate of myelin 
formation (Chan et al., 1998) and are elevated after brain injury as part of the innate 
immune response (Glezer and Rivest, 2004).  
In conjunction with decreased callosal white matter thickness and increased 
MBP-staining, we found electrophysiological evidence of deficient CC conductivity after 
jTBI compared to shams (Figure 8), suggesting a possible functional basis for some of 
the behavioral deficits. The decreased CAP suggests that the increase of MBP observed 
in CCI animals is non-functional and insufficient to compensate for the loss of axons 
after CCI. Our findings are similar to a recent report in mice showing that myelin 
proteolipid protein (PLP1) overexpression was associated with decreased axonal 
conductance velocity (Tanaka et al., 2009). Interestingly, Kodama et al (2008) used the 
same mouse anti-MBP antibody (Chemicon) and found increased MBP protein levels in 
adulthood following early weaning. They ascribed their MBP increase to the 21.5 kDa 
isoform only, which suggests that increased MBP observed in their study and our jTBI 
model may not be necessarily localized in the myelin sheath. This hypothesis is 
supported by our electrophysiological data that showed decreased axonal conductance 
in spite of increased MBP staining, but additional electron microscopy studies would be 
needed for confirming precise localization.  Further, our data showing decreased CC 
87 
thickness post-TBI is consistent with a decrease in the number of fibers that may 
contribute to a decrement in function.  
Morphological and functional changes in white matter tracts after jTBI may 
explain the persistence of motor dysfunction and the development of anxiety-like 
behaviors in adulthood. Clinically, non-mechanical stressors early in life are associated 
with long-term behavioral changes and can also result in altered myelin development 
and reduced size of white matter tracts. For example, children with post-traumatic stress 
disorder have a smaller CC volume compared to healthy subjects when they reach 
adulthood (Bremner et al., 1995). In rodent models, early weaning of rats pups at P17 
induces an increase in MBP and development of anxiety-like behaviors (Kodama et al., 
2008). Our induction of a cortical mechanical-stress (CCI) at the same developmental 
age also induced an increase in MBP immunoreactivity and development of anxiety-like 
behaviors that emerged during adulthood.  In the rodent, P14-P21 is a critical maturation 
period for central axonal myelination (Akiyama et al., 2002), and it is likely that a stressor 
(early weaning or TBI) during this critical period may induce long-term changes in 
myelination and behavior. The developmental changes in myelin proteins (MBP, PLP) 
were associated with a physiological response to stress and emotional states, including 
anxiety and depression in adulthood (Kodama et al., 2008, Ono et al., 2008, Tanaka et 
al., 2009). Thus, despite the presumed neuroplasticity of the juvenile brain after jTBI, 
there is likely insufficient cortical reorganization or compensation to completely reverse 
injury-induced deficits. 
 
Conclusion  
Our findings showed that a focal TBI results in lasting behavioral deficits 
(decrements in motor function and late emergence of anxiety-like behaviors) similar to 
those seen in human TBI patients, as well as global alterations in white matter 
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(decreased thickness of white matter tracts, increased MBP immunoreactivity), leading 
to long-term changes in neuronal function (decreased neuronal number and axonal 
conduction). A mechanical stress to the cortex during a sensitive developmental window 
of myelin formation resulted in long-term changes in the morphology of white matter 
tracts as seen with changing MBP immunoreactivity that appear concurrently with 
decreased axonal output and behavioral changes. However, the molecular mechanisms 
and changes in oligodendrocytes underlying MBP increases in adulthood after TBI have 
yet to be determined, and would suggest new avenues for development of novel 
pharmacological therapies. 
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PROLOGUE TO CHAPTER 2B 
EARLY BRAIN INJURY ALTERS THE BLOOD–BRAIN BARRIER 
PHENOTYPE IN PARALLEL WITH Β-AMYLOID AND COGNITIVE 
CHANGES IN ADULTHOOD 
 
This second section of chapter 2 describes alterations to blood-brain barrier 
(BBB) phenotype which are detectable in adult rodents that had been subjected to 
juvenile traumatic brain injury (jTBI) at a developmental time period (P17). This change 
in BBB phenotype was studied in conjunction with: (a) accumulation of β–amyloid (Aβ), 
and (b) changes in cognitive function. The section demonstrates that there are both 
structural and functional changes in the BBB at long-term, brought about by jTBI at a 
developmental time period. It provides some evidence in support of the theory that TBI 
at a young age could predispose the brain’s blood vessels as well as the BBB to 
detrimental long-term changes with possible functional deficiencies, such as alteration in 
clearing of Aβ and lowering of cognitive abilities. BBB alterations may therefore be 
explored as a therapeutic avenue in jTBI. 
The customized controlled cortical impact (CCI) injury model in P17 rats 
(reported in section 2A) was used as a developmental model of TBI. Morris Water Maze 
(MWM) test was customized to assess not only spatial learning and spatial memory, but 
also preferred swim strategies used by the tested rodents at 30 and 60 days post injury 
(dpi).  Immunohistochemical methods were used to test for both BBB marker proteins 
such as claudin 5 and Immunoglobulin G (IgG). Immunolabeling and western blotting 
techniques were also employed to assess Aβ accumulation.  The hypothesis for this 
section is that acquisition of TBI in early life may yield detectable long-term changes in 
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BBB components, such as tight junctions and influx/efflux transporters, in parallel with 
aberrant Aβ accumulation and cognitive dysfunction.  
This section of chapter 2 has been published as a scientific article in the 
November 14, 2012 edition of the Journal of Cerebral Blood Flow & Metabolism (volume 
33, pages 205 - 212) under the same title as above. It is complete with abstract, 
introduction, methods, results and discussion sections.  
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Abstract 
Clinical studies suggest that traumatic brain injury (TBI) hastens cognitive decline 
and development of neuropathology resembling brain aging. Blood–brain barrier (BBB) 
disruption following TBI may contribute to the aging process by deregulating substance 
exchange between the brain and blood. We evaluated the effect of juvenile TBI (jTBI) on 
these processes by examining long-term alterations of BBB proteins, β-amyloid (Aβ) 
neuropathology, and cognitive changes. A controlled cortical impact was delivered to the 
parietal cortex of male rats at postnatal day 17, with behavioral studies and brain tissue 
evaluation at 60 days post-injury (dpi). Immunoglobulin G extravasation was unchanged, 
and jTBI animals had higher levels of tight-junction protein claudin 5 versus shams, 
suggesting the absence of BBB disruption. However, decreased P-glycoprotein (P-gp) 
on cortical blood vessels indicates modifications of BBB properties. In parallel, we 
observed higher levels of endogenous rodent Aβ in several brain regions of the jTBI 
group versus shams. In addition at 60 dpi, jTBI animals displayed systematic search 
strategies rather than relying on spatial memory during the water maze. Together, these 
alterations to the BBB phenotype after jTBI may contribute to the accumulation of toxic 
products, which in turn may induce cognitive differences and ultimately accelerate brain 
aging. 
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Introduction  
Traumatic brain injury (TBI) is defined as damage resulting from a direct or 
indirect biomechanical force on the brain, and pathophysiological outcomes emphasize 
damage to neurons and glia. However, the blood-brain barrier (BBB) and vascular 
integrity are also compromised following TBI. Primary injury occurs at the moment of TBI 
impact, with disruption of blood vessels and the BBB, contributing to vasogenic edema 
formation (Pop and Badaut, 2011). BBB disruption precedes several downstream events 
contributing to secondary injuries, such as changes in cerebral blood-flow and hypo-
metabolism, brain swelling and increased intracranial pressure, hypoxia/ischemia, and 
related molecular events such as cell death, inflammation, oxidative stress, and 
pathology (Pop and Badaut, 2011). BBB disruption normalizes within one week in 
several injury models, yet recent studies show BBB permeability up to 30 days after 
ischemic insult (Strbian et al., 2008). Collectively, these observations suggest that BBB 
integrity represents a complex and dynamic sequelae meriting attention during acute 
and delayed stages post-TBI.  
Vascular dysfunction is a critical element of brain aging and neurodegeneration, 
especially in Alzheimer disease (AD) (Nicolakakis and Hamel, 2011). Age-related brain 
Aβ accumulation may depend on progressively impaired clearance mechanisms, as 
measured by in vivo kinetics of Aβ in cerebrospinal fluid of AD and control patients 
(Mawuenyega et al., 2010). At the endothelial interface, the central molecular 
participants in the bidirectional flow of substances are the transporters P-glycoprotein (P-
gp) and low-density lipoprotein-related receptor protein 1 (LRP1) for brain-to-blood 
efflux, and the receptor for advanced glycation end products (RAGE) for blood-to-brain 
influx (Ueno et al., 2010). In fact, decreased P-gp or LRP1 on endothelial cells are linked 
to increased Aβ and neurodegeneration in human brain aging, AD, and aging rodents 
(Silverberg et al., 2010). In addition, P-gp knock-out mice administered intra-cerebral Aβ 
94 
peptides have decreased brain-to-blood clearance and increased brain Aβ (Cirrito et al., 
2005), suggesting P-gp as a key player in parenchymal Aβ clearance. After brain 
trauma, little is known about the pathophysiological timeline of vascular damage and 
healing, or whether BBB changes affect long-term TBI outcome.  
Clinically, several lines of evidence demonstrate long-term pathological and 
behavioral modifications after TBI. These long-term changes may lead to premature 
aging and neurodegenerative processes like AD with higher risk for aberrant Aβ protein 
accumulation (Johnson et al., 2010). In support of this, brain Aβ immunolabeling was 
detected within hours after clinical TBI (Ikonomovic et al., 2004) and in long-term 
survivors (1 to 47 years) of a single injury (Johnson et al., 2012). As for patient outcome, 
many TBI survivors endure lifelong consequences, with 3.2 to 5.3 million US residents 
currently suffering physical and/or mental disability which can result in long-term 
complications (Zaloshnja et al., 2008). Young children, followed by adolescents and 
older adults, are at greatest risk for incurring TBI (Faul et al., 2010). Therefore, long-term 
studies on cellular and molecular changes after TBI are needed in juvenile experimental 
models, especially regarding collective changes in the BBB phenotype, neuropathology, 
and behavior.  
We hypothesized that an early life juvenile TBI (jTBI) may result in several brain 
changes. We evaluated BBB components (tight junctions, influx/efflux transporters) in 
parallel with neuropathology and aberrant protein accumulation (Aβ) and cognitive 
outcomes (learning and memory). A controlled cortical impact (CCI) was delivered to the 
parietal cortex of juvenile (17 day old) rats and outcomes are described in adults at 60 
days post injury (dpi).  
 
 
 
95 
Materials and Methods 
Animals 
All protocols and procedures were approved by the Institutional Animal Care and 
Use Committee of Loma Linda University. Juvenile (Literature descriptions for “juvenile” 
include a broad range of post-natal ages (Babikian et al., 2010). Based on previous 
publications and our recently published data (Ajao et al., 2012) , we used post-natal day 
17 as “juvenile” which is identical to methods in the present manuscript.) (17 day old) 
male Sprague-Dawley rats (Harlan, Indianapolis, IN) were housed with their dams on a 
12-hour light-dark cycle at constant temperature and humidity. Only male rats were 
selected, as prior studies suggest the existence of gender differences following TBI 
(Wagner et al., 2004). Pups were weaned 7 days after the surgery, housed 2 rats per 
cage, and fed with standard lab chow and water ad libitum. At 60 dpi, animals were 
euthanized, and brain tissue was collected for immunohistochemical studies (n=8 sham 
and n=8 jTBI). An additional group of animals (n=10 sham, n=10 jTBI) was studied 
longitudinally in the water maze (30 and 60 dpi).  
 
Juvenile Traumatic Brain Injury Model 
Controlled cortical impact (CCI) was induced in rats as previously described 
(Ajao et al., 2012). Briefly, rats were anesthetized with isoflurane (Webster Veterinary 
Supply, Sterling, MA) and given a 5 mm diameter craniotomy over the right fronto-
parietal cortex (1 mm posterior, 2 mm lateral from Bregma) and CCI was delivered to 
jTBI animals using a 3 mm impactor at a 20° angle to cortex, 1.5 mm depth, 200 ms 
impact duration, 6 m/s velocity. Body temperature was maintained at 37°C during 
surgery. A subcutaneous buprenorphine injection was administered for pain relief 
(0.01mg/ml/kg at 1 hr and 24 hrs post-surgery) and animals were returned to their dams. 
All Sham animals underwent the same procedures as jTBI animals, except for the CCI. 
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Table 1.     Description of MWM swim strategies observed after jTBI 
Learning             Swim pattern               Description                                        
Strategy 
                           Spatial direct               Animal swims directly to the 
platform  
Spatial                Spatial indirect            Animal swims to the platform with 
slight deviation from a true course    
                            Focal correct              Animal swims to and searches in 
proximal quadrant for platform 
                            Scanning                    Animal searches the interior 
portion of the tank without spatial 
bias 
Systematic          Random                      Animal searches entire tank 
without spatial bias 
                            Focal incorrect            Animal swims to and searches in 
an incorrect portion of the tank 
                            Chaining                     Animal swims in repetitive loops in 
the middle of the tank 
Looping               Peripheral                   Animal swims in repetitive loops 
looping                        around  the tank’s perimeter 
jTBI, juvenile traumatic brain injury; MWM, Morris Water Maze 
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Water Maze Design and Testing 
Water maze (WM) testing has been previously described for this model (Ajao et 
al., 2012). Briefly, testing occurred at 30 and 60 dpi over a 3-day paradigm, with 5 blocks 
of 2 trials each (10 total trials) including cued testing (visible platform), spatial learning 
(hidden platform) and probe trials for spatial memory (no platform). Swim strategy 
analysis (Brody and Holtzman, 2006) revealed 8 different swim patterns grouped into 
three general learning strategies (Table 1 and Figure 5A): Spatial strategy (spatial direct, 
spatial indirect, focal correct), Systematic strategy (scanning, random, focal incorrect), or 
Looping strategy (chaining, peripheral looping). 
 
Brain Tissue Processing and Immunohistochemistry 
At 60 dpi, rats were anesthetized with a combination of Ketamine (Ketaject 
100mg/ml, Phoenix, St. Joseph, MO) and Xylazine (AnaSed 100mg/ml, Lloyd 
Laboratories, Shenandoah, IA) at the appropriate dose/body weight, and then 
transcardially perfused with 4% paraformaldehyde. Brains were excised and 
cryoprotected in 30% sucrose solution for 48 hrs, and frozen on dry ice. Coronal cryostat 
free floating sections (50 µm) were cut and collected as serial sections spaced 1.2 mm 
apart, then processed for standard immunohistochemistry experiments as previously 
described (Ajao et al., 2012).  
 
Immunoglobulin G Extravasation Staining for Blood–Brain 
Barrier 
Sections were rinsed in PBS and blocked for 1 hour in 1% bovine serum albumin 
(BSA) (Sigma-Aldrich Co., St. Louis, MO) made in PBS, pH=7.4 (Fisher Scientific, 
Pittsburg, PA) prior to incubation for 2 hrs at room temperature with Alexa-Fluor-800 
biotin conjugated affinity purified goat anti-rat IgG (1:500, Rockland Immunochemicals, 
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Gilbertsville, PA) in PBS containing 0.25% Triton X-100 and 0.25% BSA (Sigma-Aldrich 
Co., St. Louis, MO) made in PBS, pH=7.4. After washing, sections were scanned on an 
Odyssey infra-red scanner to quantify fluorescence in the cortex and striatum. 
 
Immunolabeling of Blood–Brain Barrier Proteins 
For P-gp staining, sections were pre-treated for antigen retrieval using 33% 
acetic acid + 66% EtOH solution for 10 min at 20°C (Fisher Scientific, Pittsburg, PA). For 
claudin 5, glial fibrillary acidic protein (GFAP), P-gp, LRP1, and RAGE, sections were 
blocked for 1 hour in 1% BSA in PBS prior to overnight primary antibody incubation at 
4°C. All antibody incubations were in 0.25% BSA with 0.25% Triton X-100 made in PBS, 
pH=7.4. For immunolabeling, we used mouse anti-claudin 5 (1:500, Life Technologies: 
Invitrogen, Grand Island, NY), mouse anti-P-gp (1:100, Abcam Inc., Cambridge, MA and 
Calbiochem, EMD Chemicals, Merck KGaA, Darmstadt, Germany), mouse anti-LRP1 
(1:1000, Calbiochem, EMD Chemicals, Merck KGaA, Darmstadt, Germany), rabbit anti-
RAGE (1:500, Abcam Inc., Cambridge, MA) and chicken anti-GFAP (1:1000, Millipore, 
Temecula, CA). After PBS rinses, we incubated in secondary antibody for 2 hrs at room 
temperature at 1:1000 as appropriate for each primary antibody: goat anti-mouse 
secondary antibody coupled with Alexa-Fluor-488 or with Alexa-Fluor-594, goat anti-
chicken coupled with Alexa-Fluor-568, and for infra-red analysis either goat anti-mouse 
secondary antibody coupled with Alexa-Fluor-800 or goat anti-rabbit secondary antibody 
coupled with Alexa-Fluor-680 (all secondaries from Invitrogen, Grand Island, NY). After 
washes in PBS, sections for classical immunofluorescence were mounted on glass 
slides and coverslipped with vectashield anti-fading medium containing DAPI (Vector, 
Vector Laboratories, Burlingame, CA). Sections for infra-red analysis were mounted on 
glass slides and air-dried. Control sections for all studies in which primary or secondary 
antibodies were omitted resulted in negative staining (not shown). 
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Immunolabeling for Aβ 
Sections for amyloid analysis were pre-treated for 4 min in 88% formic acid at 
room temperature and all other immunostaining procedures were identical to the 
procedure described above. We used a monoclonal antibody raised in mouse, against 
rodent Aβ at the N-terminal amino acids 1-16 (1:1000, from M. Paul Murphy) and 
visualized staining with goat anti-mouse secondary antibody Alexa-Fluor-488 (1:1000; 
Life Technologies: Invitrogen, Grand Island, NY). Adjacent sections were co-incubated 
with the mouse rodent-Aβ antibody and either the C-terminal antibody against Aβ1-42 
(rabbit, 1:1000, Covance, Emeryville, CA), or the microglial marker ionized calcium 
binding adaptor molecule 1 (IBA1) (rabbit, 1:1000, Wako Chemicals, Richmond, VA). To 
control for non-specific binding of mouse antibodies on rat tissue (Figure 3F), sections 
received only the secondary antibody, goat anti-mouse Alexa-Fluor-594 (staining was 
negative), followed by a full protocol with both the rodent-Aβ antibody and goat anti-
mouse Alexa-Fluor-488. Sections were also stained with the 6E10 anti-human-Aβ1-16 
antibody (mouse, 1:5000, Covance, Emeryville, CA) or using protocols excluding primary 
or secondary antibodies, resulting in negative staining (not shown).  
To determine any fibrillar beta-pleated sheet structures, sections were double 
stained with a rodent-Aβ (see above) followed by Thioflavin S staining. Briefly, tissue 
was immersed for 5 min in double-distilled (dd) H20, followed by a 5 min incubation in 
1% Thioflavin S (Sigma-Aldrich Co., St. Louis, MO) made in ddH20, and subsequent 
differentiation using consecutive 5 min washes in 70% EtOH, 95% EtOH, and ddH20 
(Fisher Scientific, Pittsburg, PA). Slides were then coverslipped as described above.  
 
Quantification of Immunohistochemistry 
Coronal sections immunostained with infra-red secondary antibodies (IgG and 
RAGE) were scanned using the same parameters for sham and jTBI at a 21 µm 
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resolution (Li-Cor Odyssey Bio-Science, Lincoln, NE) and identical regions-of-interest 
(ROIs) were drawn using Li-Cor Odyssey software (Ajao et al., 2012). For IgG, average 
values per animal were obtained from ROIs in the perilesional parietal cortex and 
striatum in the hemisphere ipsilateral to the lesion, and analogous areas were evaluated 
in the hemisphere contralateral to the lesion or craniotomy, for a total of 3-5 serial 
coronal sections as available (n=4 sham, n=4 jTBI). For RAGE, average values per 
animal were obtained from ROIs in the parietal and temporal cortex in hemispheres both 
ipsilateral and contralateral to the lesion or craniotomy from 4 coronal sections at 
bregma levels -1.6 mm, -2.8 mm, -4.0 mm, and -5.2 mm (n=3 sham, n=3 jTBI).  
For quantification of classical immunolabeling of claudin 5, P-gp, LRP1, and Aβ, 
images were evaluated and collected using an epifluorescent microscope (Olympus, 
BX41, Center Valley, PA). The threshold and morphological user-defined parameters 
were selected to maximize visualization of positive staining in the ROIs for each protein 
staining pattern. These parameters were kept consistent for all animals during image 
acquisition. For claudin 5, P-gp, and LRP1 a series of images were taken in the parietal 
and temporal cortex, both above and below the rhinal fissure on each hemisphere 
ipsilateral and contralateral to the lesion or craniotomy using a 20X objective (422 µm X 
338 µm). For claudin 5, images of large intra-parenchymal vessels (30-100μm diameter) 
and a separate analysis on microvessels (10-20μm diameter) were acquired from two 
serial coronal sections at bregma level -2.8 mm and -4.0 mm (n=4 sham, n=4 jTBI; 8 
images/animal for large vessels and 8 images/animal for small vessels). For P-gp, 
images were acquired from four serial coronal slices at bregma level -2.8 mm, -4.0 mm, -
5.2 mm, and -6.4 mm (n=6 sham, n=6 jTBI; 24 images per animal). For LRP1, images 
were acquired from two serial coronal slices at bregma level -4.0 mm and -5.2 mm (n=3 
sham, n=3 jTBI; 8 images per animal). Individual images were analyzed with MorphoPro 
software (Explora-Nova, La Rochelle, France), using the following procedure: 1) Top Hat 
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morphologic filter to outline vascular staining, 2) user-defined thresholding value applied 
to each image, 3) calculation of area of staining from background for each protein of 
interest (claudin 5, P-gp, or LRP1). Final values are represented as a percentage of the 
sham group. 
For quantification of rodent-Aβ immunoreactivity, we used 8 whole serial coronal 
slices per animal spaced 1.2 mm apart, from bregma levels +3.2 mm to -5.2 mm as 
shown in Figure 4 (n=8 sham, n=6 jTBI; 112 total individual values). Mercator software 
(Explora-Nova, La Rochelle, France) was used to automatically calculate the area (µm
2
) 
of positive staining that was normalized to the total area (µm
2
) of each respective 
coronal slice and presented as % of Aβ load. 
 
Brain Tissue Processing for Western Blotting 
A Protein FFPE extraction kit (Qiagen, Hilden, Germany) was used to process 
perfused brain slices for Western blotting. Parietal and temporal cortical tissue above the 
rhinal fissure was excised from three coronal sections at bregma levels -1.6 mm, 2.8 
mm, and -4.0 mm, that were adjacent to slices of interest used for 
immunohistochemistry. Briefly, tissue was homogenized and processed according to kit 
instructions, and then samples were assayed for total protein concentration by 
bicinchoninic assay (BCA, Pierce Biotechnology Inc., Rockford, IL). The human Aβ1-40 
and Aβ1-42 peptides (Biopeptide Co., San Diego, CA) were prepared using a 1mg 
sample that was reconstituted to obtain 231µM Aβ1-40 and Aβ1-42 peptides in NaOH 
(Sigma-Aldrich Co., St. Louis, MO). Peptides were then incubated overnight at 37°C and 
aliquoted for storage at -80°C, then thawed on ice when ready for use. For gel 
electrophoresis, all samples were prepared with loading sample buffer and reducing 
agent (Invitrogen, Carlsbad, CA) for a total of 40 µg of rat protein, 4 µg of Aβ1-40 
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peptide, and 0.5 µg of Aβ1-42 peptide, loaded on a 4-12% SDS polyacrylamide gel 
(Nupage, Invitrogen, Carlsbad, CA). Proteins were transferred to a polyvinylidene 
fluoride membrane (PVDF, PerkinElmer, Germany), blocked for 1 hr in Odyssey blocking 
buffer (Li-Cor Bio-Science, Lincoln, NE), and incubated with the same monoclonal 
antibody against rodent-Aβ used in immunohistochemistry (1:2000; from Dr M. Paul 
Murphy, University of Kentucky) or a monoclonal antibody anti-human-Aβ 6E10 (1:750; 
Covance, Emeryville, CA). P-gp and claudin 5 antibodies were used as in the 
immunostaining, namely mouse anti-P-gp (1:100, EMD Chemicals, Merck KGaA, 
Darmstadt, Germany) and mouse anti-claudin 5 (1:200, Life Technologies: Invitrogen, 
Grand Island, NY), and these blots were incubated with Biotin-SP-conjugated goat anti-
mouse (1:5000; Jackson ImmunoResearch Laboratories, West Grove, PA) for 1.5 hours 
at room temperature, followed by PBS washes. The blots were then incubated for 1 hour 
at room temperature with Streptavidin-conjugated-IRDye 800 (1:10000; Li-Cor Bio-
Science, Lincoln, NE), before scanning. Each western blot was co-incubated with a 
rabbit polyclonal antibody against beta-actin (1:1250; Sigma-Aldrich Co., St. Louis, MO) 
in Odyssey blocking buffer (Li-Cor Bio-Science, Lincoln, NE) overnight at 4°C. After PBS 
washes, proteins were visualized using a co-incubation with goat anti-mouse secondary 
antibody coupled with Alexa-Fluor-800 (1:10,000; Rockland Immunochemicals, 
Gilbertsville, PA) and goat anti-rabbit secondary antibody coupled with Alexa-Fluor-680 
(1:10,000; Life Technologies: Molecular Probes, Grand Island, NY) for 2 hrs at room 
temperature. After PBS washes, the PVDF membrane was visualized using the Li-Cor 
infra-red scanner. 
 
Statistical Analyses 
All data are presented as mean ± SEM, statistical analyses were done using 
SPSS, and graphs obtained using SigmaPlot. For the Aβ analyses, we utilized a 
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repeated measures ANOVA with group (jTBI, sham) x bregma level (8 serial coronal 
sections) and a conservative Huyhn-Feldt adjustment to the degrees of freedom was 
used to protect against any violations of the sphericity and compound symmetry 
assumptions underlying this ANOVA model. For the behavioral strategy analysis, data 
were analyzed using independent samples t-tests to test between-group differences at 
each time point, and paired-samples t-test to analyze within-group effects across time 
points. All other histological data between sham and jTBI animals met statistical 
assumptions and were analyzed using student t-tests. 
 
Results  
Blood–Brain Barrier Phenotype 
While disruption of the BBB after jTBI lasts only for a short period of about 7 days 
(Pop and Badaut, 2011), little is known about its recovery and structural properties at a 
delayed post-jTBI time point. We evaluated several BBB markers at anatomical sites 
near the lesion, as well as on coronal slices at a distance from the injury site at 60 dpi.  
IgG extravasation staining (Figure 1A, B) and quantification (Figure 1C) did not 
show any difference between sham and jTBI groups in perilesional parietal cortex and 
striatum, suggesting that the BBB is no longer disrupted. IgG extravasation was 
observed as expected in regions without a BBB, such as the median eminence (Figure 
1A, B). In accordance with this result, claudin 5 immunolabeling was positive and 
outlined the elongated endothelial membrane structure of large vessels (Figure 1D,E) 
and microvessels (Supplemental Figure 1A-B) of both sham and jTBI animals. Claudin 5 
staining was significantly increased in the large intracortical blood vessels of jTBI 
animals compared to sham (Figure 1F, p<0.045), but no changes were observed in 
microvessels (Supplemental Figure 1C). Collectively, these data indicate that although 
BBB disruption is no longer present at 60 dpi, protein expression within the BBB is 
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changed long after injury. 
To further address phenotypic changes at the BBB, we characterized the 
distribution of P-gp, LRP1, and RAGE proteins known to be involved in BBB trafficking. 
P-gp immunostaining was observed primarily on endothelial cells, in both jTBI and sham 
animals co-labeled with the astrocytic marker, GFAP (Figure 2D-F).  
Sham animals exhibited more intense and widespread staining patterns on microvessels 
(Figure 2D), whereas jTBI had more diffuse vascular staining of P-gp (Figure 2E). 
Quantification of images from the parietal and temporal cortices revealed significantly 
decreased levels of P-gp immunoreactivity in jTBI cortical vessels compared to sham 
(Figure 2F, p<0.05). Similarly, western blot analysis revealed significantly lower P-gp 
protein levels in jTBI compared to sham, as shown in representative cases (Figure 2G) 
and blot quantification (Figure 2H, p<0.05). LRP1 immunostaining in the parietal and 
temporal cortices showed a positive signal in both neuronal and vascular compartments 
(Figure 2A-B), that are consistent with prior reports of LRP1 staining in neurons, 
endothelial cells, and astrocytes (Silverberg et al., 2010). Quantification of LRP1 
immunoreactivity showed a decrease in jTBI animals without reaching significance 
(Figure 2C, p<0.1). RAGE immunolabeling also revealed a ubiquitous staining pattern 
encompassing several cell types. No differences were found in RAGE immunoreactivity 
between sham and jTBI in the parietal and temporal cortex, as measured using infra-red 
immunolabeling (data not shown). Altogether, our data indicate jTBI alters BBB proteins 
involved in efflux (P-gp) without significant changes to LRP1 or influx (RAGE) at the 
endothelial interface between the blood and brain.  
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Figure 1. Changes in endothelial tight junctions 2 months after juvenile traumatic 
brain injury (jTBI). (A, B) Immunoglobulin G (IgG) extravasation using infrared 
immunolabeling showed higher staining intensity at the median eminence and glia 
limitans of both (A) sham and (B) jTBI. (C) IgG levels were unchanged as 
quantified in the bilateral parietal cortex and striatum, thus indicating an overall 
lack of overt blood–brain barrier (BBB) leakage. (D, E) Endothelial tight-junction 
protein claudin 5 (Cld5) was observed on endothelial cells of intraparenchymal 
vessels in both (D) sham and (E) jTBI and (F) Cld5 quantification in the parietal 
and temporal cortices shows that jTBI have significantly increased Cld5 staining 
(p< 0.05), perhaps as a restorative mechanism to improve BBB function (*p< 0.05; 
values are represented as mean±s.e.m.; IR, infrared; Cld5, claudin 5; white 
arrowhead in B = lesion cavity; scale bar in (D, E) = 50 μm).
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Figure 2. Juvenile traumatic brain injury (jTBI) changes proteins involved in cellular 
trafficking at the blood-brain barrier. (A, B) LRP1 immunostaining is demonstrated 
in both the vascular walls (white arrowheads in D, E) as well as neuronal 
compartments (white arrows in A, B) in the cortex of a representative sham. (C) 
Quantification of LRP1 immunostaining in the parietal and temporal cortex shows 
that jTBI animals have lower overall staining of LRP1, but no significant differences 
were found between groups. (D, E) P-gp immunostaining is specific for endothelial 
cells (green), as shown in close proximity to the end-feet of GFAP-positive 
astrocytes (red) in both (D) sham and (E) jTBI. (F) P-gp quantification in the 
parietal and temporal cortices shows a significant decrease in vascular P-gp 
transporter in jTBI compared to sham (p<0.05). (G, H) Protein levels of jTBI are 
also significantly lower than sham, as shown in representative cases and 
quantification (p<0.05). (*p<0.05; values as mean +/-SEM; BBB, blood-brain 
barrier; jTBI, juvenile traumatic brain injury; LRP1, lipoprotein receptor-related 
protein 1; P-gp, p-glycoprotein; GFAP, glial fibrillary acidic protein; scale bar in A = 
20 µm; B, D, E = 50 µm)  
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Widespread Aβ Accumulation 
Using a rodent-Aβ antibody specific to the N-terminus and a formic acid pre-
treatment, we detected a diffuse pattern of immunoreactivity that is both extracellular 
(Figure 3 A, C-H) and perivascular (arrowheads in Figure 3C, E-H). Examples of positive 
rodent-Aβ immunolabeling are shown at a distance from the injury, such as the frontal 
(Figure 3C, E-H), temporal (Figure 3A), and parietal cortex (Figure 3D). Positive staining 
was also detected in the entorhinal cortex, striatum, and thalamus (Figure 4A), with no 
staining using the secondary antibody alone (Figure 3A).  
Western blot showed that the rodent-Aβ antibody was specific for rat tissue but 
not for human Aβ1-40 and Aβ1-42 peptides, while the anti-human 6E10 antibody 
detected bands for human Aβ peptides, but no signal for rat tissue (Figure 3B). The 
6E10 antibody detected monomeric Aβ species (4kDa) in both human Aβ1-40 and Aβ1-
42 peptide preparations, and several Aβ aggregates that are more abundant in the Aβ1-
42 preparation (Figure 3B). In the rat tissue, the rodent-Aβ antibody reveals a beta-
amyloid precursor protein (APP) signal near the expected region ~110kDa and several 
additional bands, possibly APP fragments or Aβ aggregates of various sizes (Figure 3B).  
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Figure 3. Immunoreactivity patterns with a rodent-Aβ antibody. (A-H) Positive 
staining is detected in several brain regions following formic acid pre-treatment and 
classical immunostaining using the specific rodent-Aβ antibody, as shown in 
representative sections from jTBI animals. (A) Temporal cortex shows specificity of 
the rod-Aβ antibody (labeled with goat anti-mouse λ488 nm), with negative staining 
using the secondary antibody alone on the same section (2nd alone, pre-incubation 
protocol with goat anti-mouse λ594 nm). (B) Western blotting from the 
parietal/temporal cortex shows the rod-Aβ antibody has high specificity for rat cortex, 
but not for human Aβ1-40 or Aβ1-42 peptides, while the 6E10 antibody has high 
specificity for human Aβ peptides at 4kDa and larger aggregates, but no signal for rat 
tissue. In the rat, the rod-Aβ antibody reveals a prominent APP band and several 
smaller fragments, indicating positive immunoreactivity for both Aβ aggregates or 
APP fragments. (C) In an example from the frontal cortex, rod-Aβ stains a cluster of 
several extracellular diffuse deposits (white arrows) and vascular labeling (white 
arrowheads) near the molecular and superficial cortical layers. (D) In an example 
from the parietal cortex, rod-Aβ staining is often surrounded by IBA1-positive 
microglial processes with an abnormal morphology (white arrowheads) suggestive of 
an immune response. (E, F, G, H) Co-incubation with both rod-Aβ antibody (raised in 
mouse, secondary λ488 nm) and a C-terminal antibody against Aβ42 (raised in 
rabbit, secondary λ594 nm) in the frontal cortex, shows several areas of 
colocalization (white arrowheads) as well as areas without overlap, indicating the 
presence of several Aβ species.  
(Aβ, beta-amyloid; rod-Aβ, rodent beta-amyloid antibody; 2nd alone, secondary 
antibody alone; APP, beta-amyloid precursor protein; M, marker; kDa, kilodalton; 
IBA1, ionized calcium binding adaptor molecule 1; scale bars in A, C = 100 µm, D = 
40 µm; E, F, G, H = 30 µm)  
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Rodent-Aβ immunoreactivity was associated with microglial cells, stained with 
IBA1. Microglia exhibited an elongated soma, little somatic cytoplasm, and multiple 
thinner processes, as shown in an example from the jTBI parietal cortex (Figure 3D). No 
activated microglia were detected at this time point (data not shown). Rodent-Aβ 
immunoreactivity colocalized with C-terminal-Aβ1-42 staining in several brain regions, 
such as the frontal cortex (Figure 3E-H). Thioflavin S staining (data not shown) is 
negative despite positive rodent-Aβ immunoreactivity, suggesting a lack of fibrillar beta-
pleated sheet structures. Overall, these data are consistent with an early Aβ 
accumulation pattern having a diffuse morphology and containing Aβ1-42 species.  
Total rodent-Aβ immunoreactivity was quantified using the Mercator program and 
expressed as % Aβ load relative to total coronal brain area at each bregma level (Figure 
4A-C). Representative jTBI animals are shown with the lesion location (black 
arrowheads in Figure 4A) and outlines of positive staining at individual bregma levels 
(Figure 4A). By 60 dpi, the cortical jTBI lesion cavity is apparent from bregma -1.0 mm 
up to -4.0 mm (not shown) and higher rodent-Aβ immunoreactivity was observed in more 
anterior and posterior levels from the lesion site (Figure 3B). Repeated measures 
ANOVA showed significant changes across all coronal sections regardless of group 
(Figure 4B, p<0.042), with moderate changes across bregma levels in jTBI group alone 
(p<0.057), but no changes observed in sham alone (p>0.1). Similarly, the jTBI group 
showed a trend for higher staining in total brain compared to sham (Figure 4C, p<0.073). 
These data suggest that early brain injury may exacerbate a process of endogenous 
rodent-Aβ accumulation throughout vulnerable regions over time.  
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Figure 4. Anterior to posterior patterns of rodent-Aβ distribution. (A) Representative 
coronal sections with outlines of rodent-Aβ positive staining in jTBI are shown at 
bregma +1.7 mm, -0.4 mm, -1.4 mm, and -5.2 mm. The jTBI lesion cavity is apparent 
in the parietal cortex at -1.4 mm and still visible at bregma -0.4 and -3.8 mm to a 
lesser extent (black arrowheads). (B) All positive rodent-Aβ immunoreactivity was 
quantified to obtain %Aβ load relative to total brain area at 8 bregma levels, with 
significant changes along the anterior-to-posterior axis (p<0.042), but no significant 
changes between groups at any single level. (C) Summation of total brain Aβ load 
was higher in jTBI versus sham (p<0.073), with jTBI animals showing high staining 
variability common in models of natural Aβ accumulation. (Values are represented 
as mean +/-SEM; mm, millimeter; Aβ, beta-amyloid; jTBI, juvenile traumatic brain 
injury)  
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Changes in Strategy during Water Maze 
As previously reported, sham and jTBI animals showed no overall performance 
differences across trials on swim speed, cued learning, or spatial learning/memory at 30 
or 60 dpi (Ajao et al., 2012). The cumulative distance travelled for both groups showed 
no differences in spatial learning at 30 dpi (Figure 5B) and 60 dpi (Figure 5C). As 
expected due to repeated testing, performance during block 1 of day 60 was better than 
block 1 of day 30 (Figure 5B versus 5C, p<0.05) for both jTBI and sham animals, and 
both groups traveled the same average distance for remaining blocks. In addition, we 
analyzed swim patterns and learning strategies for individual spatial trials (Table 1, 
Figure 5A). Generally, jTBI animals used fewer spatial strategies, and more systematic 
and looping strategies, compared to sham animals at 60 dpi (Figure 5E) but not at 30 dpi 
(Figure 5D). Specifically, the stacked bar graphs (Figure 5D, E) represent a breakdown 
of the % spatial testing trials classified under spatial, systematic, or looping swim 
strategies. We observed no significant differences between groups in any strategy 
categories at 30 dpi. However, we detected significant changes at 60 dpi where shams 
used more spatial strategies than jTBI animals (88.9% versus 62.5% respectively, 
p<0.05). In addition, shams exhibit an increased use of spatial strategies from 30 to 60 
dpi (37.5% versus 88.9% respectively, p<0.05). In contrast, jTBI animals have nearly 
identical strategy groupings at both time points, displaying an inability to improve 
performance over time.  
 
Discussion 
We evaluated long-term changes following TBI in a juvenile rat model to address 
the concordance with clinical observations of delayed behavioral modifications, and 
emerging data on changing BBB properties during brain aging and neurodegenerative 
disease. Our results at a delayed two-month time point show parallel changes in 
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structural BBB phenotypes of claudin 5, altered P-gp expression, rodent-Aβ 
immunoreactivity, and altered water maze performance. Together, our data suggest that 
an early brain injury may commence with vascular damage that promotes long-term 
phenotypic changes to the BBB that can influence cognition.  
 
Physiopathological Changes in the Blood–Brain Barrier 
We explored BBB phenotypes at a delayed time point after juvenile injury as a 
unique platform for addressing whether jTBI disrupts the neurovascular unit (NVU) and 
contributes to brain pathophysiology. Within the first days post-injury, we observe high 
IgG staining (Pop and Badaut, 2011). BBB disruption is repaired by two months in our 
jTBI model, as evidenced by the absence of IgG extravasation and increases in tight 
junction protein claudin 5 (Figure 1). Other studies also report that improved BBB 
integrity coincides with altered expression of tight junction proteins at later time points. 
Similar to our model, claudin 5 levels are up-regulated after Evans blue and IgG leakage 
subsides at 1 and 2 weeks after rat cortical injury(Lin et al., 2010). Claudin 5 is also 
increased, along with resolution of Evans blue staining, after 4 and 8 weeks in mice 
exposed to an infectious agent targeting the BBB (Liao et al., 2008). Thus, altered levels 
of claudin 5 long after jTBI suggest delayed modifications in BBB structural properties. 
Furthermore, our differential observations on large and small vessels (Figure 1, 
Supplemental Figure 1) indicated a more complex phenotypic response of the 
endothelium which may be related to location along the vascular tree.  
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Figure 5. Differences in water maze strategies in adulthood. (A) Eight swim 
patterns/learning strategies (red lines) were identified and divided into 3 categories 
from the most (+) to the least (-) efficient: spatial, systematic, and looping. (B-C) 
Water maze performance is unchanged between groups at (B) 30 days and (C) 60 
days post-jTBI, however both groups improve and learn the task within each time 
point (Block 1 to 5) and between testing time points (comparison of Block 1 at 30 
versus 60 days). (D) Swim strategy use was evenly distributed among sham and 
jTBI groups at 30 days, but not at 60 days. By 60 days, jTBI animals used strategies 
similar to those used at 30 days (primarily systematic and looping patterns), but 
sham controls relied on significantly more spatial memory strategies compared to 
jTBI and to their prior performance at 30 days (p<0.05). (Values as mean +/-SEM; 
jTBI, juvenile traumatic brain injury; + and – in A= most and least efficient, 
respectively)  
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We investigated the triad of endothelial cell proteins (P-gp, LRP1, and RAGE) 
previously shown as potential mediators of Aβ trafficking and other proteins across the 
BBB (Figure 6) (Miller, 2010, Ueno et al., 2010). P-gp is well known as an efficient 
gatekeeper on the luminal side and often pharmaceutically by-passed to allow efficient 
drug delivery. Its expression is influenced by several distinct molecular pathways and its 
putative role in disease and injury is emerging (Kooij et al., 2010, van Assema et al., 
2012). We observed a significant decrease in P-gp in cortical vessels following jTBI by 
immunostaining and protein blot analyses. Similar to our findings, brain P-gp protein 
level and function decreased after irradiation of normal rats (Bart et al., 2007), in aged 3 
year old rats (Silverberg et al., 2010), and in sporadic AD (van Assema et al., 2012). 
Additionally, P-gp expression and function were impaired during multiple sclerosis 
pathology and its dysfunction coincides with lymphocyte infiltration and inflammation in 
experimental allergic encephalomyelitis (Kooij et al., 2010).  
Our observed P-gp decreases may be one result of long-lasting 
neuroinflammation, contributing to an increase in rodent-Aβ immunoreactivity. 
Importantly, P-gp knockout mice exhibited decreased LRP1 in brain capillaries without 
changes in RAGE proteins (Cirrito et al., 2005) and aged 3 year old rats showed 
decreased vascular levels of P-gp and LRP1 associated with accumulation of Aβ 
(Silverberg et al., 2010). We did not detect significant changes in LRP1 between sham 
and jTBI, but LRP1 was positive in blood vessels and neurons within the temporal cortex 
of jTBI animals. Our findings are in line with several model systems and age groups, 
which emphasize the putative role of the BBB in chronic brain pathophysiology after 
acute injury. Our observed P-gp decrease may have a complex relationship to 
accumulation of rodent-Aβ in multiple brain areas. Frontal and temporal lobes are 
vulnerable to neuropathology after TBI (Johnson et al., 2012). In our model, these same 
regions exhibited reduced P-gp (Figure 1) and increased rodent-Aβ immunoreactivity in 
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the brain parenchyma and vessel walls (Figure 3, 4). Clinically, our findings are similar to 
low endothelial P-gp that correlated with increased parenchymal Aβ1-40 or Aβ1-42 
plaques in the medial temporal lobe of aged non-demented humans (Vogelgesang et al., 
2002). Following peripheral Aβ1-42 injections in adult mice, brain endothelial cells show 
downregulated expression of RAGE, LRP1 and P-gp at the mRNA level, however P-gp 
immunostaining remained unchanged (Brenn et al., 2011). Collectively, these findings 
highlight complex interactions between Aβ species and the BBB transporters that may 
be influenced by injury type and study time point.  
 
Aβ Accumulation and Blood–Brain Barrier Changes after 
Juvenile Traumatic Brain Injury 
The important consequences of cerebrovascular dysfunction and the role of the 
BBB neuropathological protein trafficking are gaining momentum. In normal rodents, 
classical AD-like pathology with fibrillar amyloidosis is rare. This may be due to Aβ 
sequence differences of three amino acids at the N-terminal (Istrate et al., 2012). 
However, we used an N-terminal specific antibody for rodent Aβ (McGowan et al., 2005), 
and endogenous accumulation has been reported long after a brain insult in normal 
experimental injury models. For example, increased APP and Aβ immunostaining was 
observed in thalamic nuclei for up to 9 months after stroke in normal rats (van Groen et 
al., 2005). In normal adult rats, intranasal nerve growth factor administration resolved 
increases of Aβ1-42 for up to two weeks post-TBI (Tian et al., 2012). In a rodent model 
of aging, senescence accelerated mice (SAMP8) showed increased BBB disruption at 
12 months and exhibited vascular Aβ compared to their littermate controls (Del Valle et 
al., 2011). These data indicate the close relationship of BBB disruption and brain 
pathology in aging and post-injury.  
BBB phenotypic changes at 2 months occurred in parallel with higher rodent-Aβ 
118 
immunolabeling in the parenchyma and vasculature of jTBI animals (Figure 3, 4). 
Notably, we observed diffuse Aβ deposition in regions remote to the original site of 
impact, especially in the superficial cortical layers. Additionally, diffuse Aβ in superficial 
cortical layers is the primary conformation present in other models of natural Aβ 
accumulation, such as aged beagles (Pop et al., 2012). Diffuse Aβ is also more common 
in clinical cases with mild cognitive impairment (MCI) (Jicha et al., 2006) and is 
becoming recognized as an important contributor to disease progression by the National 
Institute of Aging-Alzheimer’s Disease (Montine et al., 2012). Aβ load, evaluated by 
immunohistochemical staining similar to our methodology, was the best predictor for 
dementia in very old individuals (Robinson et al., 2011). Interestingly, we observed 
sparse rodent-Aβ immunoreactivity in some shams (n=3 of 8 total) and only modest 
effects of increased rodent-Aβ immunolabeling throughout the brain of jTBI animals (n=6 
total). In a similar TBI model, sham animals with a craniotomy exhibited brain tissue 
modifications and deficits in learning and memory post-surgery (Bertolizio et al., 2011). 
Therefore, we expect that inclusion of additional animals or a more appropriate naïve 
control group may improve our data variability and improve statistical power.  
 
Parallel Changes in Vascular Phenotype and Behavioral 
Dysfunction 
In our injury model, we observed changes in behavioral outcome by two months 
post-injury (Ajao et al., 2012), which indicate the brain may be undergoing compensatory 
mechanisms. Here, we observed strategic water maze impairment without overt memory 
deficits, which may reflect underlying brain-repair mechanisms occurring post-injury. 
Interestingly, clinical defects of initial strategy formulation affected performance on a task 
of complex visuospatial executive function in individuals with amnestic MCI who are 
more likely to develop AD (Papp et al., 2011). In a CCI study in adult mice, sham and 
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TBI animals exhibited similar water maze outcomes after two months, but TBI animals 
exhibited thigmotaxic strategy impairment with increased percent time swimming along 
maze walls, similar to our looping category (Blaiss et al., 2011). In comparison with adult 
models, juvenile rats may be especially vulnerable due to a lack of cognitive reserve. 
While the neural correlates are unclear, clinically it is thought that having increased 
cognitive reserve from education and other life experiences may be protective against 
brain aging and disease (Honer et al., 2012). Thus, brain injury at a developmental stage 
may influence underlying mechanisms and reduce cognitive reserve. Our observations 
of delayed impairments in jTBI suggest a parallel with acceleration of brain aging and 
disease due to trauma.  
 
Concluding Remarks  
Juvenile traumatic brain injury may induce initial BBB dysfunction which 
progresses over time to affect protein trafficking at a time point relevant for cognition. 
Our data are consistent with clinical and experimental findings in studies of TBI and Aβ 
in transgenic models, as well as studies on BBB dynamics with aging and non-traumatic 
brain injuries. However, only the use of further target-specific studies may address 
whether these changes are interconnected, or whether they are independent parallel 
events in the same trauma-affected brain. In this study, we described lasting effects of 
jTBI with phenotypic BBB changes after two months, including a lack of IgG 
extravasation and compensatory increases in structural tight junction protein claudin 5 
(Figure 6) (Andras et al., 2010). However, the reduction in P-gp may be sufficient to 
impair normal Aβ clearance and promote its accumulation inside the brain. Overall, we 
show the presence of continued modifications in the BBB phenotype long after injury, 
and propose the BBB as a meaningful therapeutic target for resolving detrimental post-
traumatic dysfunction.   
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Figure 6. Summary of parallel changes in adulthood after early brain injury. A 
schematic representation of events two months after jTBI shows phenotypic 
alterations to the BBB changes occurring in parallel with molecular and behavioral 
dysfunction. Specifically, lack of IgG extravasation from the blood into the tissue 
and increased levels of tight-junction marker Cld5 indicate an intact BBB during 
adulthood. However, in an environment with decreased levels of P-gp, and 
unchanged levels of LRP1 and RAGE, proper metabolism of toxic proteins such as 
Aβ can be hindered. As a result, the BBB phenotype impairs normal clearance of 
rod-Aβ and may promote its abnormal accumulation inside the brain in the 
parenchyma and vascular walls (figure adapted from Andras et al., 2010).  
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PROLOGUE TO CHAPTER 3 
LONG-TERM INCREASE OF CAVEOLINS IN THE ENDOTHELIUM 
AND IN ASTROCYTES AFTER JUVENILE TRAUMATIC BRAIN 
INJURY 
 
A reproducible juvenile TBI (CCI in P17 rat pups) model and the histopathological 
features and functional deficits resulting from the injury at both acute and chronic time 
points have been described in chapters 2. In keeping with the experimental aims of this 
project, chapter 3 focuses on caveolins and their association with BBB disruption, and 
possibly with other secondary processes following juvenile TBI. Caveolin-1, -2, and -3 
are a family of integral membrane proteins that constitute the coat of caveolae – small 
invaginations of plasma membrane in lipid rafts – and perform various roles ranging from 
transcytosis and endocytosis to cholesterol metabolism and modulation of numerous 
intracellular signaling pathways. Regulation of tight junction permeability is suspected to 
be one of the functions of caveolins in the developing brain following TBI.  
The relevance of caveolin expression and activation to the secondary 
pathophysiology of juvenile TBI has been reviewed in chapter 1 (and is also reviewed in 
the introductory section of this chapter 3). In chapter 4, the therapeutic potential of 
cavtratin – an injectable peptide mimetic of the caveolin scaffolding domain is 
investigated with respect to slowing and/or reversing BBB disruption and cerebral 
edema, and also in terms of improving functional outcomes. 
The aim of this chapter is to characterize changes in the expression pattern and 
immunoreactivity of caveolin-1, -2 and -3 following juvenile TBI in conjunction with BBB 
disruption and edema formation. The hypothesis is that decrease in tight junction protein 
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levels and the resultant opening of BBB will be associated with increased expression of 
caveolins-1, 2, and 3 in brain endothelial cells and other cells following juvenile TBI.  
The chapter follows the blueprint of a scientific manuscript. It contains 5 figures 
with detailed figure legends. Authors’ names and affiliations are on the first page. 
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Abstract 
Caveolins are structural proteins involved in caveolae formation as well as in 
modulating the activities of a wide variety of signaling molecules. Three isoforms of 
caveolin are known to be present in the mammalian brain and hypothesized to be 
involved in blood-brain barrier (BBB) dysfunctions after brain injury with vascular 
phenotypic changes. Traumatic brain injury (TBI) is one of the major causes of death 
and disability in children and adolescents, and results in a complex cascade of events 
including the disruption of BBB. Juvenile TBI (jTBI) induces long-term alterations on 
endothelial phenotypes such as increase of claudin-5 and a decrease in p-glycoprotein. 
In the present study, we explored the changes of the caveolin expression and 
distribution after jTBI.  Using a controlled cortical impact on post-natal 17 day-old rats as 
a model of jTBI, BBB was observed to be disrupted from 1 to 3 days after injury and 
went back to normal at day 7. Caveolin (cav)-1 was increased from day 1 to 60 after 
injury in the endothelial cells and in the reactive astrocytes. In contrast, cav-2 
expression, only present in the endothelium, was not modified over time after injury. 
Cav-3 was observed in astrocytes and increased in the border of the lesion in the 
reactive astrocytes at 1 and 3 days after injury.  The long-term change observed in cav-1 
after jTBI makes this a good molecular candidate for controlling endothelial phenotypic 
changes after injury. Increase of cav-1 and 3 in the astrocytes also raises an interesting 
question regarding their roles in the reactive astrocytes after jTBI. 
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Introduction  
Traumatic brain injury (TBI) affects about 1.7 million people annually and 
accounts for about 30.5% of all injury-related deaths in the United States. Children and 
adolescents aged between 0 to 14 years represent a vulnerable population with half a 
million TBI-related emergency department visits annually (Faul et al., 2010). As such, 
juvenile TBI (jTBI) is a leading cause of death and disability in children and adolescents 
in the United States (Schneier et al., 2006). TBI is defined as brain damage that results 
from an external mechanical force (e.g. rapid acceleration or deceleration), blast waves, 
penetration by a projectile, or direct impact, and it is often accompanied by a post-injury 
concussion or similar form of altered consciousness (Maas et al., 2008). In connection 
with the primary injury, TBI is associated with secondary events, which include 
hemorrhage, disruption of blood-brain barrier (BBB), and vasogenic edema (Pop and 
Badaut, 2011). TBI in the juvenile population has been associated with greater risks of 
cerebral hemodynamic dysfunction, hypoxic-ischemic injury, and diffuse cerebral edema 
compared to adults (Armstead, 1999, Suh et al., 2001, Giza et al., 2007, Freeman et al., 
2008). In an experimental model of jTBI, we have previously shown an increase in brain 
water content during the first week post-injury using T2-weighted MRI (Fukuda et al., 
2012). Further post-traumatic secondary events include brain swelling, decrease in 
cerebral blood flow (CBF), perturbation of ionic homeostasis that induce dysfunction in 
neuronal firing, excitotoxicity, apoptosis, oxidative stress, and inflammation (Baethmann 
et al., 1988, Armstead, 1999, Sahuquillo et al., 2001, Gaetz, 2004, Zweckberger et al., 
2006). All these events contribute to neurological deterioration, leading to mortality and 
morbidity after TBI.  
TBI-induced vascular changes have been shown to alter endothelial phenotypes 
both acutely and chronically after injury (Pop and Badaut, 2011, Pop et al., 2012). In 
addition to early breakdown of BBB and edema formation, we have observed a 
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compensatory increase in the expression of claudin-5, a protein involved in tight junction 
formation, and a decrease in p-glycoprotein (P-gp), an ATP-binding protein, at 2 months 
post-injury (Pop et al., 2012). The molecular mechanisms contributing to these long-term 
endothelial phenotypic changes are still unknown. However, recent studies showed that 
the caveolins are involved in molecular signaling and contribute to the changes in 
claudin-5 and P-gP (McCaffrey et al., 2007, McCaffrey et al., 2012).  
Caveolins are structural proteins that form the backbone of the caveolae, which are 
known to function in endocytosis, transcytosis, and exocytosis in endothelial cells 
(Predescu and Palade, 1993, Jodoin et al., 2003, Salaun et al., 2005, Choudhury et al., 
2006, Predescu et al., 2007). Three isoforms of caveolin are known to be present in the 
mammalian brain (Cameron et al., 1997, Virgintino et al., 2002). Caveolins-1 (cav-1) and 
2 were mostly observed in brain endothelial cells (Lisanti et al., 1994, Virgintino et al., 
2002) although cav-1 has also been observed in some neurons and astrocytes 
(Cameron et al., 1997, Virgintino et al., 2002, Head et al., 2010). Cav-3 has been 
predominantly described in the astrocytes (Virgintino et al., 2002, Shin et al., 2005). 
Besides facilitating the caveolae sequestration of several receptors and ligands, the 
caveolins also serve as active modulators of activities of a wide variety of signaling 
molecules, including inhibition of endothelial nitric oxide synthase (eNOS) (Bucci et al., 
2000, Bauer et al., 2005, Lajoie et al., 2009). This modulation is performed via the 
caveolin scaffolding domain (CSD), a 19-amino acid sequence (amino acids 82 – 109) 
that binds proteins via a binding site, caveolin-binding motif (CBM), that are present on 
proteins such as eNOS (Sargiacomo et al., 1995, Cameron et al., 1997, Lajoie et al., 
2009).  
Despite abundant literature on the role of cav-1 in modulating eNOS and its 
physiological consequences in the periphery (Bernatchez et al., 2005), little is known 
about the potential roles of caveolins after brain injury (Nag et al., 2007). In an adult rat 
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model of cold cortical injury, the level of expression of cav-1 is increased in the 
endothelium for several days following injury (Nag et al., 2007, Nag et al., 2009). Similar 
increases have been reported in models of brain ischemia (Jasmin et al., 2007) and 
experimental spinal cord injury (Shin et al., 2005, Shin, 2007). Although cav-1 increase 
in some of these brain injury models was associated with BBB or blood-spinal cord 
barrier breakdown (Nag et al., 2007, Nag et al., 2009), the exact role of these changes in 
cav-1 is still unclear. Experiments using cav-1 knockout (cav-1-/-) mice suggest beneficial 
roles for cav-1 in rodent models of brain disorders (Jasmin et al., 2007, Gu et al., 2011). 
In fact, cav-1-/- mice presented higher vascular permeability (Schubert et al., 2002, 
Miyawaki-Shimizu et al., 2006, Siddiqui et al., 2011) and intriguingly have a worse 
outcome than the wild-type (WT) with increased cerebral volume of infarction after stroke 
(Jasmin et al., 2007). Interestingly, claudin-5, a protein involved in tight junction (TJ) 
formation, was shown to bind to cav-1 and be stabilized by it in some cases (McCaffrey 
et al., 2007, Stamatovic et al., 2009). It is therefore plausible that increase in cav-1 
expression may be contributing to the recovery of TJ and BBB functions after injury.  
However, cav-2 is also abundant in the endothelial cells, and cav-2-/- mice showed a 
decreased lesion volume compared to WT (Jasmin et al., 2007). This suggests that cav-
2 may have a detrimental role in brain injury, in contrast with cav-1.  
Lastly, cav-3 expression was also shown to change in spinal cord astrocytes in a 
model of experimental autoimmune encephalomyelitis (Shin et al., 2005). The changes 
in expression of these caveolins are potentially contributing to the neurovascular 
dysfunctions observed after jTBI (Fukuda et al., 2012, Pop et al., 2012). The expression 
and distribution profiles of cav-1, 2, and 3 within the neurovascular unit after jTBI in 
conjunction with BBB disruption have not been investigated. The goal of this present 
study is, therefore, to report changes in the level of expression of cav-1, 2, and 3 after 
jTBI, in parallel with the changes in the BBB. 
129 
Materials and Methods 
Animals 
All animal related protocols and procedures in this study were approved by the 
Institutional Animal Care and Use Committee of Loma Linda University. Male Sprague-
Dawley rat pups at postnatal day 10 (P10, Harlan, Indianapolis, IN) were housed on a 
12-hour light-dark cycle at constant temperature and humidity for one-week prior to 
surgery to allow sufficient time for acclimatization. Following induction of experimental 
brain injury or sham procedure at P17 (30± 4 g, n=36 rats), the pups were returned to 
their cages with their dams and subsequently weaned at 7d. They were housed two rats 
per cage, and fed with standard lab chow and water ad libitum. Identical sham or 
controlled cortical impact (CCI) surgical parameters were used for the experimental brain 
injury.  
Juvenile Traumatic Brain Injury Model 
Controlled cortical impact (CCI) was induced in P17 old rat pups as previously 
described (Ajao et al., 2012, Fukuda et al., 2012). Briefly, rat pups were anesthetized 
with isoflurane (Webster Veterinary Supply, Inc., Sterling, MA) and placed into a 
stereotaxic frame (David Kopf Instruments, USA). A 5 mm diameter craniotomy was 
drilled over the right parietal cortex at 3 mm anterior-posterior and 4 mm medial-lateral to 
bregma. CCI was induced in the jTBI group using a 2.7mm diameter rounded-tip metal 
impactor fixed to an electromechanical actuator (Leica Microsystems Company, 
Richmond, IL) and centered over the exposed dura at a 20° angle to the cortical surface. 
The impact was delivered at a velocity of 6 m/s, with impact duration of 200 ms, and to a 
depth of 1.5 mm from the cortical surface. Bleeding and convexity of the injured cortex 
were recorded and showed no significant difference within the jTBI animals. The surgical 
site was sutured closed. Appropriate pain management was provided through 
subcutaneous administration of Buprenorphine (0.01 mg/kg; dilution: 0.01 mg/ml) 
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immediately following end of suturing. The body temperature was maintained at 37°C 
throughout the surgical procedure. Sham animals underwent identical procedures with 
the exception of cortical impact. All rats recovered from anesthesia within 25 minutes 
post-injury. No seizures resulting from experimental procedure was observed within the 
2 to 3-hour observation period immediately following injury when the animals were 
returned to their cages. 
 
Tissue Processing and Immunohistochemistry  
Rats were transcardially perfused with 4% PFA prepared in PBS at 1d, 3d, 7d, 
and 60d with n=5 rats per group (jTBI and sham) for each time points. The brains were 
removed and immersed in 30% sucrose at 4°C for 48 hours and then frozen on dry ice 
and stored at -20°C pending tissue cutting. Coronal cryostat sections (Leica CM1850, 
Leica Microsystems GmbH, Wetzlar, Germany) were prepared. 
 
IgG Extravasation Staining for BBB Assessment 
To evaluate the BBB disruption, IgG extravasation staining was performed as 
previously described (Badaut et al., 2011). Briefly, the sections were incubated with 
biotin conjugated affinity purified goat anti-rat IgG coupled with Infrared-Dye-800-nm 
(1:500 dilution; Rockland, Gilbertsville, PA) in PBS containing 0.1% Triton X-100 and 1% 
bovine serum albumin (BSA) for 2 hours at room temperature. After washing, sections 
were dried and scanned on an infra-red scanner (Odyssey-system, LiCor, Germany) to 
quantify the area of the IgG extravasation for three adjacent slices covering the lesion 
with the LI-COR Odyssey system. 
 
Double Immunohistochemical Staining: 
All antibody incubations were carried out in PBS (Fisher Scientific, Pittsburgh, 
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PA) containing 0.25% Triton X-100 and 0.25% BSA (both from Sigma-Aldrich Co., St. 
Louis, MO). After washes in PBS, sections were blocked for 1.5 hours in PBS with 1% 
BSA, and then incubated overnight at 4°C with one of the following: mouse anti-cav-1 or 
-2 or -3 (each diluted 1:200; BD Biosciences, San Jose, CA), rabbit anti-cav-1 (1:200; 
Abcam Inc., Cambridge, MA), mouse anti-claudin-5 (1:100; Invitrogen, Camarillo, CA), 
mouse monoclonal antibodies for NeuN (1:500; Abcam Inc., Cambridge, MA), rabbit 
polyclonal antibodies for IBA-1 (1:300; Wako), and chicken anti-glial fibrillary acidic 
protein (GFAP, 1:1000; Millipore, Billerica, MA). After 3x10min PBS rinses, sections 
were incubated for 2 hours at room temperature with a mixture of goat anti-mouse 
secondary antibody coupled with Alexa-Fluor-488 and goat anti-rabbit secondary 
antibody coupled with Alexa-Fluor-568 (both at 1:1000; Invitrogen, Camarillo, CA) and 
subsequently rinsed again in PBS for 3x10 minutes. Sections stained with the antibodies 
mentioned were all mounted on glass slides and coverslipped with anti-fading medium 
vectashield containing DAPI (Vector, Vector Laboratories, Burlingame, CA). 
Negative control staining where the primary antibody was omitted showed no 
detectable labelling. 
The area of cav-1 and cav-2 immunolabeling was quantified at 1, 3, 7, and 60d 
from a series of images collected at 20X objective (422 µm X 338 µm) in perilesional 
parietal cortex and ipsilateral temporal cortex using an epifluorescent microscope with 
the same parameters for all animals (Olympus, BX41, Center Valley, PA). Images were 
acquired from five serial coronal slices separated by 500 μm (24 images per animal). 
The area of cav-1 and cav-2 staining was measured for each individual image with 
MorphoPro software (Explora-Nova, La Rochelle, France) according to the following 
procedure: 1) Top Hat morphologic filter to outline vascular staining from the 
background, 2) user-defined thresholding value applied to each image. Final values 
were represented as a percentage of the sham group.  
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Cav-3 was mainly observed in astrocytes and scored in the perilesional parietal 
cortex adjacent to the lesion site on 5 sections separated by 500 μm per animals. 
Scoring was given a value from 0-4 with (0) no staining seen; (1) faint staining in a few 
positive cells, (2) bright staining in a small area, or low intensity staining in a larger area 
(more positive cells), (3) bright staining in a larger area, or (4) very intense staining over 
a large area. 
 
Western Blotting  
A second set of rats was prepared with four animals per group at 1d and brains 
were freshly dissected and the cortical tissue adjacent to the site of the impact was 
collected. Tissues were prepared in RIPA buffer with a cocktail of protease inhibitors 
(Roche, Basel, Switzerland) and sonicated for 30 s (Hirt et al., 2009). After BCA protein 
assay, 10g of protein was then subjected to SDS polyacrylamide gel electrophoresis 
on a 4-12% gel (Nupage, Invitrogen, Carlsbad, CA). Proteins were then transferred to a 
polyvinylidene fluoride membrane as indicated by the supplier (PerkinElmer, Germany). 
The blot was incubated with a rabbit polyclonal against cav-1 (BD Biosciences, 1:2000) 
and a monoclonal antibody against Tubulin (Sigma, USA, 1:10,000); a monoclonal 
antibody against cav-2 or cav-3 (BD Biosciences, 1:2000) and a polyclonal antibody 
against actin (Sigma, USA, 1:25,000) in Odyssey blocking buffer (LI-COR, Bioscience, 
Germany) overnight at 4°C. After washing, the blot was incubated with two fluorescence-
coupled secondary antibodies (1:10,000, anti-rabbit Alexa-Fluor-680nm, Molecular 
Probes, Oregon and anti-mouse IR-Dye-800-nm, Roche, Germany) for 2 hours at room 
temperature. After washing, the degree of fluorescence was measured using an infra-red 
scanner (Odyssey, LI-COR, Germany). 
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Statistical Analyses 
All data are presented as mean ± SEM, statistical analyses were done using 
SPSS, and graphs obtained using SigmaPlot. The IgG extravasation, cav-1, cav-2 
immunolabeling, and western blot data were analyzed using student t-tests for normally 
distributed data with comparison between the sham and jTBI groups for each individual 
time points. Cav-3 data were analyzed using a non-parametric Mann-Whitney test with a 
comparison between the sham and jTBI. 
 
Results 
Blood-Brain Barrier Disruption in Early Time Points after jTBI 
IgG extravasation staining was used to evaluate BBB disruption from 1d to 7d 
(Fig. 1). Increased staining of extravasated IgG was observed in the perilesion and 
contralateral cortex of jTBI animals (Fig. 1) at 1d and 3d compared to the sham group. 
The IgG staining decreased back to the normal (i.e. sham) level at 7d (Fig. 1A). 
Quantification of the surface area of extravasated IgG showed a significant increase in 
the perilesion cortex of the jTBI rats at 1d and 3d compared to sham (respectively 0.023 
 0.033 mm2 vs. 0.002  0.001 mm2 and 0.035  0.042 mm2 vs. 0.002  0.001 mm2, 
p<0.05, Fig. 1E).  This suggests that BBB disruption is maximum at 1d and 3d post-
injury, which is in agreement with our previous observations that showed vasogenic 
edema formation between 1d and 3d, followed by normalization after 7d (Fukuda et al., 
2012). 
In parallel with increased IgG extravasation staining, immunostaining for claudin-
5 showed a decrease at 1d and 3d in the cortical perilesion in the jTBI group (Fig. 1D) 
compared to the sham group (Fig. 1C). At 7d, claudin-5 immunoreactivity was 
comparable to the sham level (Fig. 1D), suggesting a return to normal as observed for 
the IgG extravasation (Fig. 1A, B). 
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Changes in Vascular Expression of Caveolin-1 and -2 after 
jTBI 
Caveolin-1 Expression and Distribution after jTBI 
Mouse and rabbit cav-1 antibodies were used in double immunostaining to 
identify the cell distribution of cav-1 after jTBI in the tissue adjacent to the lesion and 
remotely. As previously described in adult brain (Nag et al., 2007), the rabbit anti-cav-1 
antibody was observed in brain endothelium and also in other cell types such as 
astrocytes and neurons (Fig. 2A, B, C, D). At 1d and 3d, when BBB disruption was 
maximal (Fig. 1), double immunolabeling of GFAP and cav-1 showed co-localization, 
suggesting the presence of cav-1 in the reactive astrocytes at the border of the lesion at 
1d and 3d in jTBI (Fig. 2A, B, C). Rabbit anti-cav-1 staining also co-localized with mouse 
anti-NeuN staining (Fig. 2D), suggesting an increased immunoreactivity of cav-1 in 
neuronal nuclei located around the lesion site at 3d post-injury. However, cav-1 staining 
did not co-localize with IBA-1 staining, a marker of microglia cells (Fig. 2E). As 
previously described in literature, mouse anti-cav-1 staining showed that cav-1 is 
predominantly expressed in brain endothelial cells (Fig. 2E, F) of all cerebral blood 
vessels, independent of the diameter (from the pial vessels to intracerebral arterioles 
and capillaries) in normal brain (not shown) and at distance from the site of the injury. 
The presence of cav-1 in the endothelium was also observed with the rabbit anti-cav-1 
(Fig. 2C, D). 
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The regional observation of the cav-1-IR showed an increase in the staining of 
brain cortical blood vessels from 1d to 60d (Fig. 3B) in the perilesion compared to the 
sham groups (Fig. 3A). The quantification showed that cav-1-IR at the perilesional cortex 
is significantly increased by 36% at 1d, 105% at 3d, 92% at 7d and 88% at 60d 
compared to the sham groups (p<0.05, Fig. 3C).  The relative change in cav-1-IR at 1d 
was confirmed by western blot quantification performed on the perilesional cortical tissue 
at 1d. Both monomeric (molecular weight at ~ 22 kDa) and oligomeric forms (molecular 
weight at ~ 66 kDa) of cav-1 were significantly increased in jTBI compared to sham (Fig. 
3D, E; p<0.05).  
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Acute Change in Vascular Caveolin-2 after jTBI 
Similar to cav-1-IR, cav-2-IR was observed in brain endothelial cells in brain 
blood vessels of all sizes (Fig. 4A, C, D) including pial blood vessels in both shams and 
jTBI group. The western blot showed a band around 20 kDa in both sham and jTBI, 
without any difference between the groups (Fig. 4B). The analysis of the level of cav-2 
IR was performed on the same regions of interest that was used for cav-1. There was a 
slight decrease of cav-2 IR in jTBI group at 1d post-injury (Fig 4C, D; not significant). 
This was followed by a significant increase in cav-2 in the jTBI animals on at 3d post-
injury (p<0.05; Fig. 4, C2, D2 and E). No significant changes were seen between the 
sham and jTBI animals at 7d (not shown) and 60d post-injury (Fig. 4C, D, E). This result 
was confirmed by quantification of Cav-2-IR in the perilesional cortex over the timeline 
(Fig. 4E) and by the western blot quantification (not shown).  
 
Changes in Astrocytic Caveolin-3 Expression after jTBI 
Cav-3 staining was observed in astrocytes located in the glia limitans, cortex, 
hippocampus, white matter tract (Fig. 5A, B), and hypothalamus (data not show). Double 
immunolabeling of GFAP and cav-3 confirmed the presence of cav-3 in astrocytes (Fig. 
5B). Interestingly, cav-3-IR is also highly co-localized with eNOS staining in the 
astrocytes at the border of the lesion cavity (Fig. 5C). Western blot of cav-3 showed a 
band around 20kDa (Fig 5D) that is significantly higher in the jTBI group compared to 
sham at 1d (Fig. 5D). Immunohistochemical observation showed increase of cav-3-IR in 
reactive astrocytes in the vicinity of the lesion in the cortex (Fig 5A, E). In addition, 
increase of cav-3 staining was also observed in the corpus callosum and in hippocampal 
structures below the site of the impact, but there was no such increase in the 
contralateral cortex (data not shown). These observations were confirmed by categorical  
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scoring of the Cav-3 staining over several sections covering the lesion. It showed that 
cav-3 staining was increased in jTBI compared to sham groups in the perilesional brain 
structures at 1d (Fig. 5F1, G) and 3d (Fig.5F2, 5G) compared to the sham groups (Fig.  
5E1, E2, G). After 7d and 60d, there were no longer differences between the groups 
where the cav-3 staining was observed in the astrocytes in both groups (Fig. 5E3, E4, 
F3, F4, G). 
 
Discussion 
The level of expression of cav-1 is increased in the endothelium and astrocytes, 
cav-2 increased only in the endothelium, and cav-3 is increased in astrocytes after jTBI 
during the first week post-injury, which is also known to be a period of active BBB 
disruption. This increased expression level for cav-1 is still maintained even at 2 months 
after injury, suggesting phenotypic changes in the endothelium after jTBI, in accordance 
with our previous studies showing an increased claudin-5 and decreased PgP (Pop et 
al., 2012). These observed changes in caveolin expression following jTBI, coupled with 
the fact that caveolins are central to caveolae formation and function, as well as in the 
regulation of several endothelial signaling pathways, indicate that cav-1, cav-2, and cav-
3 may be good molecular targets to mitigate the neurovascular changes at early and 
later time points after jTBI. The functional roles of these proteins, however, need to be 
determined in vivo in this pathological model. 
 
Acute Increase in Endothelial Caveolins-1 and -2 Precedes 
BBB Recovery 
 As indicated in the introduction, TBI in the juvenile population is known to be 
associated with greater risks of cerebral hemodynamic dysfunction, BBB disruption, and 
diffuse cerebral edema, compared to adults (Armstead, 1999, Suh et al., 2001, Campbell 
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et al., 2007, Giza et al., 2007, Freeman et al., 2008). BBB disruption in clinical patients is 
known to be a major cause of mortality and long-term neurological deficits in victims with 
moderate to severe TBI (Shlosberg et al., 2010). There are also more recent evidence 
indicating that in mild-TBI such as in blast injury, the BBB is impaired early on after the 
injury (Readnower et al., 2010). Hence, there is a need to study BBB changes in jTBI at 
early and long-term. 
The jTBI model showed a significant increase in IgG extravasation at 1 and 3d, 
paralleled with the loss of claudin-5 staining in the cortex (Fig. 1), and these indicate a 
physical BBB disruption during the development of the secondary injuries. It is 
interesting to note that BBB disruption parallels the peak of edema formation previously 
observed on the T2-weighted MRI in a similar jTBI model (Fukuda et al., 2012). At 7d, 
the extravasation of IgG as well as the claudin-5 staining returned to sham levels, 
suggesting a recovery of the BBB. Similarly, BBB recovery parallels the decrease in 
vasogenic edema previously observed as a return to the normal T2 values on T2-
weighted MRI scans at 7d in a similar injury model (Fukuda et al., 2012). Despite this 
return to normal T2 values at 7d, long-term phenotypic changes at the endothelium still 
occur (Pop et al., 2012).   
Endothelial cav-1 and 2 could be good molecular candidates to study with regard 
to changes in BBB properties because of their possible involvement in the regulation of 
several intracellular signaling processes (Bucci et al., 2000, Razani et al., 2002, 
Schubert et al., 2002, Minshall et al., 2003, Stamatovic et al., 2009, Gu et al., 2011). 
Cav-1 was shown to be involved in the regulation of eNOS activity (Garcia-Cardena et 
al., 1997, Bucci et al., 2000, Bernatchez et al., 2005), c-Jun N-terminal kinase activation 
(Tourkina et al., 2008, Tourkina et al., 2010), as well as in the stabilization of tight 
junction proteins such as claudin-5 within the lipid raft domain and P-gp (Jodoin et al., 
2003, McCaffrey et al., 2007, McCaffrey et al., 2012).  
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In the juvenile rodent population, cav-1 and cav-2 distribution were observed in 
the endothelial layer of brain blood vessels of all sizes (from capillaries to pial arteries, 
Fig. 2A) in accordance with previous studies carried out in adult mammalian brains 
(Cameron et al., 1997, Virgintino et al., 2002). In contrast to the distribution of cav-2, 
cav-1-IR was also observed in some astrocytes and neurons in the jTBI group, which is 
in accordance with previous studies (Ikezu et al., 1998, Virgintino et al., 2002, Head et 
al., 2008, Head et al., 2010).  The potential role of cav-1 changes in the astrocytes after 
jTBI is reviewed later in the discussion. Cav-2 expression was changed significantly only 
at 3d after jTBI, which was the peak of edema formation. In contrast, increased cav-1 in 
the endothelial cells in the ipsilateral cortex was observed not only throughout the acute 
injury phase (from 1d to 7d), but also at a later time point (2 months) after the injury. 
Similar findings were reported from other adult rodent models of CNS insults with an 
early increase of cav-1 in the endothelial cells preceding the decrease of claudin-5 and 
occludin (Nag et al., 2007, Nag et al., 2009). From that study, the authors concluded that 
the increase of cav-1 could potentially contribute to BBB disruption (Nag et al., 2007, 
Nag et al., 2009).  
Intriguingly, tight junction proteins, claudin-5 and occludin, have been shown to 
bind to and be stabilized by cav-1 within the caveolae (McCaffrey et al., 2007). After 
hypoxia-reoxygenation, levels of claudin-5 and occludin found within the caveolae were 
all together reduced (McCaffrey et al., 2007, McCaffrey et al., 2009). Cav-1 was 
therefore proposed to play key roles in the maintenance of these tight junction protein 
subunits (McCaffrey et al., 2007, McCaffrey et al., 2009, Stamatovic et al., 2009). 
Moreover, cav-1-/- mice presented higher endothelial permeability in the systemic 
vasculature compared to WT (Razani et al., 2001, Schubert et al., 2002). Therefore, a 
decrease in cav-1 may suggest a disruption in the BBB integrity, whereas an early 
increase of cav-1, as observed in our model during the first week, may be beneficial 
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toward the recovery of the BBB integrity after jTBI. In support of this hypothesis, cav-1-/- 
mice showed a larger lesion volume compared to WT in a transient middle cerebral 
artery occlusion model (Jasmin et al., 2007). That study concluded that the absence of 
cav-1 is detrimental due to a decrease in angiogenesis in the cav-1-/- mice compared to 
WT (Jasmin et al., 2007). Cav-1 has a CSD sequence that binds to eNOS and inhibits its 
activity (Bucci et al., 2000). A decrease of NO formation following increase of Cav-1 in a 
stroke model was shown to be associated with decreased activation of MMPs (Gu et al., 
2011) and consequently protected the BBB. The recent experiments with cav1-/- suggest 
that early increase of cav-1 in endothelium following jTBI may be an endogenous 
mechanism aimed at facilitating BBB recovery during the first week. Until now, the exact 
role of cav-1 in brain injury and especially in jTBI is still unknown, and detrimental effects 
of acute cav-1 increase cannot be ruled out. 
 
Long-Term Caveolin-1 Overexpression may be Detrimental 
In our model, the level of cav-1 expression was also increased in the 
endothelium (Fig. 3) when claudin-5 is up-regulated at 2 months after injury (Pop et al., 
2012).  Long-term changes of cav-1 expression was also reported at 14d after spinal 
cord injury in adult rodent (Shin et al., 2005), when usually the tight junctions and BBB 
have already recovered. This higher expression of cav-1 at 2 months after injury is 
possibly a part of the endothelium phenotypic changes observed after jTBI (Pop et al., 
2012). Cav-1 could be a molecular pathway in the increase of claudin-5 as well as the 
decrease of p-glycoprotein. In fact, increase of cav-1 was associated with a decrease of 
the P-gp activity (McCaffrey et al., 2012).  We cannot rule out the possibility that an 
increase in cav-1 staining could be associated with an increase in the number of 
caveolae, which in turn is responsible for increased transcytosis (Jodoin et al., 2003, 
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Regina et al., 2004) and the entrance of albumin, which may contribute to the 
dysfunction of the brain tissue homeostasis (Komarova and Malik, 2010). 
  
Caveolin-1 and -3 in Astrocytes: Role in Astrogliosis? 
 Reactive astrocytes after jTBI showed increase in cav-1 and 3 expressions 
during the first week. As described previously, the increase of cav-1 staining in the 
reactive astrocytes was mostly detected with rabbit polyclonal anti-cav-1 (Virgintino et 
al., 2002, Shin et al., 2005). Cav-1 and 3 are co-localized with GFAP staining, which is 
consistent with previous studies in adult models (Ikezu et al., 1998, Shin et al., 2005). 
Although cav-3 has been reported in smooth muscles (Ikezu et al., 1998), we did not 
observe any staining in intraparenchymal cerebral blood vessels. The expression and 
localization of cav-3 in the jTBI brains appears to coincide with astrogliosis, which is 
similar to findings in experimental autoimmune encephalomyelitis (Shin et al., 2005). The 
exact roles of these proteins in the astrocyte functions in vivo are still unknown. 
Caveolins were associated with eNOS, which was previously shown in the astrocytes in 
the rat brains (Colasanti et al., 1998, Wiencken and Casagrande, 1999). Excess NO 
produced after brain injury can overload its inactivating enzyme, superoxide dismutase, 
resulting in a cascade of events that have several cytotoxic effects on the brain tissue as 
well as activation of the MMPs (Gu et al., 2011). Activated MMPs cleave key proteins 
that are important for maintaining the BBB including matrix proteins in the basement 
membrane and inter–endothelial junctional proteins such as the claudins and occludins 
(Yang et al., 2007).  
After jTBI, both cav-3 and cav-1 are present in the astrocytes and cav-3 was co-
localized with eNOS. In the periphery, cav-3 was shown to interact with neuronal NOS 
(nNOS), and in astrocytic culture, cav-1 was observed to function as an endogenous 
inhibitor of eNOS (Colasanti et al.). Therefore, increase of Cav-1 and 3 in the astrocyte 
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may be linked with the regulation of eNOS activity to prevent the release of excess NO. 
Interestingly, the changes of the level of expression of cav-1 in astrocyte cultures were 
associated with the glutamate transporter, GLT1 (Zschocke et al., 2005, Gonzalez et al., 
2007). The application of transforming growth factor-alpha (TGF-α) induced a decrease 
of cav-1 and an increase of GLT1 (Zschocke et al., 2005, Gonzalez et al., 2007). 
Increase of cav-1 in the astrocytes may, therefore, induce a decrease of GLT1 in the 
astroglia. This decrease will have a consequence on the glutamate uptake and the 
excitotoxicity after jTBI. 
 
Conclusion 
Cav-1 and cav-3 showed immunoreactivity changes in the astrocytes and 
endothelial cells after jTBI at early time point as well as long-term. These proteins have 
several physiological roles within the cells and in the neurovascular unit. This study 
shows for the first time changes in the expression of these molecules in a model of jTBI. 
Further studies will be needed to characterize the role of each caveolin in each cell type 
after jTBI. 
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PROLOGUE TO CHAPTER 4 
CAVTRATIN AMELIORATES EDEMA AND REDUCES BRAIN 
LESION VOLUME AT ACUTE TIME POINTS AFTER JUVENILE 
TRAUMATIC BRAIN INJURY 
In chapter 3, we described acute and long-term changes in the immunoreactivity 
and protein expression levels of caveolin-1, -2, and -3 in rat brains following juvenile TBI, 
and highlighted the potential beneficial role of caveolin-scaffolding domain in the 
recovery of brain endothelial tight junctions and regulation of BBB permeability following 
injury. Chapter 4 now focuses on the therapeutic potential of cavtratin – an injectable 
peptide mimetic of the caveolin scaffolding domain – with respect to repair of BBB tight 
junctions, reduction of cerebral edema, and improvement in functional outcomes during 
the peak of edema (See Figure A below for a diagrammatic illustration of the proposed 
intervention strategy with cavtratin). The question of long-term impact of cavtratin 
treatment on the histopathology and functional outcome of juvenile TBI is not addressed 
in this project, and will be a subject of future studies. 
The aim of this chapter is therefore to examine the effects of cavtratin treatment 
on tight junction disruption and associated vasogenic edema, and on functional (mainly 
neurological and sensorimotor) outcomes following juvenile TBI at acute time point. The 
hypothesis is that acute treatment with cavtratin (dose = 2.5 mg/kg; injected at 3 hours, 1 
day, 2 day, and 3 day post-injury time points) following juvenile TBI will reverse the 
damage to brain endothelial tight junction proteins and restore its function, thereby 
reducing cerebral edema and consequently leading to improved functional  outcomes. 
The rationale for the technique and drug dosage used is explained in the section. 
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The chapter follows the blueprint of a scientific manuscript with detailed figures 
and figure legends. The data contained in this chapter are yet to be submitted for journal 
publication. 
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Abstract 
Blood-brain barrier (BBB) breakdown and the resultant edema formation are 
emergent therapeutic targets for addressing traumatic brain injury (TBI) in the juvenile 
brain, which is known to be vulnerable to these two secondary pathophysiological 
processes of brain trauma. Caveolin-1 has also emerged as an important protein that 
modulates brain endothelial permeability. We investigate the therapeutic potential of 
cavtratin – a caveolin mimetic peptide injected systemically – on the brain, following 
juvenile TBI (jTBI) in P17 rats. We show that intraperitoneal administration of cavtratin at 
3 hours post-jTBI results in reduction of brain lesion volume in treated rats at 1d (by 
47.9%) and 3d (by 65.8% ) post-injury. In addition, edema formation in the lesion ROI – 
measured with T2-weighted MRI – undergoes significant reduction with cavtratin 
treatment at both acute time points (1d and 3d). There is however no rapid recovery of 
neurological functions (tested with foot-faults, beam balance, and rotarod) observable in 
cavtratin-treated rats compared to saline-controls at 1d and 3d. We therefore conclude 
that systemic, acute treatment with cavtratin following jTBI protects against enlargement 
of brain lesion and edema formation, and this suggests future potential development of 
cavtratin as a therapeutic tool.  
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Introduction  
Two of the secondary pathophysiological processes most commonly associated 
with traumatic brain injury (TBI) are blood-brain barrier (BBB) disruption and concomitant 
edema formation (Werner and Engelhard, 2007, Shlosberg et al., 2010). These 
processes are especially common in juvenile cases of TBI (jTBI) and are a deadly duo 
responsible for deaths, disability and enormous economic burden (Yeates et al., 2002, 
Schneier et al., 2006, Coronado et al., 2011) . The juvenile brain is susceptible to 
disruption of its BBB and to diffuse edema formation owing to some unique 
developmental features which include weak ligamentous protection, less myelination of 
white mater fibers, and higher brain water content (Battin, 2001, Campbell et al., 2007, 
Giza et al., 2007, Freeman et al., 2008). Subtle forms of BBB disruption have been 
observed for months to years following initial TBI assault on young brains (Tomkins et 
al., 2001, Tomkins et al., 2011). In addition, the juvenile brain has a greater risk for 
hemodynamic dysfunction (Armstead, 1999, Udomphorn et al., 2008), and together, 
these unresolved pathological processes translate into long-term functional deficits 
(Thomsen, 1992, Sbordone et al., 1995, Giza, 2006). These and many more studies 
highlight post-TBI BBB disruption and edema as bona fide therapeutic targets that 
require further investigation (Aldrich et al., 1992, Adelson et al., 1997, Shlosberg et al., 
2010).  
 Caveolin-1 – the first member of the caveolin family to be discovered (Rothberg 
et al., 1992) – is abundant within lipid rafts of brain endothelial cells (Cameron et al., 
1997, Virgintino et al., 2002). Together with caveolin-2, caveolin-1 forms the 
fundamental structural framework of the caveolae (Sargiacomo et al., 1995, Predescu et 
al., 2007), and is very crucial in mediating transcellular transport through the 
endothelium into brain parenchyma via transcytosis (Schubert et al., 2002, Predescu et 
al., 2007, Frank et al., 2009). The rate of transcytosis is, however, very low, and the 
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process is tightly regulated across the BBB (Wolburg and Lippoldt, 2002). In addition to 
its role in transcytosis, caveolin-1 has the capacity to scaffold several signaling proteins, 
some of which are crucial to regulating BBB permeability (Razani et al., 2002, 
Bernatchez et al., 2005). It performs this role through its caveolin scaffolding domain 
(CSD) which recognizes specific caveolin binding motifs (CBM) on signaling proteins, 
ligands and receptors (Razani et al., 2002). A classic example of this CSD-CBM binding 
and functional interaction is found in the negative regulation of endothelial nitric oxide 
synthase (eNOS) by caveolin-1, with the resultant reduction in production of nitric oxide 
(NO) – a highly potent endogenous vasodilator and inducer of BBB permeability (Garcia-
Cardena et al., 1997, Bucci et al., 2000). In order to investigate the mechanism and 
therapeutic potential of endogenous CSD, a synthetic cell-permeable peptide which 
mimics the scaffolding domain of caveolin – termed CSD peptide or cavtratin (CSD 
peptide sequence fused with the cell-permeable antennapedia internalization sequence) 
– has been developed and used extensively (Bucci et al., 2000, Bernatchez et al., 2005, 
Argaw et al., 2012). 
  In the search for therapeutic agents to combat post-traumatic BBB disruption in 
the juvenile setting, CSD mimetic peptide cavtratin is a potentially strong candidate 
based on multiple literature evidence. Caveolin-1 knockout mice are known to display 
microvascular hyperpermeability among other phenotypic defects (Razani et al., 2001, 
Schubert et al., 2002). Using caveolin-1 knockout mice and silencing RNA against 
caveolin-1 (siCav-1), it was shown that caveolin-1 protects against BBB 
hyperpermeability after focal cerebral ischemia and reperfusion injury through a negative 
regulation of nitric oxide (NO)-mediated matrix metalloproteinases (MMPs) activity in the 
brain (Gu et al., 2011). Using cavtratin as a selective inhibitor of eNOS, improvement in 
BBB dysfunction and associated reduction in neurologic deficits were observed in a 
model of multiple sclerosis (MS) (Argaw et al., 2012). Moreover, cavtratin protects 
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against chemokine-induced breakdown of brain endothelial junctional proteins including 
occludin and ZO-1 in an in vitro model of brain microvascular endothelial cells (BMECs) 
(Song et al., 2007).   
 We therefore propose the use of intraperitoneal injection of cavtratin following 
juvenile TBI in P17 rats to investigate the drug’s potential therapeutic benefits. Our 
objective was to determine whether cavtratin, which mimics some activities of 
endogenous caveolin-1, is effective in improving BBB integrity and behavioral outcomes 
post-jTBI. We showed that cavtratin protects against TBI-induced edema formation and 
remarkably reduced the size of ensuing brain lesion. Our findings showed, however, that 
there are no appreciable sensorimotor improvements associated with cavtratin 
administration at least at the acute time points. 
 
 
Materials and Methods 
Subjects 
This experiment generally follows previously described animal and experimental 
protocols in chapters 2, 3 and 4 of this dissertation. Briefly, 12 ten-day old (P10) male 
Sprague-Dawley rats were ordered from Harlan Laboratories (Harlan, Indianapolis, IN). 
Upon delivery, they were housed with their dam on a 12-hour light-dark cycle at constant 
temperature and humidity, in accordance with standard guidelines. The rats were 
allowed to acclimatize for 7 days prior to induction of controlled cortical injury (CCI) – the 
key experimental surgical procedure – carried out on the pups at P17. The pups were 
fed with standard lab chow and water ad libitum. All groups of animals used in the study 
(total n = 12, comprising of 2 different cohorts) had identical CCI surgical parameters, 
and were randomly divided into saline-injected control and cavtratin-treated groups. The 
first cohort is comprised of 8 randomly selected rat pups (4 cavtratin-treated and 4 
saline-controls) which were all subjected to both MRI and neurological tests at 1dpi and 
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3dpi before being euthanized. The second cohort comprising of 4 rat pups (2 cavtratin-
treated and 2 saline-controls) underwent only neurological testing but no MRI. 
Euthanization and brain collection were carried out at 3dpi. All protocols and procedures 
used in this study were approved by the Institutional Animal Care and Use Committee of 
Loma Linda University and are in compliance with the U.S. Department of Health and 
Human Services Guide. 
 
Juvenile Traumatic Brain Injury Procedure 
 The procedure was carried out as we have previously described in literature 
(Ajao et al., 2012) and as earlier described in this dissertation (see chapters 2, 3 and 4). 
The same CCI surgery method and parameters were used. Briefly, each rat was 
subjected to light anesthesia with isofluorane (Webster Veterinary Supply, Inc., Sterling, 
MA) and placed in a mouse stereotaxic frame (David Kopf Instruments, USA). Following 
a midline incision on the scalp, a 5-mm craniotomy was bored over the right fronto-
parietal cortex at the following coordinate: 3 mm anterior-posterior and 4 mm medial-
lateral relative to Bregma.  The brain was then impacted by an electromagnetic impactor 
(impactor tip diameter = 2.7mm) (Leica Microsystems Company, Richmond, IL) to a 
depth of 1.5 mm from cortical surface, at a 200 angle to dura surface, at a velocity of 
6m/s and with impact duration of 200ms. Morphological aberrations to the cortex such as 
hemorrhage and herniation were recorded. The surgical site was then sutured close 
followed by subcutaneous administration of an analgesic drug – Buprenorphine (0.01 
mg/kg; dilution: 0.01 mg/ml). 
 
Systemic Administration of Cavtratin 
The cavtratin dose used in this study is 2.5mg/kg. This dose was effective for 
selective eNOS inhibition in previously reported in vivo studies (Gratton et al., 2003, 
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Hagendoorn et al., 2004, Bernatchez et al., 2005). The peptide was dissolved in 1% 
DMSO and diluted 1000-fold in saline to a desired volume before intraperitoneal injection 
(Gratton et al., 2003). The peptide was injected first at 3 hours post-TBI, and then at 
1dpi, 2dpi and 3dpi (between 7am and 9am). Control animals received equivalent 
volume of 0.9% saline. The rats were returned to their dam after treatment. 
 
Magnetic Resonance Imaging (MRI): Acquisition and Analyses 
Image Acquisition 
In vivo MRI was performed at 1 and 3 dpi for a subset of the animals (n = 8). 
Rats were prepared for in vivo MRI as previously described (Ajao et al., 2012). Briefly, 
following induction of anesthesia (with 1-2% isofluorane), each rat was placed in a 
temperature controlled cradle containing a volume radiofrequency (RF) coil and imaged 
mostly on a 11.7T MRI (8.9 cm bore) at 1d and 3d. Some animals were scanned on a 
larger bore (40 cm) 4.7T MRI (Bruker Biospin, Billerca, MA) at 3d. T2 weighted imaging 
(T2WI) was acquired in vivo with the following parameters: repetition time/echo time 
(TR/TE) = 2357.9/10.2 ms; 128 X 128 matrix; 1 mm slice thickness; 1 mm interleaved; 
average of 4 acquisitions; number of slices = 20; and field of view (FOV) = 2.0 cm for a 
total imaging time of 20 min on 11.7T MRI; and repetition time/echo time (TR/TE) = 
3563.4/20 ms; 128 X 128 matrix; 1 mm slice thickness; 1 mm interleaved; average of 2 
acquisitions; number of slices = 20; field of view (FOV) = 2.0 cm for a total imaging time 
of 15 min on the 4.7T MRI.  As previously reported, the use of two different field 
strengths for in vivo MRI did not alter our relative measurements (Obenaus and Hayes, 
2011, Ajao et al., 2012). 
 
Lesion Volume Analysis 
As previously described (Ajao et al., 2012), volumetric analyses of brain and 
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lesion volumes were performed using the T2WI in Cheshire software (Hayden Image 
Processing Group, Waltham, MA). Lesion volumes were defined as the cortical brain 
regions containing abnormal hypo- and/or hyperintense signals compared to normal-
appearing cortical brain matter on the contralateral hemisphere (Fig. 1A). Total brain 
volume encompasses both normal-appearing and abnormal brain tissues, while 
herniated tissue, if present, was excluded. In some animals, subcortical and extracortical 
abnormalities were present but were not included in the lesion. In order to correct for 
individual brain size differences in the animals and age-related brain growth, the injury 
volumes were normalized to the brain volumes. Hemispheric volumes were also 
analyzed using the same inclusion and exclusion criteria.  
 
T2 Analysis 
For each T2WI scan, a region of Interest (ROI) was drawn on the slice with the 
largest lesion area for each of the following areas: lesion, perilesion, striatum and 
hippocampus on both ipsilateral and contralateral hemispheres. The lesion and 
perilesion ROIs encompass both hypointense (which may indicate hemorrhage) and 
hyperintense pixels [which may indicate edema (Gomori et al., 1985, Kato et al., 1986)] 
within the brain parenchyma (Fig. 2A). ROIs for the hippocampus encompass all visible 
hippocampal regions along the anterior-posterior axis. All the aforementioned ROIs were 
later posted on co-registered T2 maps corresponding to each chosen brain slice for 
acquisition of T2 values. T2 value was extracted for each of the ROIs using Cheshire 
software. 
 
Neurological Tests 
Each behavioral test used in this report has been previously detailed (Ajao et al., 
2012). All tests on both saline-controls and cavtratin-treated animals were carried out 
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within a 3-hour time-block between 8am and 11am, and the animals from both groups 
were interleaved. The tests were carried out in the sequence in which they are listed 
below.  
 
Foot-fault   
This was performed using an elevated wire mesh (2.5 cm X 30 cm rectangular 
holes/grid spacing) raised 76 cm above the floor. Movements of each rat placed in the 
middle of the mesh were video-recorded for 60 sec in two separate trials at 1 and 3dpi. A 
foot-fault was counted when a rodent’s paw slipped completely through the wire mesh. 
The number of foot-fault for both groups were compared. 
 
 
Beam Balance 
Juvenile animals were tested on a 0.65 cm wide plexiglass beam which is 
commensurate to their size at 1 and 3dpi. Each animal walked unrestricted for 60 sec for 
each of two trials 20 min apart, and the distance covered was recorded and compared 
between saline-controls and cavtratin group.  
 
Rotarod   
A constant velocity rotarod paradigm consisting of 2 trials at a slow speed 
(10rpm) and 2 trials at a faster speed (20rpm) is used at 1 and 3dpi. The rotarod 
(Rotamex-5, Columbus Instruments, Columbus, OH) operates until each animals falls 
off. Latency to fall was recorded as a measure of motor coordination and balance and 
compared between the two groups. 
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Statistical Analyses 
All data are presented as mean ± SEM. Statistical analyses were done using 
SPSS, and graphs were obtained using Sigmaplot (SPSS Inc.). All the data were 
analyzed using student t-tests for normally distributed data with comparison between the 
cavtratin and control groups for each of the time points. Repeated measures ANOVAs 
(rm ANOVAs) were used for serial data collected on the same groups. 
 
 
Results 
Cavtratin Reduces Cortical Lesion Volume and Ameliorates 
Some Morphological Alterations 
 To investigate the potential therapeutic effect of caveolin in brain injuries, 
cavtratin was injected intraperitoneally at 3 hours following jTBI in P17 rats. Following 
previously established protocol (Ajao et al., 2012), T2-weighted MRI (T2WI) was utilized 
to outline and quantify cortical lesion volumes in the brains of both saline-controls and 
cavtratin-treated animals (Fig. 1A, red outlines). The lesion encompassed both visible 
hyperintense and hypointense pixels (Fig. 1A). We found that systemic administration of 
cavtratin results in significant reductions of brain lesion volume in treated rats at 1d (47.9 
+/- 13.7% reduction) and 3d (65.8 +/- 3.1% reduction; **p < 0.001, rm ANOVA) post-
injury compared to controls (Fig. 1B). Another key difference between the two groups is 
increase in lesion volume in TBI-saline group between 1d and 3d, not seen in the 
cavtratin-treated group (Fig. 1B).  
There are intragroup differences in hemispheric volumes (Fig. 1C, D). In the SAL 
group, the ipsilateral hemisphere volumes are significantly increased compared to the 
contralateral hemisphere at 1d (*p < 0.03, t-test), but these differences have been 
neutralized by 3d (p < 0.23, t-test) (Fig. 1C). Similarly, in the treated group, the ipsilateral 
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hemisphere volumes are significantly increased at 1d (*p < 0.04, t-test) but not at 3d (*p 
< 0.06, t-test) (Fig. 1D).  
 Moreover, there were no prominent midline shifts observed in brains of both 
saline and cavtratin-treated subjects. There were also no significant weight differences 
between the two groups over the experimental period. 
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Cavtratin Reduces Edema in the Lesion Region Following 
Brain Injury 
We used serially acquired T2WI on the animal subjects to profile T2 changes 
over the acute time points (Fig. 2A). Shown in Fig. 2A are representative T2WI from 
saline and cavtratin groups at 1d and 3d, with boxed regions enlarged in the lower 
panes, and with some major brain structures and ROIs labeled (HPC = Hippocampus; 
Cx = Cortex; Str = Striatum; CC = Corpus Callosum; L = Lesion; PL = Perilesion). 
Interestingly, there was a statistically significant decrease in T2 values acquired from 
lesion ROI (Fig. 2A, red outlines with red letter “L”) in the cavtratin-treated animals 
compared to saline controls at both 1dpi and 3dpi (**p < 0.007, rm ANOVA) following 
jTBI (Fig. 2A, B), suggesting that cavtratin treatment attenuates edema formation 
acutely. Not surprisingly, there are no significant intragroup changes in T2 values at the 
lesion ROI between 1d and 3d (Fig. 2B; p < 0.635, rm ANOVA). In the brains of saline 
control rats, T2 values in the perilesion ROIs (Fig. 2A, yellow outlines with yellow letter 
“PL”) at 1d and 3d were significantly lower compared to corresponding T2 values in 
lesion ROIs (Fig. 2A, red outlines with red letter “L”) (** p˂0.001, Student’s t-test).  This 
distinction is, however, not seen in brains from cavtratin-treated rats which had similar 
T2 values from both lesion and perilesion ROIs over the acute time points (Fig. 2B, C) 
(p˂0.748, Student’s t-test). Unlike T2 values in lesion ROI, there are no intergroup 
differences in T2 values in the perilesion ROI at both 1d and 3d (Fig. 2C; p˂0.703, rm 
ANOVA). Other regions of the brain besides lesion and perilesion (e.g. contralateral Cx, 
HPC, and Str, and ipsilateral HPC and Str) show no significant changes in T2 values 
between the two groups at both time points (data not shown).  
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Cavtratin Does Not Improve Sensorimotor Functions at Acute 
Time Point 
Because the injury is centered on the somatosensory cortex, it was important to 
test for the functional impact of the treatment during the peak of edema.  To this end, a 
previously validated set of neurological and behavioral tests were carried out to 
investigate the impairment and/or recovery of sensorimotor functions which include foot-
fault, beam balance and rotarod tests at 1d and 3d post-treatment (Fig. 3) (Ajao et al., 
2012). There were no significant differences in the number of foot-faults between the two 
groups at 1dpi and 3dpi (Fig. 3A; p<0.35, rm ANOVA).  Likewise, beam balance test 
showed no differences between the two groups at both time points (Fig. 3B; p˂0.33, rm 
ANOVA). Consistent with the two previous tests above, rotarod tests showed no 
intergroup differences either in the 10RPM (p˂0.79, rm ANOVA) or 20RPM (p˂0.48, rm 
ANOVA) constant speed paradigm at 1d and 3d (Fig. 3D). Overall, these neurological 
test results suffer from low statistical power. With increased group sizes, sensitivity may 
be enhanced for detecting fine motor improvements in between the groups for some of 
the tests. 
 
 
Discussion 
Multiple reports in scientific literature have highlighted some beneficial effects of 
the synthetic caveolin-1 scaffolding domain (CSD) peptide, cavtratin, in various 
experimental models, but not yet in juvenile TBI models. These include studies that 
utilized in vitro (Song et al., 2007, Schmitz et al., 2011) and in vivo (Bucci et al., 2000, 
Gratton et al., 2003, Jasmin et al., 2006, Desjardins et al., 2008) models of disease and 
system.  Caveolin-1 plays a role in regulating endothelial hyperpermeability as 
demonstrated by the microvascular hyperpermeability of caveolin-1 knockout (-/-) mice 
(Razani et al., 2001, Schubert et al., 2002). In addition, Song and colleagues (2007) 
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showed in vitro that cavtratin is effective in inhibiting microvascular hyperpermeability in 
chemokine-stimulated brain microvascular endothelial cells (BMECs) which models BBB 
in vitro. They also found that treatment of BMECs with silencing RNA against caveolin-1 
not only reduced caveolin-1 expression, but also reduced expression of key tight junction 
proteins (Song et al., 2007). More studies are providing further evidence of strong link 
between endothelial caveolins and TJ proteins. Claudins and occludins are found in 
isolated caveolae, putatively interacting with caveolins (Nusrat et al., 2000, McCaffrey et 
al., 2007, Song et al., 2007, Stamatovic et al., 2009). The level of oligomeric claudin-5 
and occludin seen in normal brain endothelial caveolae is reduced during pathological 
conditions such as hypoxia-reoxygenation (McCaffrey et al., 2009). Such reduction 
engenders TJ and BBB disruption (McCaffrey et al., 2008). Gu and colleagues (2011) 
recently showed that caveolin-1 protects the BBB against hyperpermeability following 
focal cerebral ischemia and reperfusion injury through its negative regulation of nitric 
oxide (NO)-mediated  matrix metalloproteinases (MMPs) activity in the brain. These 
studies above and many more (Miyawaki-Shimizu et al., 2006, Siddiqui et al., 2011) 
suggest that caveolin-1 is functionally associated with brain endothelial junctional 
integrity. 
 Interestingly, recent studies have suggested that caveolin-1 plays crucial roles in 
regulating efflux transporters in the BBB (Barakat et al., 2007, McCaffrey et al., 2012). 
McCaffrey and colleagues (2012), for instance, showed that in λ-carrageenan-induced 
paw edema model (a peripheral inflammatory model in rats), P-glycoprotein (P-gp) – a 
key efflux transporter at the BBB – was rapidly trafficked to the membrane lipid raft 
domain, where it colocalized with phosphorylated caveolin-1. This colocalization 
promoted the redistribution of P-gp at the microvascular endothelial luminal membrane 
with increased ATPase activity, which suggests functionally active P-gp. Using a rat 
brain endothelial cell line, Barakat et al (2007) previously suggested that phosphorylated 
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caveolin-1 may impact the transport property of P-gp. Hence, caveolin-1 is implicated in 
the maintenance of both molecular TJ proteins as well as transport barriers at the BBB. 
 A crucial secondary pathophysiological phenomenon commonly observed in 
juvenile brain trauma that needs to be addressed therapeutically is BBB disruption – 
which has been shown to last for months and in some cases years after primary injury 
(Seiffert et al., 2004, Tomkins et al., 2011) – with resultant edema formation (Bolton and 
Perry, 1998, Schutzman and Greenes, 2001, Stock, 2011).  Given literature evidence 
stated above linking caveolin-1 to regulation of endothelial permeability, we set out to 
study the effect of systemic administration of caveolin-1 mimetic peptide, cavtratin, on 
brain lesion, edema formation and, by extension, on neurological function at acute time 
points following juvenile TBI in P17 rats.  
 
Reduction of Lesion Volume and Amelioration of 
Morphological Alterations by Cavtratin 
We found that cavtratin treatment results in significantly lower lesion volumes in 
the brains of treated rats compared to saline controls at both 1dpi and 3dpi (Figs. 1A, B). 
Analyzed along hemispheric lines (Fig. 1C - F), the ipsilateral hemispheres of both 
control (Fig. 1E) and cavtratin brains (Fig. 1F) had higher volumes compared to their 
contralateral hemispheres, suggesting a uniformity in injury profile for both groups. The 
lowered lesion volume in cavtratin group (Figs. 1A, B) however suggests that cavtratin is 
functionally limiting the extent of the injury. This set of results is important for potential 
therapeutic application of cavtratin as a caveolin-mimicking pharmacological agent 
(Desjardins et al., 2008) in jTBI.  
There are a few studies in other models of brain injuries that support these 
findings. In an ischemic stroke (MCAO) study in mice, Jasmin and colleagues (2007) 
reported that caveolin-1 knockouts (KOs) have a generally worse outcome than the wild-
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type (WT), with increased cerebral volume of infarction coupled with impaired 
angiogenesis and increased apoptotic cell death. Acute and sometimes sustained 
increase in caveolin-1 expression has been reported following various forms of CNS 
injuries (Shin et al., 2005, Nag et al., 2007, Shin, 2007, Nag et al., 2009), but opinions 
are divided on whether this is beneficial or detrimental to the structural and functional 
recovery of the BBB and brain tissues (Nag et al., 2007, Song et al., 2007). Based on 
findings in this study, endogenous increase in caveolin-1 could be a form of innate 
protective mechanism that the brain deploys during active evolution of injury to minimize 
damage. In further support of this hypothesis, down-regulation of caveolin-1 expression 
in ischemic-reperfusion stroke model in rodents is concomitant with increased infarction 
volume, neurological deficit and BBB disruption (Ding-Zhou et al., 2002, Shen et al., 
2006, Gu et al., 2011). 
 
Reduction of Acute Edema Formation at Lesioned Brain 
Region by Cavtratin 
 Our findings on reduced edema formation (indexed by reduced T2 values) in the 
lesion ROIs of brains of cavtratin-treated animals (Fig. 2A, B) constitute a strong support 
for the theory that this CSD mimetic peptide helps in maintaining and protecting the 
BBB. This effect however was not found in the outlying perilesion ROI (Fig. 2C), 
suggesting that the drug’s therapeutic effect is focused more on clearly lesioned brain 
regions. In a study that utilized an in vivo model of multiple sclerosis (MS) in mice, 
researchers confirmed that systemic administration of cavtratin reduced eNOS-
associated BBB disruption and its resultant edema (Argaw et al., 2012). Argaw and 
colleagues (2012) further showed that cavtratin increases the expression of TJ proteins 
claudin-5 and occludin both in vitro in human brain microvascular endothelial cells and in 
vivo in VEGF-A null mice model of MS. These findings support a tight junction protein-
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maintaining role for caveolin-1 and provide solid support for its role in preventing BBB 
permeability and edema formation.   
 
Absence of Improvement in Neurological Function  
 There was a general lack of functional improvements at acute time points (1d 
and 3d) following cavtratin treatment (Fig. 3), which could be explained in two possible 
ways. A possible drawback is the shortness of testing period (within 3 days following 
jTBI) which coincides with period of maximum edema formation (Fukuda et al., 2012). 
We have previously shown that in this brain injury model, there were no clear increases 
in the number of foot-faults in jTBI animals compared to shams until 7d post-injury (Ajao 
et al., 2012). Hence, testing both sensorimotor and cognitive functions at later time 
points (7d, 30d and 60d) could provide an extended opportunity for picking up subtle 
functional differences that might have been masked by the evolution of the injury at 
earlier time points. Later time point testing also affords cavtratin the opportunity to act for 
a longer time. Given the effects of cavtratin on lesion volume and edema, it is plausible 
that there would be beneficial functional effects that could be picked out by the right tests 
at the right time points. Secondly, drugs may confer other functional benefits that may 
not be reflected in neurological and cognitive tests. For instance, electrophysiological 
recordings of neuronal firing (such as the measurement of compound action potential – 
CAP) may be helpful in picking out more subtle functional changes like we demonstrated 
in a previous report using this jTBI model (Ajao et al., 2012). Given the effects of 
cavtratin stated above, there is a need for investigating the mechanism(s) of action of 
this drug. 
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A Potential Mechanism of Action for Cavtratin – Blood-Brain 
Barrier Protection 
 One of the mechanistic possibilities for cavtratin action is through BBB protection. 
Caveolins are highly enriched in brain microvasculature, although they are found, albeit 
in smaller amounts, in other cells in the brain such as neurons and vascular astrocytes 
(Cameron et al., 1997, Virgintino et al., 2002, Head et al., 2010). Caveolins act as 
scaffolding proteins which bind and modulate the activities of a wide variety of signaling 
molecules that are segregated within the caveolae compartments not only in brain 
endothelial cells but also in the periphery (Palade, 1953, Sargiacomo et al., 1995, 
Cameron et al., 1997, Razani et al., 2002, Lajoie et al., 2009, Lajoie and Nabi, 2010). 
Tight junction proteins have been shown to actively bind to and be regulated by 
caveolins (McCaffrey et al., 2007, Stamatovic et al., 2009). Hence, a logical mechanism 
for the neuroprotective effect of cavtratin seen through reduced lesion volume is the 
protection against uncontrolled and prolonged BBB breakdown through decreased tight 
junction protein expression (Song et al., 2007, Gu et al., 2011). This BBB-focused 
mechanism is evidenced by reduction in edema formation (Fig. 2A, B) – which often 
results from disrupted BBB – seen in cavtratin-treated subjects and discussed in the next 
section below. Furthermore, caveolin-1 is known to negatively regulate eNOS which 
produces NO which in turn activates tight junction proteins-degrading MMPs in the brain 
(Gu et al., 2011).  
 There is also a strong positive correlation reported in TBI literature between 
extent or size of post-TBI brain lesion and BBB disruption (Tomkins et al., 2011). 
Tomkins and colleagues (2011) noted in their study that the set of patients with larger 
volume of BBB disruption (measured with T1-weighted MRI and the contrast agent 
gadolinium/Gd-DTPA) also had significantly larger volume of lesioned and dysfunctional 
cortex (measured with standardized low-resolution brain electromagnetic tomography 
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[sLORETA]). Subtle BBB disruption with concomitant functional cortical dysfunction was 
found in up to four TBI patients in the study (Tomkins et al., 2011). These reports 
support the theory that cavtratin may be acting mechanistically through protection of TJ 
proteins and BBB. Increased endogenous caveolin post-TBI may also constitute a 
compensatory mechanism aimed at limiting BBB damage. These proposed mechanisms 
need to be investigated by further studies. 
 Meanwhile, increased immunoreactivity of claudin-5 and decreased 
immunoreactivity of the efflux transporter p-gp at the BBB have been reported at 2 
months following the juvenile TBI model used in this study (Pop et al., 2012). Since 
caveolin-1 have been implicated in the regulation of both claudin-5 (Liu et al., 2012) and 
p-gp (Barakat et al., 2007, McCaffrey et al., 2012), it is possible that cavtratin may 
modulate beneficial changes in these BBB components at long-term following juvenile 
TBI. This hypothesis needs to be investigated in the future. 
 
 
Conclusion 
We have shown in this study that systemic administration of cavtratin at 3 hours 
after juvenile TBI is effective in reducing lesion volume and edema formation. We further 
proposed that these protective effects might be modulated by cavtratin’s beneficial 
activities on the tight junction proteins that make up the BBB. More elaborate studies are 
highly encouraged to investigate mechanistic details of cavtratin with respect to BBB 
maintenance, as well as test for functional improvements in cavtratin-treated animals. 
Such studies may shed further light on the caveolins as potential therapeutic targets in 
combating BBB disruption following juvenile TBI. 
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PROLOGUE TO CHAPTER 5 
ACUTE ADMINISTRATION OF DJNKI-1 FOLLOWING JUVENILE 
TBI IN RATS IMPROVES NEUROIMAGING, HISTOLOGICAL AND 
FUNCTIONAL OUTCOMES 
 
Having dealt with the caveolins and cavtratin in chapters 3 and 4 respectively, 
the second set of molecules that are of interest for early intervention in juvenile TBI 
(jTBI) are c-Jun N-terminal kinases (JNKs). DJNKI-1 is used as a competitive inhibitor of 
JNK pathway. See Fig. 1 below for a diagrammatic representation of the proposed 
intervention strategy for juvenile TBI using DJNKI-1.  
The aim of this chapter is to examine the effect of acute DJNKI-1 treatment on 
BBB disruption, edema formation, and neurological and behavioral outcomes following 
juvenile TBI. The underlying hypothesis is that acute inhibition of the JNK pathway 
through the administration of DJNKI-1 will limit the extent of BBB disruption and 
vasogenic edema, with concomitant improvements in histological and functional 
outcomes both short-term and long-term. 
Results in this section show that intraperitoneal administration of DJNKI-1 at 3 
hours post-jTBI produces a reduction of brain lesion volume in DJNKI-1 treated rats at 
both acute and chronic time points.  Furthermore, there is concomitant reduction in 
edema formation at acute time point in lesioned cortical region with DJNKI-1 treatment. 
Immunohistochemical staining showed lower Immunoglobulin G (IgG) extravasation in 
the brains of treated subjects. There is also a significant recovery of neurological 
functions in the DJNKI-1 treated rats compared with controls as examined by a battery of 
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tests which include: foot-fault, rotarod, zero maze, and Morris Water Maze (MWM) tests. 
These results suggest beneficial effects of early DJNKI-1 intervention in jTBI.  
The chapter follows the blueprint of a scientific manuscript with abstract, 
introduction, methods, results and discussion sections. It is also replete with detailed 
figures and legends, and a table. 
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Abstract 
The juvenile brain is known to be susceptible to Blood-Brain Barrier (BBB) 
damaging secondary processes which occur for days to weeks following brain trauma. In 
this study, we investigate the therapeutic potential of competitively inhibiting the 
activation of c-Jun N-terminal kinases (JNKs) acutely in the brain following an 
experimental model of juvenile TBI (jTBI) in P17 rats. We show that intraperitoneal 
administration of DJNKI-1 – a competitive inhibitor of JNK pathway – at 3 hours post-
jTBI results in reduction of brain lesion volume in DJNKI-1 treated rats at 1d (by 47.3%), 
3d (by 37.2%), 7d (by 51.7%), 30d (by 38.1%), and 60d (by 45.8%) post-injury.  
Furthermore, edema in the cortical lesion – measured with T2-weighted magnetic 
resonance imaging (MRI) – is reduced significantly at acute time points (e.g. 3d by 
26.4% and 7d by 26.9%) with DJNKI-1 treatment. Immunohistochemical staining for IgG 
showed lower IgG extravasation in DJNKI-1 treated subjects. In addition, there is 
significant recovery of neurological functions in the DJNKI-1 treated rats compared with 
controls as examined by foot-fault (**p<0.0001, rm ANOVA at 1d – 60d), rotarod (at 3d, 
*p<0.02 and at 7d, **p<0.002, t-test), zero maze (at 60d, *p<0.04, t-test), and Morris 
Water Maze tests (e.g. 30d West spatial, **p<0.008, rm ANOVA). We conclude that 
acute inhibition of JNK pathway following jTBI protects against prolonged BBB disruption 
and edema formation, and aids in the recovery of some sensorimotor and neurocognitive 
functions at both acute and later time points.  
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Introduction  
The mechanical impact that initiates traumatic brain injury (TBI) is known to 
induce secondary pathophysiological and biochemical processes, which progressively 
determine the consequent outcomes of the injury (Adelson and Kochanek, 1998, Park et 
al., 2008). Among these secondary processes are: blood-brain barrier disruption, edema 
formation, impaired metabolism, alteration in cerebral blood flow (CBF) and 
hemodynamic regulation, hypotension, hypoxia, free radical formation, 
neuroinflammation, and excitotoxicity (Werner and Engelhard, 2007, Shlosberg et al., 
2010). TBI in the juvenile population (jTBI) is particularly associated with greater risks of 
cerebral hemodynamic dysfunction (Armstead, 1999, 2005, Freeman et al., 2008, 
Udomphorn et al., 2008, Chaiwat et al., 2009, Armstead et al., 2011), hypoxic-ischemic 
injury (Armstead, 2005), and diffuse cerebral edema (Suh et al., 2001, Giza et al., 2007), 
with resultant long-term functional deficits (Giza, 2006). The susceptibility of juvenile 
brain to tight junction (TJ) protein breakdown, edema, and dysfunction of cerebral 
hemodynamics are bona fide therapeutic targets that require further investigation 
(Aldrich et al., 1992, Adelson and Kochanek, 1998, Huh and Raghupathi, 2009, Fukuda 
et al., 2012).  
  The c-Jun N-terminal kinases (JNKs) constitute a subfamily of mitogen-activated 
protein kinases (MAPKs) which respond to various forms of internal and external stress 
stimuli such as: UV light, inflammatory cytokines, reactive oxygen species (ROS), growth 
factors, as well as physical and biomechanical perturbations (Hibi et al., 1993, Derijard 
et al., 1994). All 3 isoforms of JNKs are highly conserved across various species ranging 
from yeast to mammals (Goberdhan and Wilson, 1998, Kirkham et al., 2008), and are 
found in various cell types in the brain, including neurons (Lannuzel et al., 1997, 
Herdegen et al., 1998), endothelial cells (Etienne et al., 1998, Waetzig et al., 2006), and 
astrocytes (Migheli et al., 1997, Xie et al., 2004). Basal JNK activity level in the brain is 
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15 to 30-fold higher than in other tissues under physiological conditions (Xu et al., 1997, 
Coffey et al., 2000). JNKs in the brain are activated even further following external 
stimuli and pathological events (Borsello and Bonny, 2004). Most studies on JNK 
pathway in the brain have focused predominantly on neuronal activation triggered by 
excitotoxic events in adult rodents (Borsello et al., 2003, Cui et al., 2007, Haeusgen et 
al., 2009) or human (Ortolano et al., 2009). There is however increasing evidence that 
JNK is also activated in glial cells (Xie et al., 2004, Cui et al., 2007) and brain endothelial 
cells (Lennmyr et al., 2002, Lo et al., 2005, Kacimi et al., 2011, Tu et al., 2011), and that 
such activation in non-neuronal cells negatively impacts neuronal function and cell death 
(Xie et al., 2004, Kaminska et al., 2009).  
Hyperactivation of JNKs is a phenomenon that could mediate the secondary 
events of TJ protein breakdown and the formation of edema, which can lead to 
functional and behavioral consequences. JNK hyperactivation has been documented 
both clinically (Ortolano et al., 2009) and experimentally (Otani et al., 2002a, Otani et al., 
2002b, Raghupathi et al., 2003, Tran et al., 2012) post-TBI, in parallel with secondary 
injuries. It has also been shown in models of stroke (Borsello et al., 2003, Michel-
Monigadon et al., 2010, Nijboer et al., 2010), Parkinson’s disease (Peng and Andersen, 
2003, Kuan and Burke, 2005), and Alzheimer’s disease (Okazawa and Estus, 2002, Wei 
et al., 2002).      
 Hyperactivation of JNKs has been shown to result in downregulation of TJ 
proteins in both in vitro brain endothelial cell cultures (Tai et al., 2010) and in vivo in the 
periphery (Kojima et al., 2010, Samak et al., 2010), consequently affecting the BBB 
integrity (Tai et al., 2010, Tu et al., 2011). Interestingly, JNK inhibition with SP600125 
was shown to reverse decrease in TJ proteins such as claudin-5 in the periphery 
(Carrozzino et al., 2009). In an experimental model of pancreatitis, JNK inhibition with 
CEP-1347 was found to reduce edema formation in rat pancreas (Wagner et al., 2000). 
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Inhibition of JNK with SP600125 was also found to reduce brain swelling in experimental 
subarachnoid hemorrhage (SAH) model (Yatsushige et al., 2007). SAH induces JNK 
activation in rat cerebral arteries by 24 hours which is concomitant with increased BBB 
permeability and brain edema (Kusaka et al., 2004).  Furthermore, JNK hyperactivation 
was found to play a role in experimental jTBI-induced cerebrovascular dysregulation in 
piglets (Armstead et al., 2011). Successful reversal of pial arterial vasoconstriction that 
occurs following TBI induction was achieved with the use of JNK inhibitors, SP600125 
and DJNKI-1 (Armstead et al., 2011). JNK antagonist SP600125 has also been used in 
combination with glucagon to achieve full reversal of cerebral vasoconstriction in jTBI 
model in piglets (Armstead et al., 2012). These studies provide evidence that the 
hyperactivation of JNK pathway may be involved in jTBI-induced disruption of tight 
junction and cerebrovascular regulation. 
Investigators have up to date experimented with three main types of JNK 
inhibitors with varying efficacies (Cui et al., 2007). The first group comprises of ATP-
competitive inhibitors of JNK, such as SP600125 and CEP-1347, which are small 
organic compounds that occupy the ATP-binding site of the protein kinase (Herdegen et 
al., 1998, Haeusgen et al., 2009). However, the disadvantage of this set of inhibitors is 
that their efficacy is reduced by the high endogenous levels of ATP (Cui et al., 2007).  
SP600125 has been used in some experimental TBI (Hong et al., 2012), stroke (Gao et 
al., 2005, Guan et al., 2006) and Parkinson’s disease (Kuan and Burke, 2005) studies. 
The second and third groups of inhibitors target the substrate-binding sites and the 
allosteric regulatory sites of JNK respectively with non-phosphorylatable analogues (Cui 
et al., 2007, Comess et al., 2011). Peptide inhibitors are examples of these second and 
third groups, and these provide a more specific inhibition mechanism than ATP-
competitive inhibitors (Haeusgen et al., 2009).  Peptide inhibitors which competitively 
bind to JNK-interacting peptide-1 (JIP-1) – a scaffolding protein that act upstream of the 
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3 isoforms of JNK – have been used extensively in experimental brain research 
(Bogoyevitch and Arthur, 2008). JIP-1 scaffolding protein structurally organizes the MAP 
kinase signaling module by linking MLK-3 and MKK-4/7 (upstream kinases that 
phosphorylate JNK) with JNK and thereby providing a spatial and temporal platform for 
regulating the JNK pathway (Borsello and Bonny, 2004, Bogoyevitch and Arthur, 2008) 
(See Fig. 2). L-DJNK-1 and D-JNK-1 are examples of these peptides (Bogoyevitch and 
Arthur, 2008). 
D-JNKI-1 is a synthetic, protease-resistant and cell-penetrating peptide made by 
linking HIV-TAT transporter peptide sequence to the 20-amino acid JNK-binding motif of 
JIP-1 (Borsello et al., 2003). The D-retro-inverso synthesis (i.e. made with D-amino 
acids) of D-JNKI-1 gives it strong resistance against proteolytic degradation and 
increases its stability in the body (Borsello et al., 2003, Borsello and Bonny, 2004).  D-
JNKI-1 functions through competitive inhibition of all JNK isoforms (Fig. 2).  D-JNKI-1 
selectively blocks access of JNK to c-Jun and other downstream substrates such as 
JunB, JunD, and c-myc by competing for the JNK-binding site of JIP-1(Borsello et al., 
2003, Borsello and Forloni, 2007) (See Fig. 2 below). The therapeutic effectiveness of 
D-JNKI-1 is pegged on its potential to modulate upstream and downstream arms of the 
secondary injury cascade following jTBI, including excitotoxicity, hypoxia-ischemia, 
edema, neuroinflammation and apoptosis (Yang et al., 1997, Kuan et al., 2003, Tu et al., 
2011). 
 Meanwhile, long-term functional deficits of sensorimotor, cognitive, and 
neuropsychiatric nature which could last for years have been reported in patients with 
incidence of jTBI (Chadwick et al., 1981, Yeates et al., 2002, Jonsson et al., 2013). Most 
experimental studies of jTBI in animals have, however, focused on acute time-points 
following trauma (Saatman et al., 2008), making them inapplicable and nongeneralizable 
to clinically observed long-term sequelae of TBI (Doppenberg et al., 2004, Saatman et 
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al., 2008). This justifies the establishment of models for long-term profiling of functional 
and behavioral parameters following experimental jTBI as have been reported (Giza et 
al., 2005, Ajao et al., 2012). Such models that assess both sensorimotor (e.g. through 
the use of foot-fault, beam balance, and rotarod tests) and cognitive (e.g. through the 
use of Morris Water Maze [MWM] test) parameters can be used to determine the long-
term efficacy of potential therapeutic agents such as D-JNKI-1. D-JNKI-1 has been 
shown to ameliorate behavioral deficits in experimental models of stroke (Esneault et al., 
2008), neuroinflammation (Palin et al., 2008), and spinal cord injury (Repici et al., 2012) 
in adult rodents. D-JNKI-1 was also successfully used to arrest the progression of 
hearing loss in a model of cochlear implantation trauma (Eshraghi et al., 2006). 
To date, there have been no reports on the potential link between juvenile TBI-
induced JNK activation and post-injury BBB disruption and edema. Neither have there 
been studies on the therapeutic potential of DJNKI-1 in this model.  The working 
hypothesis for this study is that acute competitive inhibition of JNK in the brain will 
mediate rapid recovery at BBB level, and lead to reduced edema formation and lesion 
volume, reflected in improved motor and behavioral outcomes at both acute and delayed 
time points following jTBI. We report that acute treatment with DJNKI-1 following jTBI in 
P17 rats results in remarkable reduction in edema, lesion volume and neurological 
deficit, alongside with reduced BBB disruption.   
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Materials and Methods 
Subjects 
Juvenile (P10) male Sprague-Dawley rats were ordered from Harlan Laboratories 
(Harlan, Indianapolis, IN). They were housed with their dams upon delivery on a 12-hour 
light-dark cycle at constant temperature and humidity, in accordance with standard 
guidelines, and allowed to acclimatize for 7 days. Key surgical procedures were carried 
out on the pups at P17. Subsequently, the pups were weaned at P24, housed 2 rats per 
cage, and fed with standard lab chow and water ad libitum. All groups of animals used in 
the study (total n = 28, comprising of 3 different cohorts) had identical CCI surgical 
parameters, and were randomly divided into saline-injected control and DJNKI-1 treated 
groups. The first cohort of subjects (n = 5 SAL, n = 5 DJNKI-1) was studied acutely with 
MRI and behavioral tests (i.e. at 1 and 3dpi), and then euthanized, followed by brain 
collection at 3dpi. The second cohort (n = 5 SAL, n = 5 DJNKI-1) was studied 
longitudinally for MRI (at 1, 3, 7, 30 and 60 dpi) and all behavioral tests (at 1, 3, 7, 30 
and 60 dpi) over a 2-month period. The third cohort (n = 4 SAL, n = 4 DJNKI-1) was 
identical to the second cohort with the exception of MRI scans. Euthanization and brain 
collection for the second and third cohorts occurred at 60dpi, and the brains were 
prepared for immuhistochemistry.  All protocols and procedures used in this study were 
approved by the Institutional Animal Care and Use Committee of Loma Linda University 
and are in compliance with the U.S. Department of Health and Human Services Guide. 
 
Juvenile Traumatic Brain Injury Procedure 
TBI was induced in juvenile rats at P17 through a controlled cortical impact (CCI) 
as previously described (Ajao et al., 2012). Briefly, the rats were anesthetized with 
isofluorane (Webster Veterinary Supply, Inc., Sterling, MA) and afterwards placed into a 
mouse stereotaxic frame (David Kopf Instruments, USA). A midline scalp incision 
187 
followed by a 5 mm craniotomy was performed unilaterally over the right fronto-parietal 
cortex (Bregma: 3 mm anterior-posterior and 4 mm medial-lateral). A controlled impact 
on the brain was delivered using a 3 mm rounded-tip metal impactor fixed to an 
electromechanical actuator and centered over the exposed dura at a 20° angle to be 
parallel to the cortical surface (Leica Microsystems Company, Richmond, IL). The impact 
was delivered at a 1.5 mm depth from the cortical surface, with impact duration of 200 
ms, and at a velocity of 6 m/s. Aberrations to the cortical tissue, such as bleeding and 
protrusion of cortical tissue through the craniotomy, were duly recorded. Thereafter, the 
surgical site was sutured closed. Subject’s body temperature was maintained throughout 
the surgery at 37°C. For pain relief, Buprenorphine (0.01 mg/kg; dilution: 0.01 mg/ml) 
was injected subcutaneously into the subjects before they were returned to their dams. 
The time between the end of surgery and when subjects wake up were also recorded. 
There was close daily monitoring of the subjects for at least 7 days post injury, followed 
by more spaced out examinations afterwards. 
 
DJNKI-1 Treatment 
D-JNKI-1 (11mg/kg) or normal saline was intraperitoneally administered to each 
subject at 3 hours post-injury. This dosage was based on previously reported efficacy of 
DJNKI-1 in middle cerebral artery occlusion (MCAO) model in male P14 Wistar rats 
(Repici et al., 2007) where the drug was injected intraperitoneally. The same dosage has 
also been used effectively in spinal cord injury model in adult mice (Repici et al., 2012). 
The rats were returned to their dams right after injection.  
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Magnetic Resonance Imaging (MRI): Acquisition and Analyses 
Image Acquisition 
In vivo MRI was performed at 1 and 3 dpi for all animals, while a subset of the 
animals was also scanned at 7 and 30 dpi, followed by high resolution ex vivo imaging at 
60 dpi. Rats were prepared for in vivo MRI as previously described (Ajao et al., 2012). 
Briefly, following induction of anesthesia (with 1-2% isofluorane), each rat was placed in 
a temperature controlled cradle containing a volume radio frequency (RF) coil and 
imaged on a 11.7T MRI (8.9 cm bore) at 1d and 3d, and on a larger bore (40 cm) 4.7T 
MRI (Bruker Biospin, Billerca, MA) at 7d and 30d. Ex vivo imaging at 60d was carried out 
in the 11.7T magnet. 
T2 weighted imaging (T2WI) was acquired in vivo with the following parameters: 
repetition time/echo time (TR/TE) = 2357.9/10.2 ms; 128 X 128 matrix; 1 mm slice 
thickness; 1 mm interleaved; average of 4 acquisitions; number of slices = 20; and field 
of view (FOV) = 2.0 cm for a total imaging time of 20 min on 11.7T MRI; and repetition 
time/echo time (TR/TE) = 3563.4/20 ms; 256 X 256 matrix; 1 mm slice thickness; 1 mm 
interleaved; average of 2 acquisitions; number of slices = 25; field of view (FOV) = 3.0 
cm for a total imaging time of 30 min on the 4.7T MRI. Diffusion-weighted imaging (DWI) 
was acquired using a repetition time/echo time (TR/TE) = 1096.5/50 ms; 128 X 128 
matrix; 1 mm slice thickness; 1 mm interleaved; average of 2 acquisitions; number of 
slices = 20; field of view (FOV) = 2.0 cm; and b values = 116.96 s/mm2, 1044.422 s/mm2 
for a total imaging time of 17 min on 11.7T MRI; and a repetition time/echo time (TR/TE) 
= 3000/50 ms; 256 X 256 matrix; 1 mm slice thickness; 1 mm interleaved; average of 2 
acquisitions; number of slices = 25; field of view (FOV) = 3.0 cm; and b values = 43.05 
s/mm2, 441.991 s/mm2 for a total imaging time of 51 min on 4.7T MRI.   
At 60 dpi, perfusion-fixed brains were prepared as previously described (Ajao et 
al., 2012) before undergoing ex vivo scanning using the 11.7T magnet. T2WI were 
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acquired using: a repetition time/echo time (TR/TE) = 1769.9/10.2 ms; 256 X 256 matrix; 
1 mm slice thickness; 1 mm interleaved; average of 4 acquisitions; number of slices = 
15; and a field of view (FOV) = 2.0 cm for a total imaging time of 30 min on 11.7T MRI. 
DWI was carried on the same scanner and with the same parameters as the T2WI, with 
the exception of TR/TE (552.5/15.1 ms), acquisition time (70 min), and b values (116.96 
s/mm2; 1044.422 s/mm2). Apparent Diffusion Coefficient (ADC) was calculated from six 
gradient vectors. As previously reported, the use of two different field strengths and the 
use of both in vivo and ex vivo MRI did not alter our relative measurements (Obenaus et 
al., 2011, Obenaus and Hayes, 2011, Ajao et al., 2012). Acquisition of both T2WI and 
DWI was done in sequence without any apparent change in the positioning of the 
animals.  
 
Lesion Volume Analysis 
As previously described (Ajao et al., 2012), volumetric analyses of brain and 
lesion volumes were performed using the T2WI in either Cheshire (Hayden Image 
Processing Group, Waltham, MA) or Amira (Mercury Computer Systems, Visage 
Imaging, Inc., San Diego, CA, USA) software. Lesion volumes were defined as the 
cortical brain regions containing abnormal hypo- and/or hyperintense signals compared 
to normal-appearing cortical brain matter on the contralateral hemisphere (Fig. 1C). 
Total brain volume encompassed both normal-appearing and abnormal brain tissues, 
while herniated tissue, if present, was excluded. In some animals, subcortical and 
extracortical abnormalities were present but were not included in the lesion. These 
abnormalities were recorded as injury-related morphological alterations (Table 1), and 
included: ventricular hypertrophy, hemorrhage, shrunken hippocampus, disrupted corpus 
callosum (and other affected white mater structures), and cortical herniation. In order to 
correct for individual brain size differences among the animals and age-related brain 
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growth, the injury volumes were normalized to the brain volumes. Hemispheric volumes 
were also analyzed using the same inclusion and exclusion criteria.  
 
T2 Analysis 
For each T2WI scan, a region of Interest (ROI) was drawn on the slice with the 
largest lesion area for each of the following areas: lesion, perilesion, striatum and 
hippocampus on both ipsilateral and contralateral hemispheres. The lesion and 
perilesion ROIs encompass both hypointense (which may indicate hemorrhage) and 
hyperintense pixels (which may indicate edema) within the brain parenchyma (Fig. 3A, 
D). A rectangular box measuring 6-by-8 pixels constitutes the ROI for both ipsilateral and 
contralateral striatum. ROIs for the hippocampus encompass all visible hippocampal 
regions along the anterior-posterior axis. All these aforementioned ROIs were 
subsequently posted on co-registered T2 maps corresponding to each chosen brain 
slice for acquisition of T2 values. T2 values were compared between DJNKI-1 group and 
saline-control group. 
 
Apparent Diffusion Coefficient (ADC) Analysis 
The ROIs drawn for T2WI scans were copied to co-registered diffusion-weighted 
MRI-derived ADC maps on the slice with the largest lesion for each subject.  Extraction 
of ADC values from these ROIs on the maps followed. There were no overt differences 
in ADC values resulting from the use of in vivo versus ex vivo MRIs in all ROIs. 
 
Area Measurements of the Corpus Callosum 
Thickness 
A ROI was drawn around the portion of visible corpus callosum in each 
hemisphere from a selected T2-weighted MR image at bregma level +1mm, anterior to 
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the lesion in each animal. The chosen coronal slice often corresponds to the slice that is 
directly anterior to the visible lesion. Equivalent anatomical landmarks were used for 
selection of the slice chosen for analysis for all animals. The corpus callosal areas for 
each image were extracted with Cheshire software. 
 
Neurological and Behavioral Tests 
Detailed procedure for each behavioral test used in this study has been 
previously described (Ajao et al., 2012). All tests on both saline and DJNKI-treated 
animals were carried out within a 3-hour time-block between 8am and 11am, and the 
animals from both groups were interleaved. The tests were carried out in the sequence 
in which they are listed below. 
 
Foot-fault   
This was performed using an elevated wire mesh (2.5 cm X 30 cm rectangular 
holes/grid spacing) raised 76 cm above the floor. Movements of each rat placed in the 
middle of the mesh were video-recorded for 60 sec in two separate trials. A foot-fault 
was counted when a rodent’s paw slipped completely through the wire mesh. The 
number of foot-fault for both groups were compared. 
 
Beam Balance   
Juvenile animals were tested on a 0.65 cm wide plexiglass beam at 1, 3, and 7 
dpi. Adult animals were tested on a 2.5 cm wide beam at 30 and 60 dpi commensurate 
to their size increase. Each animal walked unrestricted for 60 sec for each of two trials 
20 min apart, and the distance covered was recorded and compared between saline-
controls and DJNKI-1 group.  
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Rotarod   
Two different rotarod paradigms were used: constant velocity (at 1, 3, 7, 30 and 
60dpi), and constant acceleration (2rpm/5s and 5rpm/5s at 30 and 60 dpi). The rotarod 
(Rotamex-5, Columbus Instruments, Columbus, OH) operates until each animals falls 
off. Latency to fall was recorded as a measure of motor coordination and balance. 
 
Open-field   
General activity level and exploratory behavior of the animals were assessed 
with open-field test at 30 and 60 dpi.  Each subject was video-recorded for 30 min 
(Noldus Ethovision, Noldus Information Technology, Inc., Leesburg, VA) inside an empty 
plastic bin. Total distance traveled was recorded as a measure of overall activity levels 
and compared between groups. 
 
Zero Maze   
This test was carried out on an elevated circular apparatus fitted with a brightly 
lit, open half, and also with an enclosed half. A 5-min trial was conducted at 30 and 60 
dpi, and the percentage of time spent in the enclosed half was recorded. Increased 
percentage of time spent in the dark quadrants of the track is associated with increased 
anxiety-like behaviors as previously shown (Ajao et al., 2012). 
 
Morris Water Maze (MWM)   
A 3-day assessment of subject performance in cued and spatial water maze 
paradigms was used as a measure of learning and spatial memory functions at 30 and 
60 dpi. The water maze metal tank was filled with opaque water. An escape platform (11 
cm diameter) was adjusted so that its surface was 2 cm above the water surface for 
cued testing, and submerged 1 cm below the water surface for the spatial learning and 
memory tasks. Rodent’s swim paths were recorded with a computerized tracking device 
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(Noldus Information Technology, Inc., Leesburg, VA) (Hartman et al., 2005, Ajao et al., 
2012). In the cued task, platform location was changed for each of 5 trial blocks – each 
block consisting of 2 consecutive trials (60 sec maximum for each) with a 5 sec inter-trial 
interval.  For the spatial testing, platform location was kept constant for all 10 trials, and 
there were four release points.  1.5 hrs following the spatial trials, a 60 sec probe trial 
was performed, in which the platform was removed from the tank and the rats were 
allowed to swim in search of it. Outcomes for the MWM include: distance traveled to 
reach the platform, number of entries into the target quadrant, percentage of time spent 
in the target quadrant, and swim speed.  
 
Tissue Processing and Immunohistochemistry 
A cohort of rats were transcardially perfused with 4% PFA prepared in PBS at 3d 
and 60d post-jTBI. The brains, upon removal, were immersed in 30% sucrose solution at 
4°C for 48 hours, until they sink to the bottom. They were then frozen on dry ice and 
stored at -20°C pending cryosectioning. Coronal cryostat sections were pre-mounted on 
glass slides (thickness = 20µm) (Leica CM1850, Leica Microsystems GmbH, Wetzlar, 
Germany). The sections were stored at -20°C until used.  
 
Extravasated Serum Immunoglobulin G (IgG) 
Staining and Analysis  
To evaluate disruption at the BBB, staining for extravasated IgG was performed 
as previously described (Badaut et al., 2011). Briefly, pre-mounted sections were twice 
washed (10min each) in PBS and then blocked with 1% BSA in PBS for 1.5 hrs. The 
sections were then incubated for 2 hrs at RT with biotinylated, affinity-purified goat anti-
rat IgG, coupled with an 800nm wavelength infrared dye (1:500 dilution; Rockland, 
Gilbertsville, PA), in a PBS-based antibody incubation buffer containing 0.1% Triton X-
100 and 1% BSA. The sections were washed in PBS and dried. The sections were then 
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scanned on an infra-red scanner (Odyssey-system, LiCor, Germany) to quantify the area 
of IgG extravasation on 3 to 5 adjacent slices covering the lesion. ROIs were drawn with 
LI-COR Odyssey system around the regions where extravasated IgG is observed in 
each section. The areas of these regions were then extracted for each section, 
summated for each brain, and averaged for each group.   
 
Statistical Analyses 
All data are presented as mean ± SEM. Statistical analyses were done using 
SPSS, and graphs were obtained using Sigmaplot (SPSS Inc.). All the data were 
analyzed using student t-tests for normally distributed data with comparison between the 
DJNKI-1 and control groups for each of the time points. Repeated measures ANOVAs 
were used in cases where longitudinal data were collected on the same groups. 
 
Results 
DJNKI-1 Reduces Lesion Volume and Ameliorates 
Morphological Alterations 
 Data gathered from non-invasive MRI was used to quantify lesion volume at 1d, 
3d, 7d, and 30d. It was also used for lesion volume measurements following removal of 
brains from euthanized rat subjects at the 60d time points. 3D reconstructions of 
representative saline and DJNKI brains along the rostral-caudal axis show that the 
lesions (red) constitute 1.9% and 2.2% of DJNKI brains compared to 3.5% and 3.9% of 
saline brains respectively at 3d and 60d (Fig. 3B).  The lesion is located on frontoparietal 
cortex that encompasses the motor and somatosensory cortices. Intraperitoneal 
administration of DJNKI-1 at 3 hours post-jTBI (Fig. 3A) results in significant reductions 
of brain lesion volume in DJNKI-1 treated rats at 1d (by 47.3 +/- 11.1 %), 3d (by 37.2 +/- 
17.5 %), 7d (by 51.7 +/- 12.7 %), 30d (by 38.1 +/- 19.9 %), and 60d (by 45.8 +/- 11.3 %) 
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post-injury (Fig. 3D). Repeated measures ANOVA confirms a reduction in lesion volume 
in DJNKI-treated rat brains across all time points compared to brains of saline control 
rats (**p < 0.001; Fig. 3D). Fig. 3D shows lesion volumes as percentages of total brain 
volumes for both saline and DJNKI-1 groups.  In addition, pairwise comparisons (with rm 
ANOVA) reveal intragroup variations in lesion volume as a percentage of brain volume in 
the saline group but not in the DJNKI-1 group (Fig. 3D). Compared to 1d value, lesion 
volume (in the saline group) is significantly lower at 7d (*p < 0.02) and 30d (**p < 0.005). 
Juxtaposed brain sections (consisting of the brain slice that is most central to the lesion 
and that has the largest lesion volume, for each time point) and lesion ROIs demarcated 
in red are shown in saline and DJNKI-1 brains for each time point in Fig. 3C.  Visual 
comparison reveals that DJNKI-1 brain sections have smaller lesion volume across all 
time points compared to saline brains (Fig. 3C).   
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Table 1: Morphological Observations of Tissue Alterations  
Morphological 
Observation 
Experimental
Group 
1d 3d 7d 30d 60d 
Ventricular 
Hypertrophy 
(Ipsil. Cortex) 
 
SAL 
 
DJNKI 
70%* 
 
20% 
90% 
 
40% 
100% 
 
40% 
100% 
 
100% 
100% 
 
80% 
 
Ventricular 
Hypertrophy 
(Contra. Cortex) 
 
SAL 
 
DJNKI 
60% 
 
10% 
30% 
 
20% 
80% 
 
60% 
75% 
 
40% 
100% 
 
40% 
 
Cortical 
Thinning (Ipsil. 
Cortex) 
 
 
SAL 
 
DJNKI 
50% 
 
0% 
90% 
 
0% 
80% 
 
60% 
100% 
 
100% 
100% 
 
80% 
Damaged HPC 
(Ipsil. Cortex) 
 
 
SAL 
 
DJNKI 
90% 
 
0% 
90% 
 
0% 
100% 
 
60% 
100% 
 
20% 
100% 
 
60% 
Damaged HPC 
(Contra. Cortex) 
 
 
SAL 
 
DJNKI 
0% 
 
0% 
0% 
 
0% 
10% 
 
0% 
0% 
 
0% 
0% 
 
0% 
Hemorrhage 
(Ipsil. Cortex) 
 
 
SAL 
 
DJNKI 
90% 
 
90% 
100% 
 
80% 
100% 
 
80% 
50% 
 
40% 
0% 
 
0% 
Herniation    
(Ipsil. Cortex) 
 
 
SAL 
 
DJNKI 
50% 
 
40% 
80% 
 
50% 
100% 
 
80% 
 
100% 
 
100% 
50% 
 
40% 
Cyst            
(Ipsil. Cortex) 
 
 
SAL 
 
DJNKI 
0% 
 
0% 
10% 
 
10% 
60% 
 
0% 
100% 
 
80% 
100% 
 
20% 
Disrupted 
Corpus Cal. 
(Ipsil. 
Hemisphere) 
SAL 
 
DJNKI 
 
70% 
 
0% 
80% 
 
20% 
60% 
 
60% 
100% 
 
80% 
100% 
 
100% 
       
Total n (SAL)  10 10 5 4 4 
Total n (DJNKI)  10 10 5 5 5 
* Percentage of animals in the group with the observed morphological alteration 
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Comparison of the two hemispheric volumes in saline group shows increased 
contralateral hemisphere volume at 3, 7 and 30dpi (*p = 0.03, **p = 0.003, and **p = 
0.01 respectively; t-test) (Fig. 4A). In the DJNKI-1 group, there is increased contralateral 
volume at 7 and 60dpi (**p = 0.002, and *p = 0.02 respectively; t-test) (Fig. 4B). As 
expected, the raw volumes of both hemispheres in saline and DJNKI-1 brains are 
significantly increased at 30d and 60d compared to the volumes at earlier time points 
(**p < 0.001 for each comparison), reflecting brain growth with increasing age (Figs. 4A 
and B). When compared, ipsilateral hemispheres volumes for the saline group is higher 
than that of the DJNKI-1 group only at the 60d time point (**p < 0.01) (Fig. 4C). There 
are no differences at other time points. The contralateral hemisphere volumes are 
however similar for both groups at all time-points (Fig. 4D). 
 Some alterations in brain morphology were observed at varying frequencies in 
the T2WI of the two groups (see Table 1). Of particular note are: ventricular hypertrophy 
(enlargement of the ventricles) which was less frequent in DJNKI animals at 1, 3, and 
7dpi on both ipsilateral (70% [saline] vs. 20% [DJNKI], 90% vs. 40%, and 100% vs. 40% 
respectively at 1, 3 and 7dpi) and contralateral cortices (60% vs. 10%, 30% vs. 20%, 
and 80% vs. 60% respectively) (Table 1); cortical thinning (reduction in cortical 
thickness) which was less frequent in DJNKI animals at 1, 3, and 7dpi on ipsilateral 
cortex (50% vs. 0%, 90% vs. 0%, and 80% vs. 60% respectively at 1, 3 and 7dpi), and 
damaged hippocampus on ipsilateral cortex (90% vs. 0%, 90% vs. 0%, and 100% vs. 
60%, 100% vs. 20%, and 100% vs. 60% respectively at 1, 3, 7, 30 and 60dpi). Other 
morphological changes include hemorrhage/hematoma which was less frequent on 
DJNKI brain at 3 (100% vs. 80%) and 7dpi (100% vs. 80%) on ipsilateral cortex, 
herniation (displacement and protrusion of brain tissue) which was less common in 
DJNKI brains at 1 (50% vs. 40%), 3 (80% vs. 50%), and 7dpi (100% vs. 80%) on the 
ipsilateral cortex, formation of cyst (enclosed sphere separated from the brain that is  
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made up of a mixture of fluid and abnormal brain mater) which was less frequent on 
DJNKI brain at 7 (60% vs. 0%) and 60dpi (100% vs. 20%) on ipsilateral cortex, and 
disrupted corpus callosum which was less frequent on DJNKI brain at 1 (70% vs. 0%) 
and 3dpi (80% vs. 20%) on the ipsilateral cortex (Table 1).  Representative samples of 
these morphological changes are presented in Fig. 4E with abnormalities demarcated in 
red. The reduced frequencies of these alterations in brain morphology in DJNKI-treated 
animals’ brains suggest that the DJNKI-1 treatment is protective at various levels in the 
brain. No prominent midline shifts were observed in both saline and DJNKI-treated 
brains. There were also no significant weight differences between the two groups over 
the experimental period. 
To investigate possible effect of acute DJNKI-1 treatment on white matter 
structure, we quantified the surface area of regional corpus callosum (CC) from T2-
weighted images (T2WI) at the level of +1mm from bregma (just anterior to the lesion) at 
each of the time points in each group. Overall increase in total CC surface areas was 
observed for DJNKI-1 animals across all time points compared to saline-controls (**p < 
0.001, repeated measures ANOVA; Fig. 5A, B). Individual t-test for total CC showed that 
the increased CC size was more evident at later time points, especially at 7d (p = 0.021), 
30d (p = 0.005), and 60d (p = 0.005) time points in the DJNKI-1 animals, although CC 
size at 1d is also higher for DJNKI-1 animals (p = 0.012) (Fig. 5B, C).  Comparison of CC 
size along hemispheric lines further shows overall increase for the DJNKI-1 group 
across all time points (for ipsilateral CC, **p < 0.009; for contralateral CC, **p < 0.003) 
(Fig. 5D, E).  These results are suggestive of beneficial role for DJNKI-1 in maintaining 
white matter structural integrity, especially at later time points.   
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DJNKI-1 Reduces Edema and Improves Water Diffusion after 
Juvenile TBI 
Hyperintensity on T2-weighted MRI (T2WI) has long been used as an index of 
water accumulation possibly related to edema formation (Gomori et al., 1985, Kato et al., 
1986) as shown in Fig. 6A (SAL, white box). In this study, we serially acquired T2WI on 
the subjects to profile T2 changes over the experimental timeline (Figs. 3A, 6B & C). 
Shown in Fig. 6A are representative T2WI of saline and DJNKI brains at 3d, with the 
boxed region enlarged in the lower pane and the important regions labeled (L = Lesion; 
PL = Perilesion; CC = Corpus Callosum; HPC = Hippocampus; Cx = Cortex; and Str = 
Striatum).  
The overall T2 profile in lesion ROI shows increase in T2 values at the acute 
injury phase (1d and 3d), followed by a decrease back to normal values by 7d, and 
another rise in T2 values by 30d, followed by decrease by 60d (Fig. 6B). This intragroup 
variation in T2 value over time is statistically significant (**p < 0.001, rm ANOVA, Fig. 
6B). Pairwise comparisons show that the T2 values from the lesion ROI at 7d and 60d 
are significantly lower than the T2 values at the same ROI at 1d (**p < 0.001) and 3d 
(**p < 0.001) (Fig. 6B). Overall, T2 values are higher in the lesion (Fig. 6B) than in the 
perilesion (Fig. 6C). Inter-group differences are also observed. T2 values acquired from 
lesion ROI in the DJNKI-treated animals are significantly decreased compared to 
controls at both acute (3dpi [**p < 0.003] and 7dpi [*p < 0.04], t-tests) and later (30dpi [*p 
< 0.03] and 60dpi [*p < 0.04], t-tests) time points following jTBI (Fig. 6B), suggesting that 
DJNKI treatment ameliorates edema formation acutely. The treatment may also reduce 
continued cell death and water accumulation in the lesion cavity at later time points (Fig. 
6B). Repeated measures ANOVA confirms the reduced T2 in DJNKI-treated group over 
all time points (**p < 0.002). The use of ex vivo MRI modality at 60d does not 
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significantly affect value comparison with in vivo MRI scans at earlier time points as 
earlier reported (Obenaus et al., 2011, Ajao et al., 2012). 
Significant intergroup difference in perilesion T2 is found only at 30dpi with 
reduced T2 in DJNKI-1 brains (*p < 0.05, Fig. 6C). Intragroup variation in perilesion T2 
value over time is statistically significant (**p < 0.001, rm ANOVA, Fig. 6C). Pairwise 
comparisons show that the T2 values from the perilesion ROI at 7d and 60d are 
significantly lower than the T2 values at the same ROI at 1d (**p < 0.001) and 3d (**p < 
0.001) (Fig. 6C). Other brain regions besides lesion and perilesion show the same 
pattern of stepwise T2 decrease from 1d to 60d without the transitory, upsurge in T2 
values at 30d (data not shown).  
Apparent diffusion coefficient (ADC), which is a quantitative parameter of 
diffusion-weighted MRI (DWI), is often used as a measure of water mobility in the brain 
(Le Bihan, 2007, Badaut et al., 2011). Shown in Fig. 6D are representative DWI of saline 
and DJNKI brains at 7d, with the boxed region enlarged in the lower pane and the 
important regions labeled as in Fig. 6A. There were no detectable intergroup differences 
in the ADC values in the lesion ROI across the experimental timeline (Fig. 6E). Whereas 
ADC values in the lesion ROI were fairly at the same levels at 1, 3, 7, and 60dpi, there 
was a significant spike at 30dpi in both groups (Fig. 6E; **p < 0.008).  
There is significant variation in ADC values in the perilesion ROI over the course 
of the experiment (**p < 0.01). ADC profile of the perilesion ROI is strikingly similar to 
that of the lesion ROI over the experimental timeline (Fig. 6F) with the exception of a 
significant increase in ADC in DJNKI-1 group compared to saline group at 7dpi (p < 
0.05) (Fig. 6F). The similarity in the profiles of ADC changes in both lesion and perilesion 
ROIs suggests intragroup uniformity with respect to jTBI model and effect of DJNKI-1 
treatment.  
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DJNKI-1 Improves Neurological Functions at Acute Time 
Points and Cognitive Functions at Chronic Time Points. 
 To test the efficacy of DJNKI-1 to reverse functional deficits such as motor 
coordination impairment, the rats were subjected to foot-fault, beam balance and rotarod 
tests over the experimental timeline (Fig. 7A). Significant reduction in the number of foot-
faults was found in DJNKI-treated rats at 3, 7, 30 and 60 dpi (**p < 0.01) compared to 
control rats (Fig. 7A), suggesting that DJNKI improves motor function not just acutely but 
also chronically.  A repeated-measures ANOVA confirms significant intergroup 
differences in number of foot-faults over time (**p < 0.001; Fig. 7A). There was a 
progressive, stepwise decrease in the number of foot-faults registered by all subjects 
over time regardless of group (Fig. 7A; **p < 0.001, rm ANOVA). The beam balance test, 
however, does not show any significant intergroup differences in mean distance travelled 
across all time points (Fig. 7B; p < 0.67, rm ANOVA).  Nonetheless, profile of distance 
travelled over the experimental timeline shows a stepwise decrease in value that is 
similar (although less steep) to the foot-fault graph (Fig. 7B; **p < 0.001, rm ANOVA).   
 Two different rotarod paradigms (with 2 velocity/acceleration settings on each) 
were used to further test motor balance, coordination and endurance (Figs. 7C, D, and 
E). Constant speed paradigms (consisting of 10RPM and 20RPM trials) were used at all 
experimental time points, while constant acceleration paradigms (consisting of 2RPM/5s 
and 5RPM/5s) were employed only at 30dpi and 60dpi. DJNKI-treated animals 
performed better in the 10RPM rotarod with higher latencies at 3dpi (*p < 0.02, t-test) 
and 7dpi (**p < 0.002, t-test) (Fig. 7C), and at 7dpi (**p < 0.001, t-test) in the 20RPM 
rotarod (Fig. 7D). Constant acceleration rotarod paradigms (2RPM/5s and 5RPM/5s) 
showed no differences in latency to fall between the 2 groups at 30d and 60d (Fig. 7E). 
Taken together, results from foot-fault and rotarod (constant speed paradigm) tests 
suggest that acute DJNKI-1administration ameliorates motor deficits following jTBI. 
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The open field (OF) test consists of 10 3-mins continuous recording period, with 
each 3 mins constituting a trial block. There are no significant intergroup changes in 
distance travelled across the 10 blocks either at 30d (Fig. 8A) or 60d (Fig. 8B).  The OF 
profiles follow a pattern of progressive decrease in distance moved from one block to the 
next resulting in overall variation in distance traveled across the 10 blocks for both 
groups (**p < 0.001, rm ANOVA; Figs. 8A & B). The cumulative distance graph shows a 
significant increase in total distance traveled by saline animals compared to their DJNKI-
treated counterparts at 60 dpi (*p < 0.05) (Fig. 8D), suggesting an overall decrease of 
activity in DJNKI-1 treated rats. Distance traveled during the first 3 mins of the 10-block 
test – used as a measure of exploratory behavior – showed no inter-group differences at  
30dpi and 60dpi (Fig. 8C). In addition, to evaluate anxiety behavior, the rats were 
subjected to Zero Maze test, which showed significantly reduced percentage of time 
spent in the dark arm by DJNKI animals compared to saline (42.7% vs. 73%; *p < 0.04) 
at 60dpi (Fig. 8E).  
 Cognitive outcomes were assessed by a combination of MWM trials, which 
includes cued, spatial and probe trials (Figs. 9A-E). Cued MWM test was carried out at 
30 and 60dpi to test for equivalence in visual, swimming and motor abilities between the 
2 groups. There were no intergroup differences at 30dpi (Fig. 9A; *p = 0.72, rm ANOVA). 
At 60dpi however, rm ANOVA ran on cued MWM indicates significantly lower distance 
covered by DJNKI animals to reach submerged platforms across the 5 trial blocks (Fig. 
9B; *p < 0.03, rm ANOVA). This suggests that the DJNKI-1 animals had either higher 
motor and swimming or visual ability compared to the controls at 60d. The distance 
traveled to reach submerged platforms in MWM spatial trials are indicators of spatial 
learning and working memory. Spatial MWM was carried out with a western (W) start 
location. In spatial MWM, cumulative distance covered by DJNKI-treated rats at 30dpi 
was significantly lower compared to controls across the blocks (Fig. 9C; **p < 0.008, rm  
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ANOVA). There was, however, no significant between-group difference in MWM spatial 
test at 60d (W) across the trial blocks, although there was a group-distance interaction 
(*p < 0.04). Meanwhile, in the probe trials, the number of entries to platform location, 
which is an index of spatial memory, was significantly higher in DJNKI-treated rats 
compared to controls at 60dpi (Fig. 9E; *p < 0.02, t-test), but not at 30dpi. Taken 
together, these MWM results indicate that the effect of acute DJNKI-1 treatment on 
cognitive deficits at long-term following jTBI may be sensitive to both test repetition 
which can reduce the sensitivity of the MWM tests, and to the evolution of the injury 
across time (see section 4.1 for an elaborate discussion on this). 
 
DJNKI-1 Protects Blood-Brain Barrier Integrity Acutely after 
Brain Injury 
Immunohistochemical staining for extravasated IgG was carried out to assess 
BBB disruption at 3dpi as previously described (Pop et al., 2012). Representative 
coronal slices with extravasated IgG (shown as intense green) at varying depths from 
Bregma at 3dpi are shown for each group on Fig. 10A. Student’s t-test on IgG-stained 
areas on these sections indicates that DJNKI-treated animals had significantly lower 
IgG-stained surface area compared to controls (*p < 0.02) (Fig. 10B). This suggests that 
DJNKI-1 administration helps ameliorate acute BBB disruption following jTBI. 
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Discussion 
This study was aimed at investigating the potential therapeutic impact of 
competitive inhibition of JNK pathway in a juvenile TBI (jTBI) model. Hyperactivation of 
the JNK pathway is a phenomenon that has been reported in various forms of brain 
injuries (Borsello et al., 2003, Michel-Monigadon et al., 2010, Nijboer et al., 2010). 
Experimental data from animal studies show that activation of JNK pathway peaks early 
– in usually less than 12 hours – following brain injuries (Michel-Monigadon et al., 2010, 
Nijboer et al., 2010). In broad agreement with these animal studies, Ortolano et al. 
reported an increase in phospho-JNK (an index of JNK activation) from 1 to 48 hours 
post-injury in brain tissue samples from 6 TBI patients, and confirmed this phospho-JNK 
temporal profile experimentally in a CCI model in adult mice (Ortolano et al., 2009). 
Other experimental data  from murine ischemia-reperfusion model suggest that JNK 
phosphorylation may initially drop, and then begin to rise from 1 hour until it peaks at 9 
hours following stroke (Gao et al., 2005). Phosphorylation of c-Jun – a JNK substrate – 
follows a similar pattern, peaking at 8 hours post-stroke, although it remains significantly 
elevated at 24 hours (Gao et al., 2005). The choice of 3 hour post-injury DJNKI-1 
administration time for this study therefore is appropriate, as it falls within a period of 
active JNK hyperactivation, and is linked with positive outcomes in both permanent 
ischemic brain injury model in 14d rat pups (Borsello et al., 2003) and in neonatal 
hypoxic-ischemic brain injury model in 7d rat pups (Nijboer et al., 2010).  
The drug of choice – DJNKI-1 – is a synthetic cell-penetrating peptide that is 
protease-resistant and has been shown to be very promising in inhibiting JNK action 
competitively at various levels of the pathway (Borsello et al., 2003, Borsello and Bonny, 
2004). The drug was synthesized by linking HIV-TAT carrier peptide sequence to the 20-
amino acid JNK-binding motif of the scaffold protein JIP-1 (Borsello et al., 2003).  D-
JNK-1 acts by competitively inhibiting the interaction of all JNK isoforms with JIP-1 and 
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with their downstream substrates (Borsello et al., 2003, Borsello and Forloni, 2007). The 
dosage used – 11mg/kg – was based on its previously reported efficacy in permanent 
middle cerebral artery occlusion (MCAO) model in juvenile (P14) rats (Borsello et al., 
2003) and in other CNS injury models (Repici and Borsello, 2006, Repici et al., 2007) 
where the drug was injected intraperitoneally (i.p.).  Previous reports have indicated that 
the drug is able to cross the BBB and penetrate the cerebral cortex within 1.5 hours after 
i.p. injection in rodents, and could remain stable in brain parenchyma for at least 3 
weeks (Repici et al., 2007, Ploia et al., 2011, Sclip et al., 2011). 
The key finding of this study is that early administration of DJNKI-1 not only 
improves histological, sensorimotor and cognitive outcomes at early time points but also 
confers neuroimaging and functional improvements at later time points as observed at 4 
to 8 weeks post-injury (Figs. 3D, 6B, 7A, 8E, etc.). This property is important for potential 
clinical use and bodes well for long-term clinical efficacy of DJNKI-1 in juvenile TBI. In 
the following sections, the main effects of early DJNK-1 intervention following jTBI in this 
study are discussed, together with insights into potential mechanisms mediating these 
effects. 
 
DJNKI-1 and Improvement of Neurological and Cognitive 
Functions 
In this study, we found remarkable improvements in sensorimotor and cognitive 
functions at both acute and later time points following DJNKI-1 treatment in our jTBI 
model (Figs 7, 8, and 9).  These findings are important with respect to scientific reports 
that highlighted the persistence of neurological, cognitive, and behavioral sequelae 
following moderate to severe TBI during childhood (Schwartz et al., 2003, Catroppa and 
Anderson, 2009, Anderson et al., 2012), which have been confirmed in some animal 
models of jTBI (Russell et al., 2011, Ajao et al., 2012).  
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We found robust improvement in sensorimotor functions with the use of foot-fault 
test (Fig. 7A, both short-term and long-term post-injury) and constant speed paradigm of 
rotarod test (Figs. 7C and D, only at short-term), but not with either beam balance test 
(Fig. 7B) or the constant acceleration paradigms of rotarod (Fig. 7E). Other labs that 
used comparable acceleration paradigm have established that motor deficits on rotarod 
are greatest and most evident at acute phases (1 – 7 days) following experimental TBI in 
rodents, with recovery up to 88% of preinjury values by 14 days (Onyszchuk et al., 
2007). This is consistent with our results in constant speed paradigm (Figs. 7C, D), and 
makes it improbable to see treatment effects on accelerating rotarod at later time points 
(Fig. 7E). Lack of both pre-training and customized rotarod apparatus to accommodate 
the smaller sizes of juvenile rats have been suggested to affect performance on 
accelerating rotarod more adversely compared to constant speed rotarod following jTBI 
(Russell et al., 2011). Rats have also been observed to use change in gait strategy and 
motor skill learning to improve their performance on accelerating rotarod (Buitrago et al., 
2004, Barreto et al., 2010). These results suggest that DJNKI-1 improves neurological 
function, although not all tests are sensitive enough to reveal the improvements in fine 
motor skills (Russell et al., 2011). The motor deficits observed are warranted because 
the injury encompasses parts of the motor cortex on the rat brains (Soblosky et al., 
1996, Ajao et al., 2012).  On-going morphological and functional changes in white mater 
tracts in this model (Ajao et al., 2012, Kamper et al., 2013) may also account for the 
persistent motor dysfunction observed (Caeyenberghs et al., 2011b), and as such the 
impact of DJNKI-1 treatment on the white matter should be further investigated. We 
have reported long-term sensorimotor deficits up to 6 months in this jTBI model (Kamper 
et al., 2013). Potential correction of these long-term deficits with DJNKI-1 should be 
studied. 
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With respect to emotional disorders, the decreased cumulative distance by 
DJNKI animals in open field test (Fig. 8D) coupled with decrease in time spent in the 
dark arm of zero maze at 60d by DJNKI animals (Fig. 8E) could indicate reduced 
anxiety-like behavior compared to their saline counterparts (Kodama et al., 2008) as we 
have previously reported (Ajao et al., 2012). Amelioration of anxiety-like behavior on 
zero maze test (Fig. 8E) further substantiates DJNKI-1’s positive effects on functional 
changes involving multiple brain networks. Anxiety-like symptoms and anxiety disorders 
have been reported within 6 months in over 25% of clinical cases of juvenile TBI across 
all severity levels according to one report (Max et al., 2011). Late onset of anxiety 
disorders in adult patients has been previously reported (Whelan-Goodinson et al., 
2009). Younger children were found to be at an increased risk for developing anxiety 
disorders following TBI (Vasa et al., 2002, Max et al., 2011). Damaged frontal lobe and 
frontal white-matter systems are also associated with these anxiety-related disorders in 
young TBI victims (Max et al., 2011). We have previously shown that the jTBI model 
used in this study causes alterations in some white matter tracts both proximal to and 
distal from the site of impact (Ajao et al., 2012). DJNKI-1 could hold some potential for 
counteracting these post-injury symptoms.  
Moreover, DJNKI-1 also confers some cognitive improvements at select time 
points as seen in various MWM test formats (cued, spatial, and probe) (Fig. 9) which 
assessed spatial learning and spatial memory functions.  In a previous study (Ajao et al., 
2012) where the injury location was more anterior and less lateral to Bregma (1mm by 
2mm) than in this current study (3mm by 4mm), we found no spatial learning or memory 
differences at 30d and 60d between shams and injured rats in this jTBI model. However, 
in a follow-up study, despite not showing overt spatial learning deficits, TBI animals in 
this model use cruder MWM swim strategies which are more dependent on chance at 
60d post-injury compared to sham animals which rely more on direct spatial learning 
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strategy (Pop et al., 2012). DJNKI-1 treatment may be correcting for this subtle shortfall 
in spatial learning strategy in treated animals (Fig. 9). Decrease in distance moved to 
reach the platform by DJNKI-1 animals in the 60d cued MWM test (Fig. 9B), rather than 
confounding the results of the spatial MWM, may be a further indication that DJNKI-1 
improves motor coordination capabilities of the treated animals. While DJNKI-1 animals 
displayed better spatial learning at 30d and 60d (Fig. 9C, D), all animals might have 
become used to the repetitive nature of the test, thereby potentially limiting the test’s 
sensitivity at later time points. Cognitive deficits, however, evolved over time following 
injury (Kamper et al., 2013). While not explicit at 1 and 2 months post-injury (Ajao et al., 
2012), there are spatial memory differences at 3 and 5 months post-injury, and these 
resolved at 6 months (Kamper et al., 2013). Therefore, differences in MWM test could 
show up at much later time points with DJNKI-1 treatment, and this underscores the 
potential of testing DJNKI-1 to arrest some long-term sequelae of juvenile TBI that have 
been well-documented (Sbordone et al., 1995, Yeates et al., 2002, Schwartz et al., 
2003, Ajao et al., 2012). 
The developmental time period is very important for formation of crucial 
sensorimotor and cognitive abilities, and injury to the brain during this phase could elicit 
unresolved imbalances in functional behavior (Giza, 2006, Giza et al., 2007, Ajao et al., 
2012). Scientific reports on genetic deletion (Wang et al., 2007, Yamasaki et al., 2011, 
Yamasaki et al., 2012) and pharmacological inhibition (Borsello et al., 2003, Armstead et 
al., 2011) of JNK or its upstream MAPK activators in developmental animal models have 
highlighted the importance of JNK to normal brain development as well as its deleterious 
role in developmental brain disorders. For example, deletion of JNK3 gene protects 
neonatal mice against cerebral hypoxic-ischemic (HI) injury (Kuan et al., 2003, Pirianov 
et al., 2007). BBB damage is strongly mediated by JNK hyperactivation in experimental 
hypoxic-ischemic brain injury in P7 rat pups (Tu et al., 2011). These reports underscore 
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the importance of JNK pathway in various forms of brain insults during development and 
highlight the therapeutic importance of DJNKI-1.   
Improvement in neurological and cognitive functions has been reported following 
DJNKI treatment in CNS injury models such as: MCAO (Borsello et al., 2003, Esneault 
et al., 2008), neonatal hypoxic-ischemia (Nijboer et al., 2010), intracerebral hemorrhage 
(Michel-Monigadon et al., 2010), spinal cord injury (Repici et al., 2012), and controlled 
cortical injury in adult mice (Ortolano et al., 2009). Tests utilized in these referenced 
reports (rotarod, adhesive removal, beam walking, object recognition, cylinder rearing, 
modified hole board, footprint, and forelimb placement tests) were customized and 
standardized for assessing several neuromotor, proprioceptive, and cognitive abilities. 
Chronic treatment with D-JNKI-1 has recently been shown to rescue memory 
impairments and long term potentiation deficits in an Alzheimer disease mouse 
(TgCRND8) model without any major side effects (Sclip et al., 2011). Our study provides 
additional evidence that DJNKI-1 could ameliorate functional deficits following jTBI.  
TBI in the pediatric brain exhibits both acute and chronic phases linked to the 
disruption of learning and memory consolidation (Schwartz et al., 2003, Chapman, 2006, 
Babikian and Asarnow, 2009). The pediatric population may be especially vulnerable to 
this post-TBI cognitive deficits due to disruption of normal brain development and 
emerging skills which often lead to neurocognitive stall (Chapman, 2006, Catroppa and 
Anderson, 2009). JNK hyperactivation has been shown experimentally to specifically 
mediate such stressful event in the hippocampus (Sherrin et al., 2010). The report 
further shows that injection of DJNKI-1 reduced the activity of hippocampal JNK and 
ameliorated the stress-induced functional deficit. It is plausible that in our study, DJNKI-1 
treatment is mediating similar reduction of JNK activity in the hippocampus with resultant 
improvements seen in learning and memory test (Fig. 9). We cannot however rule out 
potential beneficial effects of JNK inhibition by DJNKI-1 in peripheral systems as inferred 
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in models where DJNKI-1 was injected at a low dose that was not detected in the brain 
(Benakis et al., 2010, Benakis et al., 2012). Peripheral actions of DJNKI-1 such as 
reduction of peripheral inflammation may indirectly effect cognitive improvement (Wilson 
et al., 2002, Benakis et al., 2010). 
While it is not entirely clear how DJNKI-1 elicits these long-term improvements,  
reduced neuronal apoptosis and resultant preservation of the brain’s sensorimotor 
networks is a potential mechanism (Borsello et al., 2003). So also is preservation of BBB 
integrity and prevention of edema formation.  Neuromotor abilities have been shown to 
correlate with brain edema and BBB integrity in experimental TBI (Li et al., 2012).   
Very few pharmacological agents including several ones that failed clinical trials 
(Doppenberg et al., 2004, Beauchamp et al., 2008, Janowitz and Menon, 2010) have 
demonstrated such strong neurological and cognitive effects and for the length of time 
comparable to those shown by DJNKI-1 in these results (Figs. 7 - 9). Some of the 
problems that led to failure of several TBI-targeted clinical trials, such as insufficient 
brain penetration and lack of long-term neurobehavioral testing (Doppenberg et al., 
2004) have been addressed with the use of D-JNKI-1 in this study.  Its ability to 
penetrate the brain (Repici et al., 2007) and its beneficial effect on both short-term and 
long-term neurological and cognitive functions (Repici et al., 2012) (Figs. 7 - 9) increases 
its profile as an ideal therapeutic candidate. It should also be noted that most of the 
clinical trials in TBI have been carried out in severe TBI cases in adult patients 
(Doppenberg et al., 2004). The potential suitability of D-JNKI-1 as a candidate drug for 
moderate TBI in pediatric patients is another highlight of this study. 
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DJNKI-1, Reduction of Lesion Volume and Amelioration of 
Morphological Alterations 
In our search for additional evidence of DJNKI-1’s effects following jTBI, we 
found a consistent reduction in lesion volume over the experimental timeline in DJNKI-
treated rats (Fig. 3B, C, D). Similar reduction in lesion volume through inhibition of JNK 
pathway – either with the use of DJNKI-1 or SP600125 (another small molecule JNK-
specific inhibitor) – has been reported in various models of brain injuries, which include 
transient and permanent middle cerebral artery occlusion (MCAO) (Borsello et al., 2003, 
Hirt et al., 2004), focal ischemic brain injury (SP600125 was used here) (Gao et al., 
2005), intracerebral hemorrhage (ICH) (Michel-Monigadon et al., 2010), and neonatal 
hypoxic-ischemic brain injury (Nijboer et al., 2010). Abnormal morphological alterations 
that are coincident with massive brain contusion such as ventricular hypertrophy, cortical 
thinning, hemorrhage/hematoma, herniation, cyst formation and disrupted corpus 
callosum are also reduced in DJNKI-1 group (Table 1). This could be attributed to 
reduced lesion volume in the brains of DJNKI-treated animals. In another study, we 
reported long-term cortical thinning in jTBI animals at 3 and 6 months post-injury 
(Kamper et al., 2013). DJNKI-1 may have the potential to correct this in the long-term. 
The therapeutic effect of DJNKI-1 with respect to reduced lesion volume has previously 
been attributed to: (1) inhibition of excitotoxicity and prevention of neuronal loss [as 
shown in models of MCAO (Borsello et al., 2003, Hirt et al., 2004), and in TBI (Ortolano 
et al., 2009)]; and (2) reduction in the loss of glial cells through reduction of glutamate 
toxicity [for example in oligodendrocytes in the brain (Rosin et al., 2004)]. 
Another potential mechanism of action for DJNKI-1 is through salvaging of 
oligodendrocytes, which could ameliorate the negative effects of jTBI on white matter 
structure and function. We have previously reported a significant decrease in area 
measurement of corpus callosum (through NF-200 and MBP staining, and through MRI 
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measurement) together with a concomitant increase in MBP immunoreactivity at early 
(3d) and later (60d) time points following jTBI (Ajao et al., 2012). In another study, we 
reported that the area of corpus callosum remains decreased in jTBI animals at 3 and 6 
months post-injury (Kamper et al., 2013). Some studies have reported possible links 
between JNK pathway inhibition, viability of oligodendrocytes, and resultant sparing of 
white matter (Chew et al., 2010, Repici et al., 2012, Wang et al., 2012). Repici and 
colleagues (Repici et al., 2012) in particular reported long-term (4 months) locomotor 
recovery following administration of DJNKI-1 in a mouse model of spinal cord injury, and 
positively correlated this functional recovery with white matter sparing. It is therefore 
plausible that the short- and long-term functional recovery seen in this study is related to 
DJNKI’s positive effects on the brain’s white matter structures and functions (Ajao et al., 
2012, Kamper et al., 2013).   
To investigate possible effect of DJNKI-1 treatment on the white matter, we 
measured the surface area of corpus callosum (CC) from T2-weighted images (T2WI) at 
each of the time points. Increase in CC surface areas especially at 7d, 30d, and 60d 
time points in the DJNKI-1 animals (Fig. 5) suggests that the drug is effecting structural 
changes along the white matter that may be beneficial to recovery of function.  We have 
previously shown that this jTBI model decreases CC surface area in the injured animals 
at 60d with respect to shams, and also decreases neurofilament-200 (NF200) 
immunostaining along the CC at 7d, 30d, and 60d post-TBI (Ajao et al., 2012). This data 
on CC area is consistent with the previous report. The CC contains commissural 
pathways that enable interhemispheric communication which is essential for bimanual 
motor function and other coordinated movements.  The CC is highly vulnerable to TBI, 
and damage to the CC in humans TBI patients has been linked with deficits in bimanual 
motor functioning and coordinated movements (Caeyenberghs et al., 2011a).  Decrease 
in size and microstructural integrity of CC also underpin the poorer sensorimotor 
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coordination on tasks requiring high degree of interhemispheric interactions seen in 
older adults compared with their younger  counterparts (Fling et al., 2011). Furthermore, 
loss in the volume of deep white matter structures such as CC in children with TBI has 
been strongly linked with poorer long-term social reintegration and neuropsychological 
performance (Gale and Prigatano, 2010). DJNKI-1’s effect on the CC and possibly other 
white matter structures may therefore have a potential for ameliorating not only 
sensorimotor deficits but also behavioral deficits as well. Additional studies are being 
carried out in Dr. Badaut’s lab to determine the cellular and downstream molecular 
targets for DJNKI-1 supporting the neuroimaging and behavioral benefits. 
 
DJNKI-1, Blood-Brain Barrier, and Edema Formation 
We showed in this study that DJNKI-1 administration at 3 hours post-jTBI 
significantly reduced IgG extravasation at 3d post-jTBI around the lesion and perilesion 
ROIs (Fig. 10A, B). Water accumulation measured with T2 in these same 2 ROIs was 
significantly reduced in DJNKI-treated compared to non-treated rats not just acutely but 
also at later time points (Fig. 6A - C), suggesting that DJNKI prevents the edema 
formation early one after jTBI by improving the BBB integrity. Meanwhile, ADC 
measurements [which is used as an indicator of water mobility in the brain (Le Bihan, 
2007, Obenaus and Ashwal, 2008)] showed no differences in the lesion and perilesion 
ROIs (Figs. 6D - F) except for the increased ADC value found in DJNKI-1 group at 7d in 
perilesion ROI (Fig. 6F). This may indicate a transient availability of larger intercellular 
space in the perilesion of DJNKI-1-treated animals at this 7d time point only. While the 
increased ADC value in the DJNKI-1 group could indicate some cell death, the reduced 
ADC value in the saline group may also indicate an on-going neuronal and astrocytic 
swelling (Badaut et al., 2011) which DJNKI-1 treatment counteracted. 
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Edema formation is one of the secondary processes evident in TBI (Werner and 
Engelhard, 2007, Shlosberg et al., 2010), and it is especially pronounced in juvenile TBI 
(Giza et al., 2007, Fukuda et al., 2012, Fukuda et al., 2013).  A mechanistic explanation 
for the observation on edema above is a possible protective action of DJNKI-1 on BBB 
and brain endothelial TJ, which prevents prolonged BBB opening and preserves 
endothelial TJ integrity. In line with the proposed mechanism of action, attenuation of 
BBB disruption, edema, and apoptosis by DJNKI-1 could result in salvaging more 
neurons and glia that could have succumbed to premature cell death, and eventually 
lead to the preservation of neuronal networks that are vital to various neurological and 
cognitive functions. For example, in another study in this jTBI model in our lab that 
looked at a different treatment strategy, edema formation was decreased acutely 
alongside improved outcomes in BBB integrity and neurological functions, and reduction 
in neuronal cell death and astrogliosis (Fukuda et al., 2013). 
The action of JNK hyperactivation in disrupting inter-epithelial and inter-
endothelial tight junctional proteins have been reported in the periphery, like in tricellular 
tight junctions in human pancreatic duct epithelial cells, intestinal epithelial tight junctions 
(Betanzos et al., 2004, Kojima et al., 2010, Samak et al., 2010) and in in vitro brain 
endothelial cell cultures (Etienne et al., 1998, Adamson et al., 1999, Wolburg and 
Lippoldt, 2002, Tai et al., 2010). Moreover, JNK hyperactivation appears to contribute 
tremendously to TJ and BBB disruption in some brain disease models (Tai et al., 2010, 
Kacimi et al., 2011, Tu et al., 2011). Conversely, inhibition of JNK reversed decrease in 
TJ proteins including claudin-5 in the periphery (Carrozzino et al., 2009). JNK is actively 
involved in ICAM-1-mediated lymphocyte transmigration across brain microvascular 
endothelial cells in an in vitro model of neuroinflammation (Hudson, 2012). In human 
brain endothelial cells exposed to inflammatory cytokines, JNK inhibition reduced the 
cytokine-induced paracellular permeability (Lopez-Ramirez et al., 2012). Since capillary 
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endothelial cells are one of the first points of contact in the brain for intraperitoneally-
injected, blood-borne DJNKI-1, the agent may conceivably be acting to reverse the 
reduction in BBB TJ proteins (Berezowski et al., 2012). The reduction in IgG 
extravasation at acute time-point provides an indirect, but fairly strong support for this 
(Fig. 10A, B).  Corroborating evidence for this comes from a recently reported study of 
spinal cord injury (SCI) model performed in male Swiss mice where i.p. injection of the 
same dose of DJNKI-1 that we used (11mg/kg) at 6 hour post-injury resulted in 
significantly lower IgG extravasation volume and erythrocyte extravasation in DJNKI-1 
group compared to saline controls (Repici et al., 2012). Further studies (such as staining 
TJ proteins, etc. following DJNKI-1 treatment in jTBI) will however be needed to solidify 
this hypothesis.  
The main sites of action for DJNKI-1 in the brain endothelium that could result in 
JNK inhibition are the JNK-binding motifs of the scaffolding protein, JIP-1 (Borsello et al., 
2003, Borsello and Forloni, 2007). All 3 isoforms of JNK are present in the brain 
endothelium (Berezowski et al., 2012). DJNKI-1 competitively inhibits the interactions 
between JNK isoforms and their upstream mediators and downstream substrates. More 
than 50 substrates of JNK have been identified (Bogoyevitch and Kobe, 2006), and the 
functions of some are yet to be determined. 
Repair of disrupted BBB and preservation of brain endothelial junctional integrity 
is a unique therapeutic avenue that has been proposed for traumatic brain injury 
(Hawkins and Davis, 2005, Shlosberg et al., 2010). Disruption of BBB and brain 
regulatory vascular mechanisms is of particular concern to the juvenile population due to 
its susceptibility to brain injury-induced cerebral hemodynamic dysfunction (Armstead, 
1999, 2005, Freeman et al., 2008, Udomphorn et al., 2008, Chaiwat et al., 2009, 
Armstead et al., 2011), diffuse cerebral edema, and tight junction breakdown (Anthony et 
al., 1997, Suh et al., 2001, Campbell et al., 2007, Giza et al., 2007, Freeman et al., 
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2008). Occurrence of impaired cerebral hemodynamic autoregulation has been 
established in several clinical cases and experimental models of TBI (Armstead, 1999, 
2000) and it appears to be more pronounced in pediatric/juvenile model of TBI versus 
adult model (Armstead and Kurth, 1994, Armstead, 2000, 2004, 2005). Armstead and 
colleagues have identified hyperactivation of JNK as a major mechanism for this 
secondary consequence of jTBI (Armstead, 2003, Armstead et al., 2011). Using porcine 
(piglet) model of lateral fluid percussion injury (FPI) which mimics many of the 
pathophysiological features of jTBI including cerebral autoregulation impairment seen 
clinically (Armstead and Kurth, 1994), they reported that JNK MAPK concentration was 
increased in CSF by FPI, but blocked by JNK antagonists SP600125 and DJNKI-1 
(Armstead et al., 2011). DJNKI administration following FPI blocked NMDA-induced 
vasoconstriction and fully restored pial artery vasodilation (Armstead et al., 2011). 
Although measurements of JNK was obtained from CSF in these studies, the increased 
concentration of JNK in CSF reflects events in brain parenchyma (Armstead et al., 
2011). A major caveat is that the major cellular origin of this increased JNK is unknown, 
with the possibility of neuronal, glial, smooth muscle, and endothelial origins, or a 
combination of these sources. These reports nonetheless strengthen the theory that 
DJNKI-1 may confer a protective effect on brain vascular system and BBB. More 
investigation is needed, however, in this jTBI model to address the effect of DJNKI-1 on 
neuroinflammation and on some other relevant pathways such as the JAK-STAT 
pathway. 
 
Conclusion 
In this study, we provide evidence showing that administration of the competitive 
JNK inhibitor – DJNKI-1 – at 3 hours post-jTBI is not only effective in reducing edema 
formation and blood-brain barrier disruption at acute time points following juvenile TBI, 
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but also confers reduction in lesion volume and recovery of neurological and cognitive 
abilities that last into adulthood. Certain morphological alterations commonly seen in 
brain-injured rodents are also less frequent following acute treatment with DJNKI-1. 
These include reduction in the surface area of corpus callosum, ventricular hypertrophy, 
cortical thinning, damaged hippocampus, herniation, and hematoma. 
 DJNKI-1 has the potential to mediate cellular processes in various types of brain 
cells, including neurons, glial, smooth muscle, and endothelial, all of which could 
experience JNK hyperactivation. Processes that DJNKI-1 could ameliorate in the brain 
following jTBI may include: excitotoxicity (in neurons), apoptosis (in neurons and 
endothelial cells), and vascular permeability and edema (in capillary endothelial cells). 
Administration of DJNKI-1 through the intraperitoneal route, its facilitated passage 
through the cell membrane (by virtue of its carrier peptide sequence, HIV-TAT), and its 
lengthy half-life in brain tissue (up to 3 weeks) could ensure access of the drug to most 
of these cell types, and potentially elicit additive or synergistic effects in the brain. These 
beneficial effects appear to result in improved neurological and behavioral outcomes. 
Major effects of DJNKI-1 in the periphery can however not be ruled out. 
The prolonged efficacy of this agent makes it promising for potential clinical 
applications. But further studies are needed to expound the mechanisms of action of 
DJNKI at the BBB interface, in the gray and white matter, and in the periphery. The 
molecular targets of DJNKI-1 that mediate reduced structural and histological damage 
secondary to the primary insult, and engender beneficial functional outcomes need to be 
further investigated. Such elucidation may help move DJNKI-1 into a clinical trial phase. 
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CHAPTER 6 
GENERAL CONCLUSIONS AND FUTURE DIRECTIONS  
 
Model Development for Juvenile TBI 
Clinical observations and research evidence have shown that TBI is complex and 
heterogeneous in terms of its location, severity and pathophysiology (Saatman et al., 
2008). This heterogeneity is considered a major barrier in finding effective therapeutic 
intervention (Saatman et al., 2008) and necessitated the development of various 
experimental models of TBI (Dixon et al., 1987, Dixon et al., 1991, Cernak, 2005, 
Morales et al., 2005, Morrison et al., 2011), each of which can model only parts of the 
pathophysiological processes associated with brain injuries. Controlled cortical injury 
(CCI) and fluid percussion injury (FPI) are the two most commonly used models of TBI 
(Morales et al., 2005, Chodobski et al., 2011). Efforts have also been made to develop 
suitable models of juvenile TBI (jTBI) mostly in piglets and rodents (Armstead and Kurth, 
1994, Adelson et al., 1998, Prins and Hovda, 2003). 
In this project, electromagnetically-actuated CCI on P17 rats was used to model TBI 
in the developing brain (Brody et al., 2007). This model of choice has a number of 
advantages. First is the ability to control the deformation parameters (velocity, impact 
depth, time delay) of the model, which allows improved reproducibility of injury severity 
in our lab and in other labs (Morales et al., 2005, Ajao et al., 2012). Secondly, this CCI 
model is associated with key pathophysiological processes including acute hemorrhage 
and hematoma, axonal injury, BBB dysfunction, and edema, all of which have been 
observed clinically in young TBI patients (Duhaime et al., 1992, Giza et al., 2007, 
Chodobski et al., 2011, Maxwell, 2012). Our findings confirmed that following jTBI, there 
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were: acute increase in BBB permeability and edema, neuronal loss, white mater 
changes, and brain deformities such as ventricular hypertrophy, herniation, and 
hemorrhage (Ajao et al., 2012).  These observations demonstrate the usefulness and 
suitability of this model in investigating some important aspects of juvenile TBI. 
 
Histological and Functional Effects of Juvenile TBI in Rodents 
The traditional theory that prevailed for many decades is that brain injuries in young 
humans would be far less damaging structurally and functionally due to putative high 
plasticity and repair potential of the young brain (Kennard, 1936, Teuber and Rudel, 
1962, Anderson et al., 2005, Dennis, 2010). Several findings in this project, however, 
suggest otherwise. Some functional deficits associated with the initial injury, which are 
sensorimotor, cognitive and behavioral in nature, remained unresolved up to 2 months 
post-injury (Ajao et al., 2012, Pop et al., 2012). Electrophysiological measurement also 
showed dysfunction in axonal conductance along a major white mater fiber at two 
months post-injury (Ajao et al., 2012). This supports our hypothesis that TBI on P17 rats 
will engender neurological dysfunction and deficits that will last for weeks after the initial 
insult. Furthermore, data from similar animal cohorts have confirmed the persistence of 
sensorimotor and cognitive deficits up to 6 months following jTBI (Kamper et al., 2013). 
These observations are consistent with epidemiological data that showed prolonged 
cognitive and behavioral deficits for years following TBI (Jonsson et al., 2013), and 
suggest that injury at an early age could be detrimental to future brain development. 
Such observations have triggered a rethink of how the developing brain responds to TBI 
(Yeates et al., 2002, Anderson et al., 2005) with increasing number of investigators now 
viewing the young brain as being more vulnerable than the adult brain for 
pathophysiological signatures of TBI, such as subdural hematomas and diffuse cerebral 
edema (Aldrich et al., 1992, Giza et al., 2007, Huh and Raghupathi, 2009).  
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While there are literature evidence that the developing brain retains some ‘plasticity’ 
(defined as the ability to be remolded or reshaped after damage) (Anderson et al., 2012), 
this plasticity does not fully compensate for deficits resulting from brain injuries 
(McQuillen and Ferriero, 2004, Anderson et al., 2012, Levin, 2012). Several 
developmental processes (e.g. white mater myelination and size) (see Chapter 5) and 
overall maturation of the brain are disrupted by juvenile TBI (Ajao et al., 2012). 
Furthermore, clinical reports of long-term deficits arise not just from moderate and 
severe TBI (Yeates et al., 2002), but also in some forms of mild TBI (Rees, 2003, Carroll 
et al., 2004, Stern et al., 2011). Recognition of the potentially life-long functional deficits 
facing children who have experienced TBI, coupled with the significant socioeconomic 
burden that is associated, should spur more research aimed at both prevention (Keenan 
and Bratton, 2006) and mitigation of TBI effects (Kochanek et al., 2010).  
Meanwhile, results from chapters 2 (Fig. 6: global increase of myelin basic 
protein [MBP] in the corpus callosum observed at regions proximal and distal to lesion 
cavity) and 5 (Fig. 4: ventricular hypertrophy of the contralateral hippocampus) 
reinforced the idea that brain responses to focal brain injury is not just localized to the 
immediate surroundings of the impact locus, but reaches distal brain regions (both grey 
and white mater) as well (Ajao et al., 2012). Diffuse brain injuries have long been 
associated with global (i.e. widely distributed) changes in the brain (Andriessen et al., 
2010), but focal TBI may also trigger non-localized responses (Dunn-Meynell et al., 
1994, Ding et al., 2011). The distal effects associated with focal TBI could be partly 
attributed to the spreading out of the initial impact forces to vulnerable brain regions 
(such as hippocampus, amygdala, and basal ganglia) (Wilde et al., 2007, McAllister, 
2011) and to changes in the connection network of various brain parts (as seen with 
herniation and injury to white matter tracts) (Huh and Raghupathi, 2009). For example, in 
a follow-up study, we have reported reduced immunoreactivity for NF200 (a 
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neurofilament that forms part of the neuronal cytoskeleton which supports and maintains 
axonal/neuronal structure, and has also been implicated in intracellular transport to 
axons and dendrites) in gray and white matter regions that are proximal and distal to the 
point of initial brain impact following juvenile TBI in rats (Kamper et al., 2013). 
Interestingly, these changes were measured at 6 months post-injury in adult rat brains. 
The vulnerability of the central structures of the brain which support conveyance 
of sensory and motor information to the cerebral cortex is partly responsible for 
sensorimotor deficits seen after TBI (Wilde et al., 2007, Ajao et al., 2012) (chapter 5, 
figure 5). Moreover, TBI in all its forms affect all major cell types in the neurovascular 
unit – e.g. neurons, astrocytes, endothelial cells – as attested to in our findings (Ajao et 
al., 2013; Submitted). Any form of therapeutic intervention would therefore be more 
beneficial if it has the potential to target multiple protein molecule(s) and pathway(s) in 
more than one cell type in the brain (Vink and Van Den Heuvel, 2004, Stoica et al., 
2009). Such multidimensional effects are afforded by the two pharmacological agents 
used in this project – DJNKI-1 (for suppression of JNK hyperactivation following jTBI) 
and cavtratin (for pharmacological mimicry of endogenous caveolin scaffolding domain). 
See Figure 1 for a diagrammatical representation of the pathways affected by these two 
pharmacological agents. 
 
JNK Activation as a Therapeutic Target for Juvenile TBI   
This project provides evidence in support of the theory that DJNKI-1 confers 
protection against secondary processes of jTBI. This is through: prevention of excessive 
brain tissue damage (e.g. reduction in lesion volume over a 60-day period with acute 
DJNKI-1 treatment), reduction of injury-associated morphological alterations (e.g. 
reduced frequency of ventricular hypertrophy and prevention of white mater size 
reduction over time), reversal of BBB disruption and hyperpermeability, and consequent 
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reduction in vasogenic edema (see chapter 5). In addition, acute administration of 
DJNKI-1 promotes recovery of motor and cognitive functions both acutely and in the 
long-term (see chapter 5, figs. 7 - 9). This ability to influence longitudinal recovery makes 
DJNKI-1 particularly promising for ameliorating long-term dysfunction association with 
juvenile TBI. However, the mechanism of action of DJNKI-1 has not been fully elucidated 
in juvenile TBI.  
One possible mechanism highlighted in this work (chapter 5) is the reduction in 
vascular permeability and edema. We conclude from the observed reduction in IgG 
extravasation in DJNKI1-treated rats (chapter 5, fig. 10), and in T2 values at the lesion 
and perilesion brain ROIs in the same rats (chapter 5, fig. 6A - C), that DJNKI-1 protects 
against vasogenic edema, while not ruling out protection against other forms of cerebral 
edema (e.g. cytotoxic edema). We earlier hypothesized that DJNKI-1 treatment will 
ameliorate BBB disruption and hyperpermeability in this model, and these findings 
mostly support the hypothesis. Meanwhile, the action of DJNKI-1 may be conferring a 
global neuroprotection following jTBI. The premise for this is that JNK isoforms (JNK-1, -
2, and -3) are present not only in neurons but in other brain cell types such as 
endothelial cells, astrocytes, etc. (Waetzig et al., 2006, Haeusgen et al., 2009, Tu et al., 
2011) whose actions are vital to neuronal survival and function. Hyperactivation of these 
JNK isoforms has been shown extensively in neurons following various forms of brain 
injuries or damage (Borsello et al., 2003, Ortolano et al., 2009). Activation in glia and 
brain microvascular endothelial cells has also been highlighted (Xie et al., 2004, Wang et 
al., 2012). In fact, Wang et al (2012) showed in a juvenile model of brain inflammation 
that JNK hyperactivation is the common thread linking BBB disruption, oligodendroglial  
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apoptosis in the white matter, and microglial activation with its consequent cytokine 
production. The long-term difference in corpus callosal (CC) thickness observed 
between DJNKI1-treated rats and control (with DJNKI-1 group showing increased CC 
thickness especially at later time points, see chapter 5, fig. 5) is suggestive of a 
protective role of JNK inhibition in the white mater structures of a developing brain. Since 
DJNKI-1 is capable of inhibiting the hyperactivation of all 3 JNK isoforms in the varied 
cell types in the brain, its actions may therefore constitute a form of global 
neuroprotection following jTBI.  
It is however important to further investigate the mechanisms of brain protection 
that DJNKI-1 confers following post-TBI administration in the juvenile brain. It has been 
suggested that DJNKI-1 may be playing a role in the periphery (e.g. in the liver, spleen, 
etc.) that positively influences brain recovery following cerebral ischemia (Lehnert et al., 
2008, Touchard et al., 2010, Benakis et al., 2012). This route of action should be further 
investigated in jTBI models.  
 
Caveolins in Brain Homeostasis and in Recovery and Repair 
after Juvenile TBI   
Caveolins are believed to play important roles in brain homeostasis under normal 
conditions and in response to brain pathology. In this project, we found increase in 
caveolin-1 following jTBI at both acute and later time points (chapter 3, fig. 3). This long-
term increase following jTBI suggests that caveolin-1 may be exerting some modulatory 
effects long after the initial injury. We also found increase in caveolin-3 at acute time 
points (chapter 3, fig. 5). These agree with literature evidence showing increase in 
caveolins-1 and -3 in some forms of CNS injuries and disorders, including cold cortical 
injury (Nag et al., 2007, Nag et al., 2009), spinal cord injury (Shin, 2007), and 
experimental autoimmune encephalopathy (Shin et al., 2005). The increase in caveolins-
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1 and 3 coincided with the acute decrease in claudin-5 immunoreactivity and increased 
in extravasated IgG, showing that caveolins may be associated with BBB disruption and 
hyperpermeability. This is in broad agreement with our hypothesis that decreased tight 
junction protein levels and BBB hyperpermeability will be associated with an increase in 
expression of the caveolins, although we did not find a significant increase in the 
expression of caveolin-2.  Meanwhile, some reports have shown a lowering of caveolin-1 
expression in some forms of brain injury such as ischemic-reperfusion injury (IR) (Shen 
et al., 2006, Gu et al., 2011). This endogenous reduction in caveolin-1 in IR is 
associated with increased nitric oxide production, increased activation of matrix 
metalloproteinases (MMPs), BBB disruption, and overall poor histological and functional 
outcomes (Gu et al., 2011, Gottschall and Barone, 2012). 
We found a ubiquitous distribution of caveolin-1 in the brain following jTBI (in 
neurons, astrocytes, etc., in addition to cerebral endothelium) (chapter 3, fig. 2), which 
agrees with current literature reports (Cameron et al., 1997, Shin et al., 2005). Cav-1, 
(as well as cav-2, and -3) have been reported to be present in non-caveolae regions in 
neurons, and are associated with pro-growth and pro-survival signaling functions (Head 
and Insel, 2007).  
The role of prolonged increase in caveolin-1 expression should be a subject of 
future research. It may be a compensatory mechanism to counteract long-term damage 
in brain cells and improve function, or it could be detrimental to long-term functional 
recovery (Patel et al., 2008, Gu et al., 2011, Stary et al., 2012) (Also see chapter 3). 
We studied the effect of pharmacological mimicry of the caveolin scaffolding 
domain (CSD) with the use of cavtratin. The CSD is not restricted to brain endothelial 
cells (Song et al., 2007), but is also present in neurons (Head et al., 2008) and 
astrocytes (Cameron et al., 1997). The ability of both of cavtratin to permeabilize the 
234 
brain through its cell permeable adjunct (Antennapedia internalization sequence) and 
influence multiple brain targets makes it a promising pharmacological tool. 
 Acute administration of cavtratin resulted in reduced lesion volume at 1d and 3d 
post-injury (Chapter 4, Fig. 1). Cavtratin also reduced edema formation (as determined 
by T2-weighted MRI) acutely in the lesion region of interest (ROI), but not in the 
perilesion ROI (Chapter 4, Fig. 2). There was however no behavioral benefits (only 
sensorimotor functions were tested) associated with cavtratin treatment at acute time 
points (Chapter 4, Fig. 3). We therefore conclude that cavtratin could reduce edema 
formation and ameliorate brain damage acutely. Future work should concentrate on 
long-term study of the effect of cavtratin both on the pathophysiology of the brain and on 
brain function as several secondary processes occurring acutely after jTBI could mask 
some positive effects of the drug. Injection of cavtratin at multiple time points following 
jTBI may also show if its effect could be optimized acutely and beneficial at long-term. 
The effect of cavtratin on brain endothelial tight junction proteins (e.g. claudin-5, 
occludin, etc.) as well as on IgG extravasation should be studied to further establish 
examine the effect of the drug on the BBB integrity. The effect of cavtratin on eNOS, NO 
production and MMP9 activation [which has been implicated in BBB disruption in 
ischemic models (Gu et al., 2011)] should also be investigated to gain more insight into 
the mechanism of action of the drug. In addition, the question of how caveolin-1 interacts 
with JNKs in the brain should be studied through in vitro models. Combinatorial use of 
both DJNKI-1 and cavtratin in jTBI should also be investigated for potential additive or 
synergistic effects. 
 Overall, we have shown that acute administration of DJNKI-1 and cavtratin could 
be beneficial in ameliorating some secondary processes associated with jTBI. In-depth 
studies looking at the mechanisms of action of these drugs in juvenile TBI models should 
be undertaken to further ascertain their clinical potential.  
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